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CHAPTER I 
SOMATOSTATIN RECEPTORS 
IN THE IMMUNE SYSTEM 
Il1hrx!1!dion 
INTRODUCTION 
During the first half of the previous century, the evidence that the endocrine and nervous 
systems integrate and regnlate different functions in the human body coincided with the 
new findings supporting the concept that immune mechanisms may be influenced by these 
systems as well. In the past decades, many studies were carried out to understand the 
molecular and cellular basis of interactions between the immune system and 
neuroendocrine activities. 
TIle interactions between the inunune, endocrine and nervous systems are very complex. 
Although the accumulated information is enormous, many reciprocal interactions are 
poorly understood, several mechanisms are still difficult to interpret, and in some cases the 
results are even contradictory. Nevertheless, increasing numbers of researchers and many 
laboratories are nowadays focused on understanding how hormones, neuropeptides, 
neurotransmitters and specific products of inunWle cells exert their regulatory functions 
and act in integrating such different systems. 
How immune and neuroendocrine mechanisms may affect each other is summarized in 
Figure 1. Firstly, immune, endocrine and neural cells can express receptors for cytokines, 
hormones and neuropeptides. Secondly, immwle and neuroendocrine products may coexist 
@ 
• 
B 
FIGURE 1. Representation of the different ways of communication between immune, endocrine and nervous 
systems. A) Reciprocal receptors for cytokines, honnones and neuropeptides expressed on immune, endocrine 
and neural ceUs. B) Immune and neuroendocrine products coexist in lymphoid, endocrine and neural tissues. 
C) Specific mediators of one of the three systems can affect the others. 
I, immune cell; E, endocrine cell; N, neural cell; Cy, cytokines; Hr, honnones; NP, neuropeptides. 
in lymphoid, endocrine and neural tissues and may be produced by all this type of cells (1). 
Thirdly, specific mediators for one of the three systems can affect the other two. 
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The functional interactions between inunune, endocrine and neural cells occur at different 
levels, which underline their relevance in controlling physiological processes, any 
disturbances herein may be potentially involved in certain pathological conditions (1-2). 
Studies in animal models have demonstrated that abnormalities in the immune-neuro-
endocrine conununications may start or contribute to the development of chronic 
autoinunune diseases. In analogy, similar questions have been raised for humans. 
Direct cell-to-cell communication is one of the mechanisms involved in imnuU1o-neuro-
endocrine interaction and neuroendocrine and llmnune systems share a number of ligands 
and related receptors (3). It has been hypothesised that the majority of these signalling 
molecules are highly conserved, and that 1ia these products the systems in many species are 
able to establish a much more sophisticated physiological intra- and intersystem 
communication circuit (4). The bi-directional neuroendocrine-immune interactions may 
constitute an important homeostatic mechanism and more recent studies addressed the 
question of the role of neuropeptides in regulating immune functions, starting from the 
developmental phases of the inllUlUle system (5). 
Specific receptors for neuroendocrine regulatory peptides have been detected on cells of 
lymphoid tissues, and the pathway of interactions suggests a close topographical link 
between the various systems. In addition, lymphoid tissues are directly and extensively 
innervated, the nerve fibers being in direct contact with lymphocytes or their precursors 
and macrophages, performing their neuro-effector functions. 
This evidence, together with the co-localization of neuroendocrine .md immune cells and 
their locally released products, point for a pivotal role of neuropeptides in the modulation 
of the inunune functions. Abnormalities in the cross talk between immune, endocrine and 
nervous systems could have crucial importance in the development of severe diseases. A 
clearer understanding of these interactions may have important therapeutic applications. 
REFERENCES 
1. Besedovsky H, Del Rey A. 1996 Immune-neuro-endocrine interactions: facts and 
hypothesis. E,,&x,. Rev 17:64-102. 
2. Blalock JE. 1994 The syntax of immune-neuroendocrine commurucatlon. IIm11",:i 
Talay 15:504-511. 
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3. Blalock JE. 1994 Shared ligands and receptors as a molecular mechanism for 
communication between the imnllUle and neuroendocrine systems. AJ'm N Y Acad Sci 
741:292-298. 
4. RothJ, LeRoith D, Collier ES, Weaver NR, Watkinson A, Cleland CF, Glick SM. 1985 
Evolutionaty origins of neuropeptides, hormones, and receptors: possible applications 
to immunology.] hmurnd 135 (supp1.2):816s-819s 
5. Berczi T, Chalmers IM, Nagy E, Warrington RJ. 1996 The .ffimlme effects of 
neuropeptides. Baillieres OUIRlX1Ql1 10:227-257. 
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Adapted fir:m: 
van Hagen PM, Hotland LJ, ten Bokwn AMC, Lichtenauer-Kaligis EGR, Kwekkeboom 
DJ, Ferone D, Lamberts SWJ. 
Neuropeptides and their receptors in the immune system. 
Ann Med 1999;31(SuppI.2): 15-22_ 
NcmoP2Jllides mul tlxir rro;ptors in tlx immune sy510n 
NEUROPEPTIDES AND lHElR RECEPTORS IN THE IMMUNE SYSTEM 
Neuropeptides are classically produced and secreted by neuroendocrine cells and neurons, and 
act as neurotransmitters and/or mediators of well-defined hormonal activities in specific 
tissues and cells. Conununication through soluble effector molecules is not confined to the 
endocrine and nervous systems, but it is very important in the immune system as well. 
Moreover, various peptide hormones are involved in the three systems. TIle presence of 
peptide neurotransmitter and hormone receptors on inunWle cells suggests that the 
neuropeptides regulating the central and peripheral nelVous system and the endocrine system 
could be considered as endogenous immWlomodulatory substances, as well as bi-directional 
corrununicators between the llrunWle and neuroendocrine systems. 
Several neuropeptides and their respective receptors have been detected on cells of the 
llrunWle system. Many studies described their potential role in regulating UrunWle functions 
and the reciprocal immWlo--neuro-endocrine interactions. This chapter gives a brief overview 
on the most well characterized effector systems, focusing particularly on neuropeptides and 
their potential role in the diagnosis and treatment of inunWle mediated diseases, 
NEUROPEPTIDES IN THE IMMUNE SYSTEM 
In their physiological environment, immlUle cells are exposed to agents such as hormones and 
neuropeptides, which do not strictly belong to the immWle system. ·Moreover, immune cells 
can produce hormones and neuropeptides themselves. The first evidence was that of 
propiomelanocortin {pOMq-derived peptides, such as adrenocorticotrophic hormone 
(ACTH) and ~-endorphins. ACTIf-likeillummoreactivity was demonstrated in leukocytes (1). 
It is intriguing that corticotrophin releasing factor (CRF), which is the natural stim,dator of 
pituita!}' ACIH secretion, is also produced by immune cells (2), and that its production is 
dearly increased during inflammation (3). Moreover, POMC-derived alpha-melanocyte-
stimulating ho.tmone (C(-~'ifSH) is produced in the spleen (4), whereas, C(-~lSH can regulate 
several activities of immlme cells (5). Growth hormone (GH) and prolactin (PRL) are 
produced by distinct population of immune cells and may play a role in irnmunoregulation by 
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exerting paracrine and autocrine actions (6-8). GH induces insulin-like growth factor 1 (IGF-I) 
production by the liver, as well as in a nwnber of other tissues and organs. IGF-I mediates 
GH action and is a peptide structurally related to insulin. The production and paracrine action 
of both IGF-I and insulin has been described in immune system as well (9). The presence of 
neuropeptides such as vasoactive intestinal peptide (VIF), substance P (SP) and somatostatin 
(SS) has been demonstrated at either protein or messenger ribonucleic acid (mRNA) levels in 
immune tissues and cells (10-12). Apatt from regulating neuroendocrine functions, these 
substances are present in the innenrated irrunWle tissues as well, and may playa major role in 
immunoregulation. VIP containing nerves are distributed in many lymphoid organs. 
Moreover, VIP is produced and secreted by thymocytes (13), and may modulate immune 
functions within the thymus. In fact, through direct binding to receptors on thymOC)~es, VIP 
affects three important functions of these cells, namely cytokine production, mobility and 
apoptosis (13). 
SP belongs to a family of tachykinin peptides that share a common C terminal amino acid 
sequence (14). The mammalian tachykinins include SP, neurokinin A, neurokinin B, and two 
N-terminally extended forms of neurokinin A, i.e. neuropeptide K and neuropeptide Y. 
These molecules are involved in several aspects of nemoimmunomodulation (15). SP has 
been demonstrated in a subset of lymphocytes and monocytes/macrophages at mRNA and 
protein levels (16-18). Sequence analysis of these products confirmed that the structure was 
identical to that found in neuronal cells. Moreover, SP has been detected in the outer cortex 
of the thymus and in the peptidergic neurones innervating this organ (19-22). SP is the major 
mediator of neurogenic inflammation. It induces degranulation of both mucosal and 
intestinal type of mast cells. In addition, SP affects the functions of lymphocytes, 
macrophages, eosinophils and neutrophils (9). 
A nwnber of other mediators, including vasopressin, oxytocin, bombesin, enkephalins 
neurophysin are shared between the neuroendocrine and immune systems as well (9). Their 
localization and role are under investigation in order to understand for each mediator the 
pathways through which it does participate in the immunoregulatory network. This is crucial 
for the assessment of their potential pathophysiological significance, and for the application 
of this knowledge in clinical setting. 
Finally, SS is also present in lymphoid organs, and its localization and actions will be 
discussed in paragraph 1.4 of the present chapter. 
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Nemupeptides and tlxirn.uptors ill t/x immune system 
In Table 1 the principal neuropeptides involved in controlling the immune system are 
indicated together with their effects on immWle function. Several reports agree that 
TABLE 1. Effects of neuropeptides on immune functions. 
Main Effect 
Ncuropeptide immunoglobulin cytokiIle cell-mediated inflammation 
production secretion immuni!i' 
Adrenocorticotrophic hormone (25) I It I 
Corticotrophin releasing hormone (25) I il ) I 
Vasopressin (9,24) t 
~"ndoqiliin (9,24) t t! ! t 
et:-malanocyte stimulating hormone (25) j j ) 
Enkefalin (9,24) ! t t 
Calcitonin gene-related peptide (9) I j 
Nerve growth factor (9) t 11 
Somatostatin (29) ) t! tl 
Sub~ance P (29) tl t 1 
Vasoactive intestinal peptide (13,29) tl I tl 
administration of hormones and neuropeptides may lead to stimulate or depress 
immune/inflanunatOlY response, depending on the dose and the timing of their 
administration. Moreover, gender differences in the response of the inUlllUle system to 
neuroendocrine agents have been documented as well. In general, in females the immune 
response is stronger and the serum immunoglobulin (Ig) concentration is higher (23). 
However, females have a higher incidence of certain autoimmune disease (24). 
\"XIhile ACIH, glucocorticoids and sex steroids in general depress the inunune response in 
Urn, insulin, GH, PRL and thyroid hormones may increase it (23·28). Opioid peptides are 
reported to either stimulate or inhibit the immillle response, depending on the process 
evaluated, from the cell type and from the expetimental condition (24). SP is generally 
considered as a stimulator of the immune system, while Vll' and neuropepcide Y as 
inhibitors (29). 
Neuropeptides may affect other immtme mechanisms like the activity of lymphocytes after 
recognition of an antigen as well as negative and positive selection during their ontogeny. The 
ftrst paragraph of the next chapter will focus in part on this latter aspect, describing the 
presence and influence of neuropeptides within the thymus) which is the organ where T cell 
repertoire is generated. 
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NEUROPEPTIDEAND HORMONE RECEPTORS IN THE IMMUNE SYSTEM 
Immune cells may bind different hormones and neuropeptides. Receptors for regulatol}' 
products of the hypothalamus-pituitary-adrenal axis are widely represented along the immune 
system. CRF, ACIH and POMC-related peptides, as well as glucocorticoid receptors have 
been described in lymphoid and accessol}' cells (2, 30-33). In clinical practice, ACIH and 
glucocorticoids are still among the most effective agents for the treatment of various 
inflammatol}' conditions and diseases with underlying immune abnormalities. 
Receptors for estrogen and testosterone have been described on immune and accessory cells 
with special emphasis for their role in the thymic microenvirorunent on developing immWle 
cells (34-36). GH and PRL receptors have common features with some cytokine receptors 
and their distribution on immune cells received particular attention because of the well· 
established actions of both pituitary hormones within the immune systems, as well as for 
their local production in immwte organs (7,37). 
Two VIP1 and VIP, receptors have been cloned recently, and VIP receptor distribution on 
immune cells has been extensively investigated (38). Although the immunoregulatol}' 
properties of VIP have been not fully tmderstood, an example of the importance of this 
neuropeptide has been demonstrated in the thymus where both receptor isoforms are 
expressed on developing thymocytes (13). 
Thymocytes as well as T- and B-Iymphocytes and macrophages express specific receptors for 
SP (16,17). In addition, very high munbers of SP receptors are expressed in the germinal 
centre of lymph nodes of patients with autoimmune diseases (39,40). The distribution of SP 
receptors in immune tissues suggested that after the labeling of SP with radioactive Indium, 
this radiopharmaceutical might be used to visualize SP receptor-positive tissues. Recently 
[IIIIn-DTPA-ArgI}SP has been used to successfully visualize the thymus and inflammatory 
sites of disease in patients with autoimmune diseases during in 1iw SP receptor scintigraphy 
(41). 
SS receptor distribution on immune cells will be discussed in paragraph 1.4, together wiclt the 
respective peptide distribution in immWle cells. 
'The distribution of neuropeptide receptors has some common characteristics. Their 
expression pattern on different types of immWle cells is heterogeneous) suggesting that the 
signal mediated by these agents can preferentially target different !}'pes of immtme responses. 
Another important aspect is that the number or the activity of neuropeptide receptors on 
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Netnvpeptides «lui tbeirnuptrm in ti:eimmlfJle S)'Slon 
inUlltUlocytes may change during the specific and aspecific activation of these cells, 
suggesting that signals mediated by one of tillS effectors could be predominantly perceived by 
antigen·activated ceUs (42). This evidence may partially explain the rather common 
occurrence of conflicting obsetvations that neuroendocrine-mediated activities exert on 
inuntme cells. 
CDNCLUSIONS 
Current evidence indicates that the neuroendocrine system regulates immooe reactions and 
'liewxt the immune system signals towards the neuroendocrine system. These interactions 
can be identified either as a long loop, where the activation leads to the release of mediators 
affecting distant structures of the network, or as a short loop in which local interactions 
occtU'vta specific agents exerting their reciprocal effects within the tissue or organ where they 
have been released. TIlls integrated mechanism is essential in nonnal physiology and seems to 
be of particular importance for immune homeostasis. Moreover, abnonnalities of 
neuroinununomodulation may contribute to the aetiology of autoimmune diseases, 
immunodeficiency and chronic inflanunatOlY diseases. For example, netU'opepticle receptors 
on target cells can be up- or down-regulated by chronic exposure to the ligand, whereas 
changes in level or activity of local peptidases could alter the concentration of bioactive 
ligand (43,44). Such changes could severely affect the balance of neuropeptides locally 
present within the tissue, potentially leading to induction of an inappropriate immune 
response, and consequentlydisease. \Vhereas a malfunction of this circuit may lead to certain 
stages of specific disease, the blocking of the altered processes nlight offer an efficient way to 
abolish deleterious immune-mediated neuroendocrine and metabolic derangement. 
Importantly, the introduction of agonists and antagonists of neuropeptides involved in 
immunomodulation is starting to become of interest in the treatment of patients with 
imnuUle-mediated diseases. Finally, the receptor status in these patients, which can be studied 
with modem nuclear medicine techniques using peptide-receptor scintigraphy (chapter III), 
may be related to the disease and may be predictive for the efficacy of therapy. 
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SOMATOSTATIN AND SOMATOSTATIN RECEPTOR SUBTYPES 
As introduced in the previous paragraph, many recent studies pointed to the presence and 
functional roles of several neuropeptides such as SS, SP and VW and their receptors on 
cells of the immune system. Generally, SP may enhance immunoglobulin (Ig) M and 19A 
production from B cells, and seems to produce mainly a stimulatOlY effect (1). Conversely, 
SS and VIP seem to have a predominant inhibitOlY action on immune functions (1-3). In 
view of new recent insights, primary and secondary lymphoid organs can be considered as 
preferential sites of immune-neuro-endocrine interactions. 
Emerging data regarding the potential role of SS and its receptors in the regulation of 
imnume functions, both in animals and humans, have projected this ubiquitous peptide 
among the classical regulato!}' peptides with a proved immunomodulato!}' function. This 
section will introduce and overview the principal characteristics of SS and its 5 receptor 
subtypes. 
SOMATOSTATIN 
SS is a peptide hormone initially isolated from the hypothalamus and characterized as a 
growth hormone-releasing inhibiting factor. SS was successively found to be widely 
distributed throughout the human body. Outside the central nervous system, the peptide is 
present in a variety of endocrine and non-endocrine tissues, and it appears to have many 
functions. Since its discove!}' in 1973 by Guillemin et al., (4) knowledge of the functional 
role of SS in regulating neurotransmission in the brain, as well as in the regulation of 
secretion processes in the anterior pituitary gland, the pancreas and the gastrointestinal 
tract, has increased considerably. 
Proteolytic processing of larger precursor molecules, e.g. prepro-SS and pro-SS, results in 
the formation of SS. In mammals, after cleavage of the pro-SS molecule two biologically 
active forms of SS consisting of 14 (SS-14) or 28 (SS-28) amino acids are generated (5). 
In the cente-al nervous system SS acts as a true neurohormone and neurotrasmitter, with a 
generally inhibitory action in many regions {cerebral cortex, limbic system, brain stem, 
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spinal cord) (5,6). In the peripheral nervous system it is found in sympathetic and sensoty 
neurones (7,8) and may have a down.modulatoty effect on nociception, i.e. the perception 
of harmful and/or painful stimuli (9). 
However, the additional biological functions of this peptide, in a variety of endocrine and 
non-endocrine tissues, include inhibitory effects on secretive and proliferative processes 
and modulatory actions on the response of various cells to endocrine stimulation 
(7,8,10,11). 55 exerts an inhibitoty activity on the secretion of different pituitaty and 
gastrointestinal hormones. When produced in the hypcthalamus, 55 reaches through the 
portal circulation the anterior pituitary, where it inhibits the secretion of GH but also of 
other pituitaty hormones such as thyroid-stimulating hormone (T5H) and PRL. 55 is 
produced in specialised cells (D cells) in the gastrointestinal tract and the pancreas (12,13). 
In peripheral tissues the effect of 55 is also mainly inhibitoty, regulating amongst others the 
secretion of calcitonin, gastrin, insulin, glucagon and VW. In addition, it reduces the 
exocrine secretion of pancreatic enzymes and gastric acid and can inhibit the contractility 
of stomach, small gut and gallbladder (10,11,14). Finally, an antiproliferative action has 
been observed in many cell types invitm (15). 
SOMATOSTATIN ANALOGS 
5S has a plasma half-life shorter than three minutes. For this reason, metabolically stable 
analogs with a longer half-life have been synthesized for clinical application. 5tructure-
function analysis of native SS and peptide analogues has shown that the amino acid 
residues Plte7, Trp8, Lys9 and Thr10 are necessary for receptor binding. These residues are at 
the apex of the loop formed by the disulphide bridge connecting the two cysteine residues 
in native SS and have been shown to form a ~-turn (16). Trps and Lys9 are essential for 
biological activity whereas the flanking residues tolerate minor substitutions (17). As 
further discussed below, the development of 5S receptor (5SR) subtype-selective analogs 
has pJayed a critical role in understanding many mechanisms of receptor activities. These 
compounds are a shortened version of the native peptide and more resistant to proteolytic 
degradation. Most of them are cyclic octapeptides, however the smallest 5S analogues that 
are capable of receptor binding are hexapeptides (17). Three octapeptide 5S analogs, 
octreotide, lanreotide and vapreotide have been already introduced in the clinical practice 
(pigure 1); all of them bind to sst" sst, and sst" but not sst, and sst,. None of these analogs 
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octreotide 
lanreotide 
vapreotide 
FIGURE 1. Amino acid sequences of native somatostatin-14 and synthetic stable octapeptide analogs 
octreotide (SMS 201-995), lanreotide (BIM23014) and vapreotide (RC-l60). The dark grey colour indicates 
the amino acids essential for the binding with the receptor. 
bind to only one of the subtypes. However, recently new non-peptide subtype-selective 
agonists have been developed and preliminary evidence showed encouraging results on the 
potential role of these compounds in defining the physiological functions of each SSR 
subtype (18). 
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SOMATOSTATIN RECEPTOR SUBTYPES 
Between 1992 and 1994, five different SSR genes have been cloned and identified 
(17,19,20). They originate multiple SSR subtypes (sst,.,), which are identical in 42 to 60% of 
their amino acid sequence (19). Although the genes encoding the five SSR subtypes have a 
high degree of sequence homology, they are localized on different chromosomes, which 
allows a tissue-specific regulation of their expression (21) and suggests diverse hmctions of 
the receptor subtypes in different organs. All the genes are intronless except for the sst} 
gene, which contains a cryptic intron sequence and encodes for two receptor proteins, sst1A 
and sst", originating from alternative splicing and differing in the length of their 
cytoplasmic tail (17). 
Structllre of somatostatill receptors 
SSR belong to a superfaraily of receptors with seven transmembrane-spanning .-helical 
e" .. tmceUuJar 
FIGURE 2. Structure and orientation of the somatostatin receptors (SSR) within the plasma membrane. 
Sequence of the human SSR subtype 2, with the 7 membrane spanning a-helical segments. The im'ariant 
amino acids are shown in dark gray. rno indicates the potential site of glycosylation in the extracellular 
NH2-tCnninal domain area. Disulfide bond is indicated between two cysteine residues. The inset shows the 
possible arrangement on the 7-membrane segments. Redrafted from reference 20. 
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domains connected by short loops, having an N-terminal extracellular domain and a C-
terminal intracellular domain (Figure 2). Hydrophobic and charged amino acids within the 
transmembrane domains 3, 6 and 7 are important for the interaction with the ligand 
(22,23). However, the extracellular loop 2, between domains 4 and 5, may also be involved 
(24-26). 
Distl'iblltion and signal transduction patmVflYs 
Multiple SSR can be expressed in the same SS-target tissue and this makes difficult to 
establish their individual functional role. The expression of SSR subtypes has been studied 
firstly at mRNA level by in sitll hybridization and reverse transcriptase polymerase chain 
reaction (RT-PCR) (21). Recently, using polyclonal antibodies specific for individual 
subtypes, SSR have been investigated at protein level by irumwlOhistochemistl}' in rat 
(27,28) and human tissues (29-31). The distribution of SSR subtypes has been extensively 
characterized in the rat, where mRNA for all the subtypes has been detected in brain and 
pituitary, while sst, is the subtype apparently predominant in the pancreas and adrenal 
TABLE 1. Characteristics of the five somatostatin receptor subtypes. 
Somatostatin receptor subtypes 
Property sst, sstlA sst) SSt4 ssts 
drromosoma11ocalization 14 17 22 20 16 
Nwnber of amino acids 391 369 418 388 363 
Second messenger coupling 
=> Adenylyl cyclase ! ! ! ! ! 
=> Cachannels ! ! 
=> K channels ! 
=> NaiH exclunge ! ~t t 
=> tyrosine phosphatase ~t t i t ~ 
=> MAPkinase t ! H t ! 
Ligand binding (Ie" nM) 
=> somatostatin·14 2.3 0.2 1.4 1.8 0.9 
=> octreotide >1000 0.6 34.5 >1000 7.0 
Receptor internalization>:- +/- + + + + 
Receptor desensitization'~ ± + + + 
Receptor phosphorylation n.d. + + n.d. 
Receptor regulation byagonists t H i t t 
>:-, TIle extent of receptor internalization and receptor desensitization may change depending on 
the receptor subtypes and on the experimental conditions in cells lines and primary cultures of 
tumor cells, 
n,d., not determined; + /., contradictory results. 
Data derived from references: 21,45,46,49·59. 
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tissues. Sst] mRNA has been detected in spleen, lymph nodes and liver, whereas sst4 in the 
lung and sst, in small gut and adrenal gland (32). In htuuan brain all five SSR subtype 
rnRNAs are expressed in a characteristic, specific pattern (21). Sst1) sst2, sst], and ssts' while 
sst. mRNA is not expressed in the adult pituita!}' (33) and all five SSR subtype proteins are 
variably expressed in normal human pancreatic islets (34). Generally, tumors originating 
from 55· target tissues express a high density of S5R (35,36), and in most cases express 
multiple SSR subtypes as well (21,37). The five 55R subtypes couple differentially to the 
second messenger systems known to be activated upon SS binding to its receptor. Studies 
on signal transduction pathways have demonstrated that all five subtypes are linked to 
adenylyl cyclase via G-proteins (for reviews see 38,39). Moreover, 55R subtype, are 
associated with other signal transduction mechanisms, such as Ca2+ - and K + -ion channels, 
as well as activation of tyrosine phosphatase (PTP) or MAP kinase activity, phospholipase 
A2 and others (20,38,40). \'(Ihile the inhibitOlY effects on adenylate cyclase activity and on 
the influx of Ca2+ are linked to inhibition of secretion processes, the activation of PTP or 
MAP-kinase activity may playa role in the regulatOlY effects that 55 may exert on cell 
proliferation (15,41,42). The principal characteristics of S5R subtypes are summarized in 
Table 1 
Receptor binding 
Each SSR subtype seems to serve a distinct biological function and the signalling 
mechanisms triggered by specific subtypes seem to differ among the cells in which they are 
expressed (43). Moreover, the expression and the activity of S5R can be regulated by their 
own ligand. 
The five S5R subtypes bind S5-14 and 55·28 with high affinity but can be further divided 
into two subclasses on their ability to bind stmctural octapeptide S5 analogs. Sst, and sst. 
receptors do not bind octapeptide analogs, whereas sst2M sst] and ssts receptors display a 
high, low, and moderate affinity, respectively, towards octapeptide SS analogs such as the 
clinically used octreotide and lanreotide crable 1). 
Receptor interllalization, desensitization and regulation 
Receptor-mediated internalization of ligands after binding to their receptors has been 
described for several neuropeptides, including SS. Internalization of the hormone-receptor 
complex may playa role in regulation of receptor number of cell surface as well as in 
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honnone degradation and transport. Internalization of ligand-receptor complexes is a 
mechanism to induce desensitization of responsiveness to SS in order to keep hormone 
levels within the physiological range (44). Agonist-induced internalization of the SS-SSR 
complex may playa role in intracellular signalling as well. Moreover, phosphorylation of 
SSR may be an important mechanism involved in the internalization and desensitization of 
the receptors crable 1) (45,46). Desensitization of the inhibitory effect of SS on hormone 
release in vitro suggests that agonist-induced tachyphylaxis occurs directly at the level of the 
SSR expressing target cell and tachyphylaxis to the inhibitory effect of SS (-analogs) may 
occur in many different organ systems. SSR subtypes are differentially sensitive to undergo 
agonist-induced desensitization. 
Treatment with SS-analogs may induce either down- or up-regulation of SSR. Ligand-
induced up-regulation of membrane-expression of SSR subtypes has been observed in cell 
lines and primary cells cultures (47-49). In cell lines expressing SSR, it has been shown that 
prolonged agonist treatment resulted in up-regulation of the membrane expression of sst" 
sst, and sst, (49). 
Receptor regulation may playa relevant role in determining cellular responsiveness to SS as 
well as in investigating SSR-expressing tissues by the application of modern techniques 
based on receptor detection. Therefore, molecular mechanisms by which these 
phenomenon occur provide important new areas for future investigations. 
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DISTRlBUTION, ROLE AND FUNCTION OF SOMATOSTATIN RECEPTORS 
IN IMMUNE CELLS IN HEALTH AND DISEASE 
In the previous sections it has been discussed how the functional interactions between 
immune, neural and endocrine cells may play a relevant role in many physiological and 
pathological processes. Receptors for signalling molecules are shared between the three 
systems. Among these molecules, SS appeared to be one of the most representatives 
(Figure 1). In the present paragraph we will focus on the distribution and the functional 
role of 5S and SSR on immune cells. 
:N euroendocriile 
dispersed cells· 
Cells of immune 
system 
FIGURE 1. Schematic representation of how nervous, endocrine and immune systems can affect each other. 
Neural, endocrine and immune cells express receptors for neuropeptides, such as somatostatin. 
Neuroendocrine products coexist in neural, endocrine and lymphoid tissue. 
Since Bhathena and co-workers in 1981 firstly identified SS-binding sites on human 
mononuclear leukocytes (1), a nwnber of srudies pointed to the presence of SS and its 
receptors on immune cells and to the significance of this neuropeptide as an intersystem 
signalling molecule. The first line of evidence indicated that SS downwlllodulates a 
number of immune functions, like lymphocyte pro1iferation, Ig production and the 
release of pro-inflammatory cytokines such as interferon gamma (IFN-y) (for a review 
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see 2). Moreover, lymphoid organs are highly innervated by neurones containing peptide 
neurotransmitters and the nervous system can influence cells of lymphoid organs directly 
with release of its products from nerve endings or by regulating the local blood flow. 
Neuropeptides in the gastrointestinal tract may regulate in a paracrine fashion the function 
of cells of the gut-associated lymphoid tissue and other immune cells present in this 
compartment (3,4). Signals mediated by hormones and neuropeptides may influence 
different types of imm,me responses and the number and the functionality of receptors 
may increase during the activation of imnume cells, indicating that antigen-activated cells 
might be more susceptible to neuroendocrine signals (5). These and other peculiar aspects 
of this interactive system should be taken into consideration when evaluating the large 
number of in viw and in vitlO studies on the effects of SS and on the presence and 
significance of specific SSR in lymphoid tissues. 
SOMATOSTATIN RECEPTORS IN THE IMMUNE SYSTEM 
Distribution of somatostatin receptors on immune cells 
Animal malels Binding of fluorescent and "'[ labelled 5S has been found on murine B and T 
Peyer's patches- and spleen-derived lymphocytes (6). The use of the universal ligand, SS, 
did not allow the identification of the specific receptor subtypes involved in the SS binding 
on these cells. However, by using molecular biology techniques, it has become possible to 
identify 5SR subtype mRNAs in rat and mouse immune cells fl-10). Sst, mRNA was found 
in spleen and lymph nodes of adult Sprague-Dawley rats (9), and sst, and sst, mRNAs were 
selectively expressed in immtme cells from Lewis rats (8). Moreover, a previous study 
showed the presence of sst2 mRNA in rat thymocytes, and demonstrated that the activation 
of cells with phytohemagglutinin and interleukin 1 up-regtdates the expression of sst, 
mRNA (10). Murine T lymphocytes selectively expressed sst, mRNA fl). TIllS difference 
between rats and mice underlines the possibility of species variability in the distribution of 
SSR in immune cells and, as it will discussed in detail below, suggests that the rat may not 
be a suitable model to study the role of SS in human immune diseases. However, the 
different experimental conditions and the rapid turnover of neuropeptide receptor 
expression on immune cells may account for these conflicting results as well. 
H'IJ1WlS In the past decades, much evidence has been accumulated on the presence of SSR 
on cells of the hmnan immune and hematopoietic systems (for a review see 2). Bhathena 
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and co-workers showed 5S binding-sites on human imnllme cells invitroJ and demonstrated 
specific, low affinity binding of iodinated SS on enriched preparations of hlllUan 
monocytes and lymphocytes; the monocyte fraction showed a higher nlllUber of receptors 
compared with lymphocytes (1). Subsequently, using fluorescent SS, a single class of low 
affinity SSR was demonstrated on human mitogen-activated peripheral blood lymphocytes 
and two classes, one of low affinity and a second with higher amnity were detected on 
lymphoblastic leukaemia cells (11). No distinct predilection of SSR positive cells among 
peripheral lymphocytes was detected, whereas in this study resting lymphocytes, 
granulocytes and red blood cells did not show SS binding. A lurkat line of human 
leukaemic T cells and U-266 IgE producing myeloma cells also showed high and low 
affinity binding sites for fluorescent and radiolabelled 5S (12). In contrast with rhis last 
observation, Nakamura and co-workers did not find SSR on the lurkat cell line. However, 
they were able to detect a large number of SS binding sites on the human adult T leukaemic 
cell line MT-2 and the human T cell line Molt-4F, while a lower number on the Epstein-
Barr virus transformed B cell line Isk (13). The Kd value in the nanomolar range of SS 
binding on leukaemic cells and the greater proportion of SSR -positive cells in Peyer's 
patches (14,15) suggest that the receptor expression on immune cells might be related to 
the activation and/or proliferation state of these cells. 
By RT-PCR, a number of lymphoid cell lines of different origin (f cell, B cell, myeloma· 
and leukaemic origin) were shown to variably express sst1J sst) sst .. and sst, mRNAs, while 
sst, was absent (16). Moreover, sst, mRNA expression in nonnal hlllUan peripheral blood 
mononuclear cells was very low compared with the expression of this SSR subtype in cell 
lines and in peripheral blood mononuclear cells from leukaemic patients. In addition, sstz 
mRNA expression in normal peripheral blood mononuclear cells increased after activation 
with phytohemagglutinin, supporting the concept that the receptor expression pattern in 
human lymphoid cells may be dependent upon their state of activation. (!6). In addition, it 
has recently been demonstrated that the lurkat T·ceHline selectively expresses sst, mRNA, 
suggesting the involvement of this SSR subtype in the regulation of T-ceH function (17). 
Finally, sst, mRNA expression in a nlllUber of cell lines of the hlllUan T - and B celllineage 
has been found as well (18). Some caution should be taken, however, with the 
extrapolation of data derived from inunortalized cell lines, which may have characteristics 
different from primary lymphoid cells (19). 
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Neuropeptide receptor expression for vasoactive intestinal peptide, substance P and SS has 
been found in different organs of the human inunune system, such as lymph nodes, tonsils, 
Peyer's patches, spleen and thymus (14,15). The binding of the sst,.preferring ligand, [1251_ 
Tyr']-octreotide, was found mainly localized in the medullruy region in the thymus, but 
diffusely in the red pulp of the spleen and in the germinal centres of lymphoid follicles. The 
distribution and potential role of SSR in the human thymus will be discussed in the next 
chapters; however, it is anticipated that the architecture of the network between SS and its 
receptors in this lymphoid organ is rather complex. SSR subtypes are heterogeneously 
expressed on different cell subsets, and this is suggestive for a specific and important 
activity of SS in thymic microenvironment. 
Lymphomas alld thymic lIeoplasms 
Most of the information on SSR expression on human immune cells derives from in Uw 
SSR scintigraphy after injection of radiolabeled SS analogs. This technique has become of 
routinely use in the localization of neuroendocrine tumors and their metastases, and is 
discussed in detail in chapter IIll. However, in recent years SSR scintigraphy has been 
employed in visualizing other non-neuroendocrine tmnors expressing SSR, as well as 
granulomatous and autoimmune diseases (20-22). SSR have been detected inUw and i",i1>o 
in both T and B non-Hodgkin's lymphoma and Hodgkin's disease and their metastase.s 
(23-26). The in Uw imaging technique using [" l ln-DTPA-D-Phe l]-octreotide has 
contributed to optimize the staging procedures in patients with malignant lymphomas. In 
-utm autoradiography demonstrated the presence of SSR predominantly in the 
lymphoblastic areas of lymphomas, which represents the active part of these tumors. 
Moreover, the expression of sst2 and sstJ mRNA in non-Hodgkin's lymphomas and sst1 
mRNA in Hodgkin's disease has been detected (27). Somatostatin binding sites have been 
detected by in viM autoradiography using [ml -T yr']-octreotide on cells from patients with 
acute lymphoblastic leukaemia and acute myeloid leukaemia (28). Moreover, somatostatin 
and octreotide inhibited spontaneous leukaemic cell growth in approximately 33% of cases 
(28). Preliminruy data demonstrated a partial remission in 36% of patients with low-grade 
non-Hodgkin's lymphomas treated with octreotide (29). The accurate evaluation of SSR 
subtype status in lymphoproliferative diseases might become of value in the medical 
treatment of these patients when new subtype selective analogs will be available for clinical 
application and/or for radiotherapy with ~-emitting radionuclide-coupled SS analogs. 
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More recently, a high inviwuptake of e"In-DTPA-D-Phe'J-octreotide has been detected in 
patients bearing a thymoma or a thymic carcinoid (30-32). Although the functional and 
clinical significance of the in viw uptake the radiolabelled SS analog in these tumors is 
unclear so far, the characterization of tumor SSR pattern might help to explain the 
successful treatment with the SS analog octreotide reported in two thymoma patients 
(32,33). In chapter III prelirninaty data on the characterization and potential significance of 
SS and specific SSR subtypes in thymic tumors will be illustrated, with special emphasis on 
the role played by different subtypes in determining the uptake of radiopharmaceutical SS 
analogs. 
Autoimmune and granulomatous diseases 
A number of autoinunune and granulomatous diseases (Table 1) have been shown to 
TABLE 1. AutoimrTIlmc and granulomatous diseases expressing 
somatostatin receptors. 
AutoinmlUne diseases Granulomatous diseases 
Arthritis 
Rheumatoid arthritis 
Systemic lupus erythematodes 
Sarcoidosis 
Henoch-Schonlein purpura 
Sjogren's syndrome 
Ophthalmic Graves'disease 
Autoimmune uveitis 
Ulcerative colitis 
Sarcoidosis 
Tuberculosis 
Wegener's granulomatosis 
Oahn's disease 
Aspergillosis 
express SSR in viw and in uno 
(34-36). Affected joints of 
patients with rheumatoid 
arthritis have been clearly 
visualized during in viw SSR 
scintigraphy with [IIIIn-DTPA-
D-Phe1]-octreotide, and in vitm 
autoradiographic studies have 
shown SSR mainly associated 
to the vascular compartment of the inflamed synovium (35,37). Recently the presence of 
SSR (1.e. sst,.) has been confirmed by inununohistochemisny using sst'A specific 
antibodies. SstlA immunoreactivity in the synoviwn of affected joints in patients with 
rheumatoid arthritis was observed not only on the endothelial cells of venules, but also on 
cells belonging to monocyte/macrophage lineage, as it was demonstrated by the co-
localization of sst", with specific markers, such as CD14 (38). Conversely sst", 
inununoreactivity did not co-localized with CD3, which is a specific marker for T 
lymphocytes (38). 
[IIIIn-DTPA-D-Phe'J-octreotide scintigraphy has been employed to visualize 
granulomatous lesions in patients with sarcoidosis, aspergillosis and \Xlegener's disease. 
Moreover, the uptake index of the radiotracer in patients with sarcoidosis has been 
reported to be lower or absent in patients scanned after successful treatment with 
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corticosteroids (34). These data suggest that SSR scintigraphy may contribute to the staging 
and the prediction of corticosteroid therapy in these patients and may optimize the choice 
of biopsy site in sarcoidosis (34). Another argument in favour of the significance of SSR 
scintigraphy in predicting and monitoring the outcome in patients undergoing 
corticosteroid therapy has been recently discussed for the treatment of Graves' 
ophtahuopathy with methylprednisolone (39). In fact, in patients showing the highest score 
at SSR scintigraphy} a significant improvement occurred in orbital indexes during treatment 
with the corticosteroid (39). This preliminary finding suggests that ['"In-DTPA-D-Phe'j-
octreotide scintigraphy may be considered a useful approach to select the patients for 
proper treatment with corticosteroids. 
SSR have been localized by in vilm autoradiography using [!2;I-Tyr'}octreotide in biopsies 
of lesions from patients with sarcoidosis and inflamed bowel disease(s) (34,40). In 
sarcoidosis the granulomas were specifically labelled in the region of epithelioid and giant 
cells, while in inflammatory bowel disease(s) mainly the endothelium of venules expressed 
somatostatin-binding sites (34,40). The presence of SSR in inflamed lesions of 
granulomatous and autoimnUllle diseases suggests an active role of the peptide in the 
pathophysiology of inflammation. The cellular localisation of sst'A protein in tissue biopsies 
from human inunune-mediated diseases has been recently investigated using a polyclonal 
antiserum directed against a consenred epitope in the intracellular C-terminal domain of the 
sstlA receptor. In biopsies from patients suffering from granulomatous diseases such as 
sarcoidosis and \'7egener's granulomatosis} sstlA expression was associated with cells of the 
mononuclear phagocyte lineage, including epithelioid cells and multinucleated giant cells 
within the granulomas (41). In none of the biopsies, sst'A expression was observed on T 
lymphocytes. 
On the basis of classical ligand-binding studies and RT-PCR studies it had previously been 
assumed that lymphocytes were the major cell types expressing sst2 in human irnmune-
mediated diseases (2,14). Based on more recent studies it seems that expression of sst2 in 
the human inunune system is mainly confined to cell subsets belonging to the monocyte-
macrophage lineage. 
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The presence of SSR on immune cells implies that they are able to show a functional 
response to the natural ligand. There is increasing evidence that S5 can influence the 
functions of immune cells, both in health and disease (for a review see 2). SS has been 
demonstrated to inhibit T lymphocyte proliferation and colony formation (42-44), although 
studies have shown a stimulatory effect on proliferation (2) and secretion of IL-2 by a 
human T cell line as well (IS). In addition, SS may display an inhibitOl), action on natural 
killer cell activity (45), as well as on the ~1-integrin-mediated adhesion of resting T-cells to 
fibronectin (46). 
In B cells, SS may have a modulatory activity on immunoglobulin secretion by plasma cells. 
SS inhibits IgE and IgG4 production, while the SS analog octreotide was shown to reduce 
the number of plaque-forming cells in mitogen-stimulated peripheral blood mononuclear 
cells (47,48). SS also possesses a modulatory effect on human monocyte function. In 
enriched monocyte fractions obtained from peripheral blood mononuclear cell~ the 
peptide has been shown to inhibit tumor necrosis factor-alpha (fNF-a). interleukin-lp (IL-
l~) and lL-6 secretion, as well as the chemotactic response to neutrophils. in parallel with a 
down-regulation of human leukocyte antigen-DR (HIA-DR) expression (49). Finally, 
short-term incubation with octreotide stimulates phagocytosis of latex particles by 
monocytes (50). 
SS may be involved in the regulation of immune cell functions via different pathways. 
Primary and secondary lymphoid organs contain nerve endings, which may release SS, 
strongly supporting a neuroendocrine modulation of inuutme functions by the 
neuropeptide via an alternative pathway as well (2,51). Moreover, like other classical 
regulatory peptides, SS immunoreactivity has been detected in lymphoid tissues, 
lymphocytes and monocyte/macrophage of different species, including humans (52-54). 
Although SS mRNA has been demonstrated only in the thymus and the spleen so far, these 
findings support the potential autocrinelparacrine regulatory role of the neuropeptide 
{55, 56). In order to derme such autocrine/paracrine actions better, the following chapter 
will focus on the in viho effects of SS, and of the SS analog octreotide, on proliferation of 
primary cultured thymic cells, as well as on the disturbances in the endogenous production 
of this neuropeptide. This latter event may be related to the pathogenesis of autoimmune 
and neoplastic diseases involving the thymus in humans. 
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Until now, few data are available on the cellular signalling mechanisms coupled to 55R 
activation in inunune cells. In peripheral blood mononuclear cells from healthy subjects 
and from patients with acute leukaemia, 55 inhibited adenylyl cyclase activity, however, 
only at very high, non-physiological concentrations (57). In a recent study, Cardoso and co· 
workers showed that 55 inhibits adenylate cyclase activity in mitogen-activated human 
peripheral blood mononuclear cells and J urkat T cells in a dose-dependent fashion at 
nanomolar concentration (15). In Jurkat T cells 55 stimulated cell proliferation and IL-2 
secretion. Considering that sst, was the only 55R subtype found to be expressed in this cell 
line, this effect may be mecliated via a functional sst, receptor negatively coupled to the 
adenylyl cyclase pathway. In the majority of the studies, the effects of 55 on immtme cell 
function, either on secretion, proliferation or on other functions, is "biphasic". This 
Antigen presentation ~ 
?! i PHQCYTES 
..... 
FIGURE 2. Potential mechanisms of action of somatostatin on immune cells. Somatostatin may inhibit cell 
proliferation and secretion. Somatostatin might playa role in regulating antigen presentation properties by 
cells of the monocyte-macrophage lineage, presumably in an inhibitory manner. 
phenomenon displays in a very narrow dose-range, with a maximal inhibitory effect at 
nanomolar concentrations, while a lower or absent effects is observed at higher 
(micromolar) concentration (17). This points to a very rapid desensitization of the 
receptors. The role of this "biphasic" response of immune cells to 5S is still unclear, but 
may involve receptor internalization with a subsequent down-regulation, an uncoupling 
from second messenger activation, or even the activation of different intracellular second 
messenger pathways via distinct 55R subtypes. 
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CoNCLUSIONS 
In conclusion, SSR subtypes are expressed on cell-specific subsets in the immune system. 
TIle expression of neuropeptide receptors on immune cells seems to be dynamically 
regulated and may depend on the traffic of these cells through and within lymphoid 
stmcture and homing in tissues. SS may regulate immune cell functions via different 
pathways. A suggestive and hypothetical pathway is proposed in Figure 2. However, further 
srudies are needed to clarify the role of the individual SSR subtypes. The synthesis and 
availability of new selective SS analogs (58) and antagonists may be of much help in this 
respect. 
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AlMs OF THE THESIS 
From the brief overview presented in the previous paragraphs it can be concluded that SS 
potentially represents an important effector molecule in the complex network of 
interactions between the neuroendocrine and the immtme systems. However, although SS 
is a highly conserved neuropeptide, which is widely distributed in the human body, a 
number of its functions are still poorly understood. Furthermore, the heterogeneous 
expression of the five SSR subtypes requires new knowledge not only abour the 
significance of its distribution pattern on specific cell subsets, but on their mechanisms of 
action as well. 
In the last decades the functional significance of SS and its receptors in the endocrine 
system has been extensively investigated, while recent studies focused on the functions of 
this neuropeptide in the cross-talk between the endocrine and the immune systems. The 
thymus is an organ in which this intersystem communication circuit is examplary 
represented. In this main lymphoid organ, precursors of T cells undergo a process of 
maturation and selection that ends with the constitution of the final T-cell repertoire. 
Alterations in this highly complex mechanism may result in disturbances of the immune 
homeostasis. 
At present, few and conrradictOlY data regarding the presence of SSR in the nonnal and 
neoplastic thymus are available. Moreover, most of this information derives from studies in 
animals, whereas data in humans are lacking. On this basis, the following questions were 
raised: 
A) First, which are the SSR subtypes expressed in the normal human thymus? 
Secondly, which impact might SS and its receptors have in the physiology of this 
primalY lymphoid organ and in the maintainance of the homeostasis between the 
different cell components? 
Taking into consideration some recent new insights, the studies carried out for this thesis 
primarily focus on the natural ligand and its receptor subtype distribution, as well as on 
their functional role in this complex organ. The cloning of the genes for the five SSR 
subtypes, together with the recent availability of antibodies raised against SSR subtypes 
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allow to study their cell.type specific distribution. Herein, fl) the distribution of SS and its 
receptors is investigated in the normal human thymus. The presence of SS and SSR 
subtypes will be investigated on the three main cell populations in the normal human 
thymus, namely thymic epithelial cells, thymocytes and macrophages using different 
techniques. Since SS acts via different receptor subtypes, b) the functional significance of 
specific SSRs expressed in the tissues, and in isolated and enriched cell preparations will be 
evaluated. The experiments mainly focus on the control of cell proliferation. 
In the microenvironmental and lymphoid compartments within the human thymus the 
neuroendocrine activities are considered of crucial importance for the homeostasis of the 
inuuune system. Since the thymus drives the generation of the T·cell repertoire, c) the 
intrathymic circuit involving SS, SSR subtypes and thymocyte maturation will be 
investigated and discussed. 
The thymus is an organ that undergoes a physiological age.dependent involution. The 
mechanisms regulating this phenomenon are poorly lUlderstood. Therefore, it is evaluated 
whether potential links exist between the presence and activity of SS and SSR within the 
human thymus and the physiological involutive process of this organ. At this purpose, d) 
the expression of SSR will be studied with two different techniques and will be correlated 
to the chronological age in a series of normal human thymus. 
B) The results of studies evaluating the role of SS and its receptors in thymus 
physiology raise a second series of questions related to their role in the pathological 
conditions of this organ, as well as to the consequences for diagnosis and therapy 
using targeted SS analogs. 
Considering the potential important functional role of neuropeptides in the regulation of 
the function of thymic celis, disturbances in their expression or in the expression of 
neuropeptide receptors might be involved in thymic diseases. Thymic tumors can be 
visua1ized by SSR scintigraphy using radiolabeled SS analogs. Since conflicting data are 
present in the literature on the expression of SSR in thymic tumors, an additional aim is to 
evaluate the presence and functional significance of SS and its receptor subtypes in thymic 
epithelial tumors. For this, fl) a paradigmatic case of thymoma, studied both in mo and in 
'linv, is firstly presented. Thereafter, b) the results of in'1iw SSR scintigraphy on a larger 
series of thymomas will be correlated with the distribution of SSR subtypes in these tumors 
evaluated in vitro. Additionally, using immunohistochemisuy and quantitative techniques, c) 
the heterogeneity of distribution as well as the level of SSR expression will be further 
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investigated in normal and abnormal hwnan lymphoid tissues, including the normal spleen 
and thymus as well as hyperplastic and neoplastic thymic tissues. The data from these 
studies might be potentially important to elucidate some of the conflicting data which exist 
in the literature on the role played by distinct receptor subtypes in determining the uptake 
of radiolabeled SS analogs in lymphoid tissues. 
These issues are important arguments to open the general discussion on the significance of 
SS and SSR subtypes in the physiology of the human thymus, as well as in pathological 
conditions involving this organ. Moreover, this latter aspect will include some 
considerations concerning the use of SS analogs in autoimmtme as well as neoplastic 
diseases involving the immtme system. 
SS analogs are currently used in clinical practice. Imaging techniques and medical therapy 
with available SS analogs are based on the selective afftnity of these analogs for distinct 
receptor subtypes. However, most of the data regarding thymic cells, and in general 
regarding the immune system, are derived from studies in transfected cells or from primary 
experimental cultures from animal models. In the general discussion, in the light of results 
from studies using hwnan tissues or cells, these studies will be revisited and discussed. 
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SOMATOSTATIN RECEPTORS 
IN THE NORMAL HUMAN THYMUS 
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THE THYMUS, GENERAL INTRODUCTION 
In this chapter, the results of investigations on the significance of 5S and its receptor 
subtypes in the human thymus are presented. The essential role of the thymus in the 
development of the immune system was demonstrated approximately 40 years ago. 
Nowadays, we should consider trus organ as an inumme·neuro-endocrine network from 
development to aging, and the interdependence of the neuroendocrine and immune 
systems and their communication circuit as well. 
STRUCTURE OF THE THYMUS 
The thymus is a central lymphoid organ in manunals, which plays a vital role in the control 
of the Urunwle system. The presence of the thymus and its functionality are required for a 
full establishment of Urununocompetence. 
The thymus is a bilobed gland derived from the third and fourth pharyngeal pouches. 
From its origin the organ descends to the anterior-superior mediastimun, where it normally 
lies in the prevascular space (1). Ectopic locations can be the cervical region as well as the 
posterior mediastinum (2). 
After birth, the thymus grows during the first year of life and normally reaches its peak size 
in early childhood. The organ has a typical arrow-head configuration with the two lobes 
cojoined along the midline. The thymus begins an involution process with age that exhibits 
a constant velocity during the first decade, then the velocity of involution decreases 
progressively (3). The most impressive change in the human thymus during aging is its 
nearly complete lipomatous atrophy (3). Although it is the most evident age-related change, 
the atrophy represents only a final state of the involution. It is preceded by several 
morphological events, which may have important immunological implications (3). It is 
important to underline that dnring adulthood most of the thymic tissue is replaced by 
connective and adipose tissues, although some functional tissue remains throughout life 
(3,4). Figure 1 shows a schematic and histologic representation of the age-related changes 
in the human thymus. Many stimuli (such as overexposure to radiation and some 
60 
chemicals) can cause accidental involution, and in these cases the organ is usually capable 
of regeneration if the offending stimulus is removed (4). 
The thymus has a typical morphology, is covered by a thin connective tissue capsule and 
lobulated by septa originating from it (Figure 2). The capsule contains blood and nervous 
supply. Septa, carrying vessels and nervous fibres, penetrate from the capsule into the 
central part of the organ designing the structure of cortex and medulla (Figure 2). These 
two regions can be distinguished because of the different density of lymphoid cells. The 
cell types are the same but their distribution within the lobules is not uniform. The 
septation of the thymus is not complete. Serial sectioning demonstrates that the different 
lobes and lobules are continuous with each other through bridges of parenchymal material 
(Figure 3). 
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FIGURE 1. Thymus histology at three different stages of physiological thymic involution. From the left to the 
right: 6 days old, 15 years old and 63 years old thymus. Top, haematoxylin/ eosin stained sections showing the 
sharp distinction between the dark-stained cortex and light-stained medulla (white and black arrows). Bottom, 
the scheme shows the division in true thymic epithelium, the site of activities for thymocytes maturation, and 
perivascular space, the site from where the involution starts, (prom: http/lwww.var.vet,uga.edu). 
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FIGURE 2. Hematoxylin! eosin stained section of human thymus clearly showing the structure of thymic lobules. 
The capsule is evident on the top of the figure as well as the septa containing blood vessels. The dark·stained 
cortex and light-stained medulla are evident as well. The diverse intensity of the coloring in the two regions is due 
to the different density of lymphoid cells, which are significandy more prevalent in the cortex. (From: 
http//www.var.vet.uga.edu). 
FIGURE 3. Hematoxylinl eosin stained section of human thymus at lower magnification compared to Figure 1. 
The lobules are easily visible and some cuts of the lobules (m red) appear like round lymphatic nodules. 
However, looking carefully at the whole section, many lobules (in green) are long and have extended pale 
medullary areas. These are characteristic for the thymus. The difference in shape of the lobules is due only to the 
sectioning area. (From: http//www.var.vet.uga.edu). 
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Blood vessels enter the thymus through the capsule, and travel along septa to the 
corticomedullaty border (Figure 4A), at which point they enter the parenchyma. Arterioles 
entering the thymus send capillaries to the cortex, which branch at the periphery and 
return. At the corticomedulhuy jlU1ction} postcapillary venules are found, which represent 
specialized sites of transit of matured lymphocytes into the blood. The vessels are 
surrounded by the perivascular space. 
The outer cortex houses many large lymphoid elements and blasts} while the inner cortex 
contains smaller lymphoid cells and a lower number of large lymphoid blasts (Figure 4B). 
The medulla exhibits small and medium-sized lymphoid cells, as well as its typical Hassall's 
corpuscles (Figure SA and B). 
CELL TYPES IN THE THYMUS 
The thymus has four priucipal cell rypes: thymocytes, the so called "lymphocytes of the 
thymus", which are the precursors of peripheral lymphocytes; few macrophages and 
dendritic cells, which are all cells of bone marrow origin. The fourth rype is a 
heterogeneous population of specialized thymic epithelial cells (TEe), which provide a 
supporting framework (the mrmd) for the parenchyma. 
Thymocytes, delldritic cells alld macrophages 
Most of the "lymphocytes in the thymus" are T-cells. In order to acqUIre 
inunlU1ocompetence, these cells must reside in the thymus for a period of time. 
Macrophages are interspersed among them, and can be identified as larger cells with 
vacuolar nuclei. Frequently coarse granules of undigested material may be present in the 
cytoplasm of macrophages. The bone marrow derived cells are differentially distributed 
between the thymic cortex and medulla. The cortex contains only immature thymocytes 
and scattered macrophages, whereas mature thymocytes, along with another small subset of 
thymic cells, the dendritic cells, and most of macrophages, are found in the medulla. This 
reflects the different developmental events occurring in the two main compartments of the 
human thymus. 
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TEC 
TEe are almost impossible to demonstrate in simple haematoxylin/eosin preparations) 
being obscured by thymocytes that cover them. Hence, it may be possible to miss them in 
currently used specimens as such, even though they are indeed present (Figure 4). 
FIGURE 4. Hematoxylin! eosin stained sections of human thymus. A) The red line runs roughly along the 
junction of the cortex with the medulla. Many mature thymocytes that emerge from the cortex enter the blood 
stream at this junctional area. The nuclei of epithelial cells are much more numerous in the medulla and visible in 
the medulla. B) The cortex of the thymus has many capillaries (C) but they are "tightn capillaries that are part of a 
blood.thymus barrier. At this low magrtification the nucleus of an epithelial (R) cell is hardly visible, while there 
arc thousands of small heterochromatic nuclei of developing thymocytes that give the thymus cortex its dark 
color. (Froip.: http//www.var.vet.uga.edu). 
A 
FIGURE 5. Hematoxylin/eosin stained sections of human thymus. A) View of the medulla of the thymus with 
epithelial cell nuclei labelled (R). It appears evident that many more of these cells are in the medulla. B) View of a 
thymic corpuscle (Hassal's corpuscle) in the medulla. In the background of lymphocytes (L) and epithelial cell 
nuclei (R). (From: http//www.var.vet.uga.edu). 
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The thymic sflrma is not fibrillar in nature, as is the stroma of other lymphatic organs. It is 
mainly cellular. TEC are branching and tree-like in shape, and put forth processes, 
supported by intracellular cytoskeletal elements. These processes come into contact with 
each other, and are held together at the points of contact with desmosomes. Most 
importantly to normal thymic function, these cells fottn a physical, cellular boundruy 
between the parenchymal thymocytes and the rest of the body. At the periphery of the 
cortex, subjacent to the capsule, and around all blood vessels, the processes form a 
'fNCin the murine thymic lobule 
FIGURE 6. Thymic nurse cell (INC) in murine th)'lTIUS is a particular lymphoepithelial complex, where one 
epithelial cell is closely associated with a variable number of thymocytes. The 'INC are located in the cortex. 
continuous cellular layer constituting the blood-thymus bartier, to limit exposure of the 
lymphocytes to blood· borne antigens. The reason for this arrangement is that the thymus 
has to be maintained as an immunologically protected site. Thymocytes here are 
undergoing maturation and specialization. TEe, together with macrophages and dendritic 
cells drive the maturation and differentiation of thymocytes into mature lymphocytes, 
through cell-to·cell contacts and via soluble products. Thymic epithelium is a 
heterogeneous tissue, and cells in different locations within the lobules may influence 
specific steps in thymocytes maturation. At least three phenotypically different types of 
epithelial cells are present in the thymus, the cortical TEC, medullruy TEC, and the 
subcapsular epithelium. However, it seems that more subsets may be distinguished and 
identified on the basis of different content and type of cytokeratin (5). Peculiar 
Iymphoepithelial complexes have been identified in murine thymic cortex and isolated in 
'1it>D (6). These are multicellular structures formed by one TEC that can contain many 
thymocytes, the complex has been called thymic nurse cell ('INC) (Figure 6). TNC can 
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create special conditions for thymocyte development and form a unique microenvironment 
where sophisticated interactions may occur. They offer an excellent model for the in'lino 
study of the intrathymic thymocyte migration mechanisms (7). Recent insights underline 
the important participation of extracellular matrix components, such as laminin and 
fibronectin and their respective integrin receptors VLA-4/VLA-5 and VLA-6, to the 
complex cascade of events leading in the maturation and selection of T ~'Itlphocytes (8-10). 
TEe may 1.mdergo degeneration, and organize themselves into concentric eosinophilic 
whorls of material, called thymic corpuscles or Hassall's corpuscles (Figure 5). These are of 
unknown function, and appear vel}' early in life. 
th)'lDocytes 
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FIGURE 7. Schematic reproduction of a thymic lobule. Thymocytcs during maturation are driven from the 
cortex to the medulla having in the mean time many contacts with a heterogeneous cellular network, 
including thymic epithelial cells (fEC), dendritic cells and macrophages. TEe represent a heterogeneous 
group with distinct subset of cells in the cortex and in the medulla. 
The schematic structure of a hunlan thymic lobule is shown in Figure 7. 
FUNCTION OF THE THYMUS 
Although both B and T cells derive from bone marrow stem cells, T cells do not 
differentiate in the bone marrow, but rather migrate at vel}' early stage to the thymus. The 
thymus provides the specialized microenvironment where receptor gene rearrangement and 
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maturation of T cells occur (11). Because T cells recognize foreign antigen only in the form 
of peptide fragments bound to molecules encoded by the major histocompatibility complex 
(MHC), only those T cells able to identify the body's own MHC molecules will contribute 
to adaptive immune responses. Thus, it is mandatory that each individual T cell is able to 
recognize foreign antigens bound to MHC molecules (self restriction). However, T cells 
should be unable to recognize self peptides (self tolerance). T cells are selected to fulfil 
these properties during their maturation in the thymus. Here, they undergo the two 
selective processes, the positive selection, in which they are screened for self MHC 
restriction, and the negative selection, which eliminates those cells specific for self antigens. 
The differentiation involves sequential expression of a variety of membrane markers and 
rearrangements of the T·cell receptor (fCR) genes (Figure S). 
In the thymus, the innnature T cells, thymocytes, proliferate and differentiate. The 
positively selected cells migrate to the T·cell dependent areas of peripheral lymphoid 
organs, such as spleen, lymph nodes and tonsil (11). This process persists throughout life, 
however, the number of developing elements decays with ageing. Together with 
differentiation, precursors of T cells interact with various components of the thymic 
microenvironment (11). During migration thymocytes follow a predisposed direction and 
are driven from the cortex to the medulla. In the first step, a&er a very active proliferative 
phase, thymocytes with high avidity are negatively selected and deleted by apoptosis, while 
those with intermediate avidity for recognition of MHc.self peptide are rescued and 
positively selected. Positive selection seems mainly mediated by TEC, whereas bone 
marrow·derived cells (macrophages and dendritic cells) essentially exert negative selection 
(11,12). 
The differentiation process involves sequential expreSSIOn and down~regulation of 
membrane proteins such as the TCR (coupled on the cell membrane with the CD3 
complex) and more molecules, including CD4 and CDS, which further define distinct 
stages of maruration (13). Most innnature and intermediate thymocytes, bearing the 
phenotypes CDlCDfCDS- and CD3+CD4+CDS" respectively, are located in the cortex, 
whereas mature CD3+CD4+CDS" and CD3+CD4-CDS+ can be found in the medulla 
(Figure S). Thymic microenvironmental cells influence thymocyte differentiation and 
proliferation vzd soluble factors, such as cytokines and thymic hormones (14-16). However, 
thymocyte-TEC interactions are bi-directional, products of thymocytes can modulate TEC 
functions as well (17,IS). 
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FIGURE 8. Thymocyte differentiation through thymic miroenvironement. Thymocytes migrate during 
differentiation from tlte cortex to the medulla. Bone marrow·derived thyrnocytes enter the thymus and 
undergo active proliferation. The ceUs start the process of maturation as triple negative (CDJ-CD4'CDS-), 
then they become double positive (CD3+(l)4+aJS+) and are fmally committed in single positive 
(CD3+CD4+ CDS- or CD3+CD4'CDS+) thYIIlocytes. The cell antigen receptor (fCR) is an heterodimer 
most commonly formed by (l. and ~-(:hains. TIle mature T cell has the phenotype expressing a marker 
called CD45RA, which characterizes T cells that have never been activated by antigen. 
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Macrophages, which are mainly located in the medulla and at the cottico-medullat)' 
junction, can also interact with differentiating thymocytes via membrane proteins and 
cytokines (11). These aspects emphasize the notion that several paracrine circuits involve 
the various cell networks within the thymic microenvironment. 
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Considering the role of irnmunomodulator attributed to several neuroendocrine factors and 
the bi-directional neuro-endocrine-immuno interactions via endocrine, paracrine and 
autocrine pathways, the various intrathymic cellular interactions described in the previous 
paragraph, as well as the development of thymocytes itself can be targets for neuropeptide 
activities. This concept is rather old, however, evidence for this concept was provided only 
in the last decades. 
The frequent association of acromegaly with thymic hyperplasia was established by 
pathologists at the beginning of the last centwy. In 1921, Harnmar showed that the thymus 
often involutes under the influence of various envirorunental or emotional factors, and 
pointed out that thymic hyperplasia is frequently associated with hormonal changes (e.g. 
castration, Graves' disease, Addison's disease, and acromegaly). Furthermore, the role of 
the pituitary in thymic growth was observed by Stuith in 1930. 
Several hormones, such as GH and its peripheral mediator IGF-I, PRL, ACIH and thyroid 
hormones as well as neuropeptides modulate the production of thymic hormones (1). 
These factors seem also to enhance the expression of extracellular matrix ligands and 
receptors, influencing the level ofTEC.thymocytes adhesion (1). These findings have been 
confirmed by the recent characterization of receptors for many of the above mentioned 
ligands on thymic cells (2-7). Special attention has been dedicated to intrathymic circuits 
involving the local production of GH and IGF-I and their activities on both the lymphoid 
and stromal compartments (4,5). Moreover, all these factors, as well as glucocorticoids, 
appear also to regulate epithelial cell growth in the thymus (8). More recently, 
glucocorticoids have been supposed to regulate the expression of MHC in the thymic 
microenvironment (9). PituitaI}' hormones, thyroid hormones, steroids, neuropeptides, 
such as VIP, SP, SS, and more recently melatonin, can indirectly and directly modulate 
thymocyte development, conveying positive and negative signals for thymoC)te 
proliferation (1,10). Moreover, consistent evidence that cytokine production by thymocytes 
may be under neuroendocrine control has been provided (11-13). 
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One of mechanisms much more studied is the control of intrathymic cell death mediated 
by steroids. In general glucocorticoids and, to lesser extend, sex steroids promote apoptosis 
of thymocytes, playing then a role in the selection of the T·cell repertoire (14.19). 
Interestingly, protection from apoptosis may be under neuroendocrine control as well. In 
fact, dihydroepiandrosterone may be able to rescue thymocytes from apoptosis induced by 
pharmacological doses of glucocorticoids ., viw (20,21). Also Vfl', as well as melatonin has 
been proposed as "protectors" of thymocytes from apoptosis induced by dexamethasone in 
Uim (22,23). 
Thymocyte traffic, in terms of entrance of precursors, driving processes within the thymus 
as well as exit from the organ, are apparently under neuroendocrine control (24·28). This 
appears of particular iruportance taking into consideration that an irubalance in this 
iruportant process may result in abnormal traffic of immature or wrongly selected cells 
towards peripheral lymphoid organs, which may lead to the development of autoimmune 
diseases. 
The intrathymic production of many of these factors which we have previously discussed, 
as well as the expression of their specific receptors have been characterized during recent 
years (fable 1). Thus, in addition to the classical endocrine pathways, paracrine and 
autocrine mechanisms are implicated in the influence of hormones and neurpeptides on the 
thymus (1). This strongly suggests that normal circulating levels as well as controlled local 
production of these factors are necessaty to preserve the homeostasis and the various 
biological functions related to both the microenvironmental and lymphoid cells of this 
important organ. 
However, the neuroendocrine control of the thymus is a much more complex 
phenomenon with a wealth of sophisticated mechanisms. In particular, the intrathymic 
biological circuit involving 0' sial production of mediators appears to be vel)' relevant in 
various aspects, including the influence of neuropeptides. Independent of which pathway is 
triggered, the neuroendocrine control of the thymus is articulated pleiotropically, with 
modulation in the expression of several genes in different celll)'pes. 
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Considerable research has now been focused on 55 and its receptors as clinical 
consequences of their local activity in the cross~talk between specific subsets of thymic 
cells in both normal and pathological events in the human thymus. 
TABLE 1. Hormones, neuropeptides and their receptor expression within the thymus. 
Effector IntrathE,!llc I?:roduction Receetor eXl?:ression 
"Classic" hypothalamic peptides 
=> GnRH + n.d, 
=> GHRH + + 
=> CRH + n.d. 
=> TRH + + 
=> ss + + 
"Classic" anterior pituitary homlOnes 
=> ACIH + + 
=> GH + + 
=> PRL + + 
=> ill + n.d. 
"CIa5sic" posterior pituitary honuones 
=> Vasopressin + + 
=> Oxytocin + + 
Steroids and thyroid homlOnes 
=> Cortisol + + 
=> Estradiol n,d. + 
=> Progesterone n.d. + 
=> Testosterone n,d. + 
=> Triiodothyroninlthyroxin n,d. + 
Miscellaneous 
=> Insulin + +/. 
=> Enkepholin + + 
=> J3-endorphln + + 
=> VIP + + 
=> PACAP n.d. + 
=> CGRP + + 
GnRH, gonadotropin releasing hormone; GHRH, growth hormone releasing hormonej CRH, corticotropin 
releasing hormone; TRH, thyrotropin releasing hormone; 55, somatostatin; ACIH adrenocorticotropin 
hormone; GH, growth hormone, PRL, prolactin; I.H, luteinizing honnone; VIP, vasoactive intestinal 
peptide; PACAP, pituitary adenylate cydase.activating polypeptide; CGRP, calcitonin gene.related peptide; 
n.d. not detected. 
Finally, many of the concepts related to the immunoneuroendocrine interactions occurring 
within the thymus may be extrapolated to the periphery and can be helpful to understand 
other still obscure mechanisms involved in the communication between these systems 
(Figure 1). 
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FIGURE 1. Neuroendocrine control of the thymus. The central and peripheral nervous system interact 
with the thymus via specific products and through the innervation; the endocrine system influences many 
thymic functions via its specific products ~ong loop circuits). However, the immuno-neuro-endocnne 
interaction in the thymus is based on the exchange of local paracrine signals as well (arrow circle). 
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SOMATOSTATIN RECEPTORS IN THE THYMUS 
INTRODUCTION 
A discussed before, thymic hormones and cytokines playa critical role in the proliferation, 
differentiation and selection of precursor cells along the T-cell lineage (1). Among the 
locally produced hormones and neuropeptides that may participate in an autocrine and 
paracrine manner to thymic functions, some have well-characterized actions, whereas SS 
has been identified, but not investigated in detail (2-8). 55-binding sites have been 
demonstrated in the thymus of adults and children ill vitlV (9,10). Moreover, ill vim the 
presence of 55R has been shown in thymic epithelial tumors (11-13). However, the precise 
localization of 55R, as well as the distribution of the different subtypes has never been 
investigated within the human thymus so far. 
Although, experimental models in animals have suggested the significant patticipation of 
55 and other neuropeptides in the activities of the thymus, the exact role of 55 in this 
contest is still obscure. The following sections will briefly illustrate the emerging clata 
regarding the potential role of 55 and its receptors in the regulation of thymic functions in 
animal models. In addition, the final paragraph will introduce preliminary observations in 
humans. 
SOMATOSTATIN AND SOMATOSTATIN RECEPTORS IN THE THYMUS 
Oassical regulatol}' peptides, such as 55, can be produced and may be involved in the 
regulation of cell functions in the thymus. These factors act directly on TEe and 
thymocytes, suggesting the existence of specific receptors on these cells. 
The presence of S5 rnRNA or immunoreactivity for S5 has been demonstrated in the 
chicken, rat and murine thymus (7,14,15). In both chicken and rat thymus the 
concentration of 55 was higher compared with the spleen, although 50 times less than that 
found in the periventricular region of the hypothalamus (15). 55-positive cells were found 
within the medulla, around the cottica-medullary jtmction and in a small subset of 
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thymocytes in the thymic medulla as well (15). Moreover, SS has been shown to exert an 
antiproliferative effect on concanavalin A-activated rat thymocytes (16), while not on 
human phythoemagglutinin {pHA)-activated thymocytes (17). A recent study demonstrated 
the expression of pro·SS in murine thymic macro phages, whereas no expression was found 
in thymocytes, dendritic cells and TEC (7). Furthermore, other pancreatic hormones such 
as preproinsulin, propancreatic polypeptide and proglucagon were found in other cell 
subsets in the thymus, indicating that these hormones are differentially expressed in mice 
(7). 
Sst, mRNA has been detected in murine resting thymocytes (18). TIlls seems to contrast 
with the expression in rat, where thymocytes selectively express sst, and sst, mRNAs (19). 
However, another study showed the presence of sst1 mRNA in rat thymocytes, and 
demonstrated that the activation of cells with PHA and IL-l upregulates the expression of 
sst, (20). Although the significance of the presence of specific SSR subtypes remains to be 
clarified, it seems that the activation of immune cells may result in modification of their 
SSR expression pattern. Moreover, the involvement of SSR in modulation of thymocyte 
proliferation and differentiation is arguable. 
In humans SS inhibits hormone secretion in virtually all neuroendocrine cell types, 
however, its biological significance in the thymus is still unknown. Intrathymic production 
of SS has been demonstrated (21,22). Endogenously synthesized regulatory peptides are 
supposed to be present in the vicinity of the receptor-expressing target cells. Reubi et al. 
first described the presence of SS-binding sites in the human thymus of both newborn and 
adult by autoradiography (9). The binding was mainly localized in the thymic medulla, 
where TEC are the predominant cell type. However, many cells in this area contain thymic 
hortnones, suggesting their neuroendocrine characteristic (23), and the diffuse and 
homogeneous labeling pattern within the thymic medulla could mean that other types of 
cells nlight contain SSR as well. 
Thymic cells are under the control of hormones and neuropeptides through specific 
receptors. In the human thymus, cortex and medulla display a low density of VIP receptors 
presumably associated with T cells, while it seems that epithelial cells in the medulla express 
SSR. In addition, blood vessels express substance Preceptors (10). These findings 
demonstrate a strong compartmentalization of neuropeptide receptors in lymphoid tissues 
and support the complex mode of action of neuropeptides in the inunune system. 
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Recently, modern nuclear medicine imaging techniques have been used to visualize in ui:o 
thymic neoplasms (11-13). Localization studies of 5SR on specific cell types within SSR 
positive tissues have demonstrated heterogeneity of receptor distribution. Howe/er, in 
many cases the precise cellular localization of the different subtypes remains difficult to 
establish. This limit appears especially evident in tissues formed by several different cellular 
components, like the lymphatic ones. Moreover, the expression of neuropeptide receptors 
on immune cells seems to be dynamically regulated and may depend on the traffic of these 
cells through and within lymphoid structure and homing in tissues. The recent availability 
of antibodies raised against selective peptide sequences of different SSR subtypes has 
allowed to document the distribution of the receptor proteins at the cellular level in 
transfected cells, animal tissues as well as in human pancreas and tumors by 
immunohistochemistty (24-30). With this new approach lymphoid tissues have been 
recently investigated for the expression of 55R subtypes as well (31.33). The main 
advantage of this technique is the possibility to localize the receptor proteins at cellular 
levels. 
In conclusion, multiple SSR subtypes are expressed on cell~specific subsets in the rat and 
murine thymus. No data are available on 5SR subtype expression in the human thymus. 
Moreover, 55 is locally produced in the thymus. 55, in a way similar to its well·known 
activity on almost all neuroendocrine cells, might modulate the functions of thymic ceUs, 
participating to the maturation of T lymphocytes. 
In tlus chapter, the results of investigations on the expression and function of SS and SSR 
subtypes in the different cell subsets of the lnuuan thymus are presented. 
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IN VITRO CHARACTERIZATION OF SOMATOSTATIN RECEPTORS IN THE 
HUMAN THYMUS AND EFFECTS OF SOMATOSTATIN AND OCTREOTIDE ON 
CULTURED THYMIC EPITHELIAL CELLS 
ABSTRACT 
Somatostatin (SS) and its analogs exert inhibitolY effects on secretive and proliferative 
processes of various cells w high afftnity SS receptors (SS-R). SS analogs bind with 
different affinity to the 5 cloned SS-R subtypes. Octreotide, an octapeptide SS analog, 
binds with high afftnity to the SS-R subtype 2 (sst,). SS-R have been demonstrated in'1iw 
and in vitm on cells from endocrine and immune systems. Among the lymphatic tissues, the 
thymus has been shown to contain the highest amount of SS, suggesting a local functional 
role of the peptide. 
\Y/e investigated the SS distribution and SS~R expression pattern in the normal human 
thymus using autoradiography, membrane homogenate binding studies and the reverse 
transcriptase polymerase chain reaction (RT-PCR). In addition, the effect of SS and 
octreotide on growth of culmred thymic epithelial cells (TEe) was smdied. 
By autoradiography, binding of [I15I-Tyr'J-SS-28 and [!2;I-Tyr'J-octreotide was detected in 
all 7 thymuses smdied. Specific [I15I-Tyr'J-octreotide binding was shown on membrane 
preparations from thymuses, while not from culmred thymocytes. RT-PCR showed the 
expression of sst!! sstlA and sst) mRNA in the thymic tissue, while sst I and sst2A mRNAs 
were found in isolated TEe. SS mRNA was present in thymic tissue and in isolated TEe. 
SS and octreotide significantly inhibited 'H-Thymidine incorporation in 3 of 3 and 6 of 6 
TEC culmres, respectively. The percent inhibition ranged from 38.8 to 66.8% for SS and 
from 19.1 to 59.5% for octreotide. 
In conclusion, SS mRNA and sstll sstlA and sst) mRNAs are expressed in the normal 
human thymus. Ct~tured TEC selectively express sst, and sst" mRNA and respond inwm 
to SS and octreotide administration with an inhibition of cell proliferation. These data 
suggest a paracrine/ autocrine role of SS and its receptors in the regulation of cell growth in 
thymic microenvironment. 
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INTRODUCTION 
Somatostatin (SS), a peptide hormone originally isolated from the hypothalamus as a 
growth hormonMeleasing inhibiring factor, has been found throughout the central 
nervous system where it predominantly acts as a neurotransmitter, as well as in widely 
distributed endocrine cells in other tissues (1-3). It has diverse biological effects on cellular 
function, including inhibitory- effects on secretive and proliferative processes and 
modulatOlY actions on the response of various cells to endocrine stimulation (2-4). The 
various actions of SS are mediated through 5 specific high affInity membrane receptors 
(SS-R) (5). These receptors have been demonstrated imiDO in normal and tumoral tissues 
by classical binding techniques, in situ hybridization and reverse transcriptase polymerase 
chain reaction (RT-PCR) (4,6-8). In addition, using radiolabeled SS analogs, several 
scintigraphic studies have shown the iuviw localization of SS-R-positive ulmors (9,10). SS 
analogs bind with different affInity to the 5 different SS-R subtypes (sstl_,). Octreotide, the 
most extensively studied SS analog, binds with high affinity to sst, and with lower affmity 
to sst, and sst, (5,8). Among the 5 subtypes, sst, seems the most important in mediating the 
antisecretive effect of octreotide (11). 
Like other regulatoty peptides found in the brain, SS has also been localized in lymphatic 
tissue (12). Among the lymphatic organs, the thymus from different species including the 
human has been shown to contain the highest anlOunt of SS, suggesting a modulatOlY role 
of the peptide in this organ (13-15). Furthermore, SS-R have been demonstrated i",dtm in 
various lymphatic tissues (16). Recently, a high in viw uptake of IllIn-DTPA-D-Phe l -
octreotide was shown in patients bearing thymomas and thymic carcinoids (17,18), and a 
successful treatment with octreotide was reported in one patient with thymoma (19). The 
presence of SS and SS-R in the thymus suggests their involvement in controlling the 
immuno- and/ Of neuroendocrine functions in this organ. Moreover, SS analog treatment 
of thymic tumors and related paraneoplastic diseases might represent a new therapeutic 
approach to these disorders. 
The present study was designed to investigate the expression and role of SS and SS-R 
subtypes in the nonnal human thymus. The receptor expression pattern in the thymuses 
was studied VI vitlV by SS-R autoradiography, membrane homogenate binding studies, and 
RT-PCR to identify SS-R subtypes. In addition, the illUDO effect of SS, octreotide, and the 
growth factors insulin-like growth factor I (IGF-I) and epidermal growth factor (EGF) on 
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cell proliferation was investigated in prima!)' hwnan thymic epithelial cell (TEe) cultures. 
Since fibroblasts often contaminate cultures of epithelial cells, we used a specific antibody 
to hlUnan fibroblasts (mAb AS02) coupled with magnetic beads for the selective removal 
of fibroblasts from these cultures. This new monoclonal antibody recognizes a human 
fibroblast-specific antigen located on the cell surface (20). 
METHODS 
Samples. Thymic tissues were removed routinely from 7 patients (age range, 1 month to 16 yr) to 
allow adequate exposure of the heart during cardiovascular surgery. Samples from these thymuses 
were used in the present study. The protocol was in accordance with the Helsinki Doctrine on 
Human Experimentation, infonned consent was obtained from patients or their parents. All 
samples were histopathologically HOnna} and were taken fresh at the opemtion, quickly frozen on 
city ice and stored at _80oe for autoradiography and RT-PCR studies. From 6 thymic tissues, 
specimens were also used for the establislunent of primaryTEC cultures. 
SS -ro:eptor aHtoradio;;tap'Y' Receptor autoradiogmphy was carned out as described by Reubi et a/., 
(21). Briefly, 10-micrometer thick cryostat OWlg CM3000, LeicJ, Gennany) sections of the tissue 
samples were mounted onto precleaned gelatin-coated microscope glass slides and stored at -80oe 
for at least 3 days before the experiment to improve the adhesion of the tissue to the slide. As 
radioligands, the SS analogs [mI·Tyr'}octreotide and [WI-T)T'}SS·28 (ANAWA Laboratories, 
\'(/'angen, Switzerland) were used. Specific activities of the radioligands amounted approximately 
2000 Cil mmol. To wash out endogenous 5S, the sections were preincubated at room temperature 
for 10 min in 170 mM Tris-HeI (PH 7.4). Thereafter, the sections were incubated for 60 min at 
room temperature in 170 mM Tris·Hd (PH 7.4),5 mM MgCI" 1% BSA, 40 ~g/ml bacitracin with 
[WI.Tyr'}octreotide (fmal concentration approximately 80-160 pmol/liter) or [I25I-Tyr'}SS·28 
(approximately 80-160 pmollliter). Nonspecific binding was determined in a sequential section in 
the presence of excess unlabeled Tyr3·octreotide (111M) or SS-28 (111M), respectively. The incubated 
sections were washed twice for 5 min in incubation buffer containing 0.25% BSA and once in 
incubation buffer without BSA. After a short wash with distilled water to remove salts, the sections 
were air dried and exposed to Kodak X·OMAT AR or HyperfIlm~H (Arnersham) for 3·7 days in 
X-ray cassettes. Histologywas perfonned on hematoxylin-eosin stained sequential cryoscctions. 
RT·PCR. Poly A' mRNA was isolated using ~abeads Oligo (dT)" (Dynal AS, Oslo, NOlway) 
from cell pellets containing approximately 1()6 cells or from approximately 50 mg frozen powdered 
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tissue that was grinded in a metal homogenizer cooled by liquid nitrogen. The cells were lysed 
during 2 min on ice in a buffer containing 100 nh\1 Tris-Hd (PH 8),500 nuVl LiCl, 10 mM EDTA 
(PH 8), 1% LiDS,S mi\[ DTT and 5 U /100 ~ RNA sIn (HI' Biotechnology Ltd., Cambridge, UK). 
The mixture was centrifuged at 14,000 rpm for 1 min to remove cell debris. To the supernatant 100 
fIt prewashed Dynabeads Oligo (dT)15 were added and the mixture was incubated for 5 min on ice. 
Thereafter, the beads were collected with a magnet, washed three times with 10 rn}.{ Tris.HCl(pH 
8),0.15 M LieI, 1 m.\1 EDTA, 0.1% LiDS and once with a similar buffer from which LiDS was 
omitted. Poly A + mRl"JA was eluted from the beads in 50 I-1l of a 2 mM EDTA solution (PH 8) 
during 2 min at 65°C. To avoid contamination by genomic DNA the isolated polyA+ RNA was 
subjected to a second purification by capturing the RNA on a fresh aliquot of prewashed 
Dynabeads Oligo (dT)15 and wasbing the captured RNA as above. Finally the captured RNA was 
washed once with buffer used for the reverse transcriptase reaction. 
cDNA was synthesized using the poly A' mRNA captured on the Dynabeads Oligo (dT)15 in a 
buffer containing 50 JTh\1 Tris-Hd (PH 8.3), 100 roM KCl, 4 JTh\1 DTT, 10 mM MgCI" 1 mM of 
each deoxynudeotide triphosphate, 10 units RNAsin and 2 units AMY Super Reverse Transcriptase 
(HT Biotechnology Ltd., Cambridge, UK) in a final volume of 20 fIl. TIllS mi.xture was incubated 
fori hr at 41 'c. 
One·tenth from each eDNA library immobilized on the paramagnetic beads was used for each 
amplification. The amplification reaction mixtures contained cDNA template, 0.5 units SuperTaq 
(HT Biotechnology Ltd., Cambridge, UK), 50 11M of each deoxynucleotide triphosphate (fIT 
Biotechnology Ltd., Cambridge, UK), 5 pmol of each of a pair of oligonucleotide primers specific 
for the human ssh-s receptor subtypes, the ~-actin gene or the human SS gene (see Table 1) in a 
buffer of 10 JTh\1 Tris-HCl (PH 9),50 roM KCl, 2 roM Mgd" 0.01% (wt/vol) gelatin, 0.1% Triton 
X-100 in a fmal volume of 50 !J1. The sequences of the primers for ssh_s are derived and/or adapted 
from Kubota et al. (8) and Wulfsen of .d. (22). The PCR reaction was carried out in a DNA thenna! 
cycler with heated lid (perkin Elmer Cetus Instruments, Gouda, The Netherlands). After an initial 
denaturation at 94°C for 5 min, the sanlples were subjected to 40 cycles of denaturation at 94°C for 
1 min, annealing for 2 min at 59°C and extension for 1 min at 72°C. After a fmal e~1:CllSion for 7 
min at 72°C, 10 , . .t! aliquots of the resulting peR products ,vere analyzed by electrophoresis on 1.5% 
agarose gels stained with etrudium bromide. 
Several controls were included in the RT-PCR experiments. To ascertain that no detectable 
genomic DNA was present in the poly A+ mRNA preparation (since the SS-R subtypes genes are 
intron-Iess), the eDNA reactions were also perfoffiled without reverse transcriptase and amplified 
with each prinler-pair. Amplification of the eDNA samples with the ~-actin specific primers served 
as positive control for the quality of the eDNA. To exclude contamination of the PCR reaction 
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mixtures, the reactions were also perfonned in the absence of DNA template in parallel with 
cDNA samples. As a positive control for the PCR reactions of the SS-R receptor subtypes, O.Olllg 
of human genomic DNA was amplified in parallel with the cDNA samples, As a positive control 
for the PCR of the tl-actin and SS cDNA aliquots of a cDNA sample known to contain SS (and t3-
actin) mRNA were amplified, because these primer-pairs did enclose introns in the genomic DNA. 
Table 1. Primers used for RT-PCRanalysis. 
Sequence (5'. 3') a Position b 
Sstl (forward) ATGGTGGCCCTCAAGGCCGG 754 
Sstl (reverse) CGCGGTGGCGTAATAGTCAA 1071 
SstlA (forward) TCCTCTGGAATCCGAGTGGG 709 
SstlA (reverse) TTGTCCTGCITACTGTCACT 1040 
Sst, (forward) TCATCTGCCfCTGCTACCTG 662 
Sst, (reverse) GAGCCCAAAGAAGGCAGGCT 882 
Sst, (forward) ATCTrCGCAGACACCAGACC 547 
Sst. (reverse) ATCAAGGCTGGTCACGACGA 869 
Sst, (forward) CCGTCTTCATCATCTACA= 596 
Sst, (reverse) GGCCAGGTTGACGATGTTGA 819 
Somatostatin (forward) GATGCTGTCCTGCCGCCTCCAG I 
Somatostatin (reverse) ACAGGATGTGAAAGTCTICCA 348 
~-actin (forward) ATCCTCACCCTGAAGTA= 190 
~-actin (reverse) GATCTCCTICTGCATCCTGT 951 
Size ofPCR 
product 
318 bp 
332 bp 
221 bp 
323 bp 
223 bp 
349 bp 
762bp 
a) The sequences of the primers for sst1.5 are derived and/or adapted from Kubota et ai, (8) and 
\'7ulfsen et a/, (22), b) The position is given of the 5' nucleotide of the primer relative to the ftrst 
nucleotide of the codine: reeion in the cDNA seQuence 
Cel/ dispersion and cell adtme. After the specimens were placed in HBSS supplemented with HSA 5% 
(Cealb', CLB, Amsterdanl, 111e Netherlands), penicillin (1Q5 UIL), fungizone (0.5 mg/L), blood 
clots and fibrous capsules were carefully removed and the specimens were dissected and washed 
several times with the HBSS + HSA. The minced tissues were enzymatically dissociated with 
collagenase (Sigma Chemical Co" St. Lewisj 2 mg/ml) for 1-2 h at 37°C, The dispersed cells were 
precultured for 5-7 days in 15 mg/cm2 collagen type I (Collagen S, type I, Boehringer Mannheim 
B.V., Mannheim, Germany) precoated 75-cm' flasks (Costar, Cambridge, MA) at a density of 5xl()6 
cells/flask in 10 ml culture medium The culture mediwn, the same used during the experiments, 
was MEM D-valine (Gibco BRL, Life Technologies LID, Paisley, Scotland) supplemented with 
10% PCS, penicillin (10' U/L), fungizone (0.5 mg/ml), L-glutaroine (2 mmoI/L). The pH of the 
medium was adjusted to 7.4. TIle cells were cultured at 3rC in a hmnid CO2-incubator. After this 
period, cell viability was detected by trypan blue exclusion and varied between 65 and 90%. The 
cells, which had not atta.ched to the flasks, mainly thymocytes, were harvested, 
The isolation of TEe was indirectly perfonned using sheep anti mouse IgG coated magnetic beads 
and a AS02 anti-human fibroblast printal}' antibody kit (Dianova GmbH, Hamburg, Germany). 
This mouse monoclonal antibody reacts speciftcally with membrane-bound protein of human 
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fibroblasts of different origin (20). The magnetic beads were coated with the specific primary 
antibody and mixed with the target cell suspension to form bead rosetted cells. Roseued cells 
(fibroblasts) were collected at the tube wall and isolated using a magnetic separator rack. For a 
complete negative selection, the supernatant, containing the cells which were not bound to the 
beads (fEC), were treated once again with the coated beads. These remaining suspension 
containing isolated TEe were used for the experiments, 
TEe (10,000-20,000 ceUs per well) were seeded in 1 ml culture mediwn in 24-well collagen type I 
precoated plates (Costar), and allowed to attach for 24 h. Then, tests substances were added, and 
the cells were incubated for 72 h. Proliferation was measured by adding 1 !lei of [mcthyPH]-
Thymidine (91 Cilmmol; Amersham, Houten, The Netherlands) for the last 24 h in each well. 
Thereafter, the mediwn was removed and the cells were washed twice with ice cold 0.9% NaCi 
solution and harvested using a 0.05% NH3 solution. These samples were exposed overnight to 10% 
trichloroacetic acid followed by another wash with 0.9% NaO solution. The cells were transferred 
to scintillation counting vials after solubilization in 1 11: NaOH and incorporated radioactivity was 
measured, after neutralization with Hel and the addition of scintillation fluid, in a liquid scintillation 
counter (Betamatic, Packard, Downers Grove, IL). For RT·PCR studies, TEe were seeded in 
collagen-coated flasks (see above) and grown to confluence. Thereafter, the cells were harvested 
and mRNA was isolated as described above. 
bnlllJOlOC)taixmical detct:tial 0/ keratin (»J adtmal TEe. For keratin staining, TEe were cultured on 
collagen-coated glass coverslips, The cells were ftxed for 10 min with methanol at the end of the 
incubation period, Cytokeratin staining was perfonned with a PAP Kit System (code K518; 
DAKO, Glostrup, Denmark). Staining for keratin was perfonned after each experiment in all TEC 
cultures studied. 
SS reapt(J( binding studies. The method of membrane isolation and the reaction conditions were the 
same as described by Reubi (23). Briefly, membrane preparations (corresponding to 30-50 flg 
protein) of tissue samples, freshly dispersed cells or cultured cells were incubated in a total volwne 
of 100 fll at room temperature for 60 min with increasing concentrations of [l25I-Tyr.l}octreotide 
with and without c-"{cess (1 flM) of unlabeled Tyr.l-octreotide in Hepes buffer (10 ru.\1 HEpeS, 5 mM 
MgCh and 0.02 g/liter bacitracin, pH 7.6) containing 0,2% BSA. After the incubation, 1 ml ice-cold 
Hepes buffer was added to the reaction mixture, and membrane-bound radioactivity was separated 
from unbound by centrifugation during 2 min at 14,000 rpm in a Eppendorf microcentrifuge. The 
remaining pellet was washed twice in ice-cold Hepes buffer, and the final pellet was counted in a y-
counter. Specific binding was taken to be total binding minus binding in the presence of 1 flM 
unlabeled Tyr3-octreotide. 
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Test sumta:nas. In all experiments SS·14 (Bachem Inc., Harmover, Germany) and octreotide 
(Novartis. BasIe, Switzerland) were used at a concentration of 10 nM, IGF·I (Bachem Inc.) at a 
concentration of 10 n..\1 and EGF (Bachem Inc.) at a concentration of 10 ng/m1. 
StatistKal analysis. Data are expressed as Mean±SEM, n = 4 wells per treatment group. All data were 
analyzed by ANaVA to determine overall differences between treatment groups. \'7hen significant 
differences were found, a comparison between treatment groups was made using the Newm.m· 
Keuls test. SS-R binding data were analyzed by the method of Scatchard. Receptor binding studies 
and RT·PCR experiments were performed at least twice. 
RESULTS 
Fibroblast-epithelial·cell separation and stailling for keratin in clIltllres of TEG. The 
cell selection system using a mouse monoclonal antibody to human fibroblasts coupled to 
magnetic beads enabled us to identify and eliminate fibroblasts from our cell cultures in 
order to obtain 95·100% pure TEe cultures. This purity was demonstrated by 
immunocytochemical staining for keratin in the cultured TEe. Figure 1 shows an example 
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FIGURE 1. Staining for keratin of thymic epithelial cells (fEe) cultured on coverslips for the same period 
as TEe used for the experiments. No fibroblastS {keratin· negative) are present. 
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of the staining for keratin of a TEe population that was used for the functional study (see 
below). Virtually no fibroblasts (keratin.negative) were present. 
SS and SS-R (sllbtype) expression. At autoradiography, [125I-Tyr"J-SS-28 binding was 
found in the 7 normal thymuses. Binding of the sst, subtype selective ligand [125I_Tyr']-
octreocide was in parallel positive in all these 7 cases (fable 2), and in agreement with a 
TABLE 2. Somatostatin and somatostatin receptor subtype expression in human thymic tissue as determine 
by somatostatin receptor-autoradiography and RT-PCR. 
Tissues Somatostatin receptor-autoradiography RT·PCR 
[125I-Tyt'}55·2S (l25I-Tr!3]-octreotide ssh sstlA sst, 55t4 sst5 55 
1. + + + + + + 
2. + + + + + + 
3. + + + + + + 
4. + + + + + + 
5. + + + + + + 
6. + + + + + + 
7. + + + + + + 
5S, somatostatin. The experiments were performed at least twice with identical results. 
previous study (16). Binding was not homogeneous and mainly localized in the medulla 
(Fig. 2). 
Using [125I-Tyr']-octreotide, specific binding was demonstrated on membrane preparations 
of thymic tissue, while no binding was found on the cultured thymocytes. Binding of [1151_ 
Tyr']-octreotide could be displaced with excess unlabeled Tyr'-octreotide. Scatchard 
analysis of the binding data revealed a single class of high affinity binding sites with an 
apparent K.! ranging from O.03±O.OI to O.7±O.1 nM and a low maximwn binding capacity 
(B..,,) ranging from 3.5±0.5 to 18.S±2.5 fmollmg membrane protein (fable 3). As a 
control for binding, rat brain cortex membranes were used. An example of saturation 
binding data with Scatchard analysis is shown in Figure 3. 
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FIGURE 2. Expression of SS-R in hwnan thymus. Photomicrograph of SSoR-autoradiography. A) hematoxylin-
eosin stained section; BJ autoradiogram showing total binding of [115IoTyr3}octrcotidc; C) autoradiogram 
showing nonspecific binding Qn the presence of 1 11M of Tyr3-octreotide). Bar, 1 mm. Identical expression 
patterns of SS-R were found in all cases that were studied. 
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FIGURE 3. Binding of [,15I.Tyr3}octreotide to a membrane homogenate preparation of a human thymus .• , total 
binding; +, non-specific binding in presence of 1 11M of Tyr3-octreotide; ., specific binding (total minus non-
specific binding). Inset: Scatchard analysis of the binding data (Kd, 0.5 nM and Bmn, 15 fmol/mg membrane 
protein; no, 4, Table 3). 
TABLE. 3. Somatostatin receptor expression in human thymic tissue determined by Scatchard analysis of 
[lHI-Tyr3}octreotide binding on membrane homogenates. 
Tissues 
4. 
5. 
6. 
Rat brain 
K, 
(nM) 
0.7±O.2 
O.OJ±O.Ol 
O.7±O.1 
O.9± 1.3 
[125I-Tyr3]-octreotide binding 
B= 
(fmol/mg protein) 
15.5±O.5 
3.5±0.5 
18.5±2.5 
196.5±46.5 
.KJ, dissociation constant; Bmu, maximum binding capacity. The data represent the Mean±SEM of two 
indipendent experiments. 
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By RT-PCR, 55, sstll sstlA and sst} mRNA expression was detected in all thymuses 
(example in Fig. 4; no.5, Table 2). Conversely, mRNAencoding for sst, and sst, was absent 
(Table 2; Fig. 4). In cultured TEC, RT-PCR analysis showed the presence of SS, sst l and 
sstlA mRNA, while in cultured thymocytes only mRNA for p-actin was detected Crable 4; 
Fig. 4). 
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FIGURE 4. Heterogeneous expression of ~~actin, sstl sstlA, sst) and SS mRNAs in the human thymus. 
Poly A+ mRNA was reverse transcribed and eDNA was amplified by PCR. PCR products of the SSh.5 
were separated on 1% agarose gel and stained with ethiclium bromide. 1, ~ -actin; 2, sstl; 3, sst2A; 4, ~J; 5, 
sst4i 6, ssts; 7, SS. M, 100-bp ladder; A) control; B) thymic tissue; C) thymic epithelial cells; D) 
thymocytes; (no. 5, Table 2). RT-PCR analysis of each tissue was performed at least twice with identical 
results. 
TABLE 4. Heterogeneity of somatostatin and somatostatin receptor subtype mRNA expression in 
cultured human thymic epithelial cells and thymocytes as determined by RT-PCRin 5 cases. 
Cell subset RT-PCR 
sstzA 55 @-actin 
TEC + + + + 
Thym~es - - - - . . + 
TEe, t)Wic epithelial cells; SS, somatostatin. Each case was evaluated at least two times in independent 
experiments and yielded identical results. 
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In vitro effect of SS, octreotide, !GF·! alld EGF 011 'H.TbYlllidille illcorporatioll ill 
cultured 'milia" TEe. SS (10 nM) significantly inhibited 'H.Thymidine incorporation by 
38.8, 61.1 and 66.8% respectively, in cultures of TEC derived from 3 different normal 
thymuses (Fig. SA). The SS analog octreotide (10 nM) significantly inhibited 'H.Th}midine 
incorporation by 38.7, 49.8 and 40.6% respectively, in these 3 cultures (Fig. SA), and by 
19.1, 48.2, and S9.5% in 3 other additional cultures of TEC (Fig. SB) derived from the 
series of thymuses which showed [125I.Tyr'J-octreotide binding at autoradiographic and 
membrane binding studies. IGF·I significantly stimulated 'H·Thymidine incorporation in 2 
out of 3 cultures and EGF significantly stimulated 'H.Thymidine incorporation in all the 3 
cultures in which were tested (fable S). Moreover, octreotide significantly inhibited EGF· 
stimulated 'H·Thymidine incorporation by 2S±S% in one culture in which it was tested 
(data not shown). 
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FIGURE 5. A) effects of SS and octreotide on JH-Thymidine incorporation in TEC cultures of 3 
different thymuses (nos. 1-3, Table 2). B) effects of octreotide on 3H-Thymidine incorporation in TEC 
cultures of 3 other thymuses (nos. 4-6, Table 2). Thymic epithelial cells were incubated in MEM + 10% 
FCS during 72 h in quadruplicate without or with 10 nM of the drugs indicated. Values are expressed as 
percentage of 3H-Thymidine incorporation by control cells and are Mean±SEM; 
*, p<O.OI w". control.~ octreotide; IIsomatostatin-14. Control values of 3H-Thymidine incorporation 
wer" 3743.8±221.9 (no.1), 897.1±18.6 (no.2), 492.0±23.0 (no.3), 410.5±2.1 (noA), 1347.3±14.6 (no.5), 
756.3±64 (no.6) epm. 
TABLE 5. Effects of IGF-I iU1d EGF on 3H-Thymidine incorporation in cultured thymic epithelial 
cells. 
Cell culture .lH-Thymidine (epm) 
incorporation 
ContrQI [GF·[ EGF 
4. 41O.5±2.1 562.2±24.4* 974.6±25.S t< 
5. 1347.3± 14.6 1624.8±75.3 3326.8±57' 
6. 756.3±64 993.5+89.3'" 4125.7+270.3* 
The data represent the Mean±SEM of 4 wells per treatment group. *, p<O.Ol 'tiS. rontrol. 
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DISCUSSION 
Neuropeptide honnones produced in the brain and gastrointestinal tract have been found 
in the thymus, and are involved in the complex pattern of interactions existing between the 
neuroendocrine and the immune systems in this organ (24). In fact, epithelial cell and 
thymocyte functions are influenced by different hypothalamic and pituitaty hormones. A 
network between these hotnlones, even locally produced, and the related receptors has 
been shown (25.28). A place in this network might be hypothesized for 55 and 55·R as 
well. 55·R have been demonstrated in various endocrine and lymphatic tissues by classical 
biochemical binding studies (4,6,7,16). In addition, 55 has been demonstrated in the 
thymus from different species including humans (12.15), where it seems to be involved in 
the main function of the gland (12,13). However, the influence of 55 and 55·R on the 
regulation of TEC function had not been studied so far. 
In the present report, we studied the distribution and the expression of 55·R subtypes and 
55 in 7 nonnal hmnan thymuses. We first demonstrated specific [125I·T~}octreotide 
binding on c'Y0stat sections from thymic tissue, mainly in the medulla, which is the thymic 
compartment where the TEe is the predominant cell type, as well as in thymic tissue 
homogenates. Furthermore, we characterized the SS-R subtype expression in the same 
thymuses that were used for receptor binding studies. In htullan thymic tissue, we found by 
RT·PCR the presence of mRNA encoding for sst, and sst'A and sst). The expression of the 
subtypes appeared heterogeneous on the different cell subsets. In fact, we found a specific 
binding of [125I.T~l-octreotide on membrane preparations from thymic tissue, while no 
binding was found on cultured thymocytes. Interestingly, RT·PCR showed the selective 
expression of sst, and sst" on the cultured TEC, while neither 55·R subtype was found on 
cultured thymocytes with this technique. Sstl and sst2A seem stronger expressed in the 
cultured TEC compared to the thymic tissue, because with the selection method used to 
establish primary TEC cultures, an enrichment of 55·R·expressing TEC was obtained. 
Again, it should be emphasized that the cultured thymocytes, which represent the major 
cellular component of the thymus, did not express any 55·R subtype. Moreover, the finding 
that 55·R are expressed on only a subset of the cells in the thymus also explains the 
relatively low 55·R levels measured by receptor binding studies on membrane homogenates 
of the whole thymic tissue. Finally, this heterogeneous 55·R expression partern in the 
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human thymus may also explain the apparent discrepancy between the SS-R levels in the 
thymic tissues and the maximal inhibitoty effect of SS and octreotide on TEe proliferatiolL 
Furthermore, TEe seems to be the major site of 55 production in the normal human 
thymus. In fact, by RT-PCR we demonstrated the presence of mRNA for SS in isolated 
TEe from all the thymuses of the present series. Because our study showed the existence 
of a specific SS-R subtype distribution pattern as well as evidence for endogenous SS 
production in the human thymus, we also studied the effects of SS and the SS analog 
octreotide on TEe proliferation. At this purpose, we established pure epithelial cell 
cultures, demonstrated by staining for cytokeratin that showed 95-100% cytokeratin-
positive cells in all the cultures. In these human TEe cultures, we observed a significant 
inhibition of cell proliferation by SS and octreotide in all cases. 
The heterogeneity of distribution of SS-R subtypes on specific cells, in combination with 
the endogenous production of SS suggest an important and dynamic regulatoty role of this 
peptide in the human thymus. The data of the present study indicate that SS may exert a 
paracrinel autocrine inhibitory action. TIllS effect seems to be mediated by the sst2A and/or 
sst" which are selectively expressed on cultured TEe. The binding of SS or its analogs to 
these receptor subtypes is associated with an activation of intracellular tyrosine 
phosphatase activity (29,30). Moreover, sst]A is also linked to cell membrane potassium and 
calcium channels in a manner that ligand binding influences the intracellular concentration 
of these ions and the cell membrane polarization (31). 
Although we did not investigate the expression of SS-R and the effect of SS analogs on 
thymic tumoral cells, it can be suggested that a disturbance in this pathway may playa role 
in the pathogenesis of neoplastic and related autoimmWle diseases in the human thymus. 
Recently, a high in vim uptake of 11l1n-DTPA-D-Phe1-octreotide was reported in patients 
bearing thymic neoplasms (17,18) and a successful treatment with octreotide was reported 
in one patient with thymoma (19). This effect might be mediated by SS-R. Although in a 
previous study no invitm evidence of SS-R has been found in 4 thymomas, it is well known 
that there is a considerable heterogeneity between and within differentiated hlmors with 
respect to the density and the specificity of SS-R binding sites (32). 
\Y/e also demonstrated the expression of sst) in the nonnal human thymic tissue, while sst) 
mRNA was undetectable in cultured TEe. This may be explained by the fact that this 
receptor subtype is expressed by a different epithelial cell subset or on macrophages. 
Emerging data regarding signal transduction pathways linked to SS-R showed a cell cycle 
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dependent induction of apoptosis by octreotide (33). Apoptosis seems signaled through the 
sst, and associated with dephosphorylation-dependent conformational change in wild.type 
p53 (34). Although controversial data about alterations of p53 expression have been 
reported in thymic epithelial tumors (35,36), octreotide-induced apoptosis might represent 
an additional mechanism involved in the regulation of cell proliferation in human thymus. 
Another important aspect involves the local production of growth factors and cytokines by 
TEe and thymocytes (27,28,37). In our study, IGF-I and EGF significantly stimulated in 
Utro TEe proliferation. Moreover, in a preliminaty experiment, octreotide significantly 
inhibited EGF·stimulated cell proliferation. Although an inhibition of the production of 
these factors might represent an indirect mechanism of action of SS and its analogs, a 
direct mechanism involving the phosphoprotein phosphatase activity associated to sst2 
could not be mled out (38). Further studies are required to investigate the precise 
mechanism of action of SS in inhibiting growth factors-stimulated TEe proliferation. 
TIlese fllldings suggest that the SS·R-mediated effects of SS and octreotide on TEe growth 
may act viii not mutually exclusive different mechanisms, supporting the physiological 
paracrinel autocrine role of SS in controlling cell growth in the human thymic 
microenvironment. A further conceptual aspect might be the implication of the role of the 
intrathymic production of SS in the main function of the thymus, namely the maturation 
and differentiation of T-lymphocytes. Moreover, a disturbance in these loops may be 
important in the pathogenesis of autoinunune and neoplastic diseases involving trus organ. 
In this respect, a better understanding of the functional significance of the presence of SS 
and SS-R subtypes in the human thymus might lead to new approaches in the medical 
management of these disorders. 
In conclusion, we have demonstrated a heterogeneous expression of SS-R subtypes within 
the human thymus. Furthermore, TEe respond in ,,1m to SS and octreotide administration 
with an inhibition of cell proliferation. These data, together with the evidence of other 
peptide hormones, cytokines and their receptors in the thymus, support the concept of the 
thymus as the organ where the interactions between the endocrine and the immune 
systems are mainly represented. Future studies should investigate the influence of SS and 
its analogs on local cytokine production, which is known to represent the other arm of the 
immuno-endocrine pathway. 
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QUANTITATIVE AND FUNCTIONAL EXPRESSION OF SOMATOSTATIN 
RECEPTOR SUBTYPES IN HUMAN THYMOCYTES 
ABSTRACT 
We recently demonstrated the expression of SS and SS receptor (SSR) subtype 1 (sstJ, sst" 
and sst, in normal human thymic tissue and of sst l and sst'A on thymic epithelial cells 
('fEe). We also found an inhibitOlyeffect of SS and octreotide on TEC proliferation. In 
the current study we further investigated the presence and function of SSR in freshly 
isolated human thymocytes, a heterogeneous cell population clisplaying clifferent levels of 
maturation. We firstly demonstrate specific high affinity [125I_Tyrll}SS_14 bincling on 
thymocyte membrane homogenates, although the number of binding sites is relatively low. 
By RT-PCR, sst" and sst, mRNA expression was detected. After separation of thymocytes 
into subpopulations, we found by quantitative RT-PCR that sst'A and sst, are differentially 
regulated in intermediatel mature and immature thymocytes. The expression of sst) mRNA 
is higher in the intermecliate/mature CD3' fraction compared with the immature 
CD2'CDY, while sst" mRNA is less abundant in the intermediate/mature CD3' 
thymocytes. In cultured thym0C)1es no SSR subtype mRNA was detectable. Since sst, is 
mainly expressed on intermecliate/mature thymocytes and most of these cells generally clie 
by apoptosis, it might be that sst, is involved in this process. SS-14 inhibited 'H-Th)ITlidine 
incorporation in thymocyte cultures, indicating the presence of functional receptors. The 
heterogeneous expression of SSR within the human thymus and the endogenous 
production of SS emphasize their potential role in the bi-directional interaction pathway 
between the two main cell components of the thymus involved in intrathymic T-ceH 
maturation. 
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INTRODUCTION 
The inunune and neuroendocrine systems cross talk by sharing ligands and receptors. 
Neurohormones modulate the function of lymphoid organs and are produced by inunune 
cells as well, thereby exerting a paracrine/autocrine action in immunoregulation (1). 
Receptors for different neurohormones, such as hypothalamic-pituitary and gastrointestinal 
hormones, are expressed by inunune and lymphoid accesso!}' cells (1,2). These 
neuroendocrine circuits seem to exert a pleiotropic control on the physiology of the 
thymus, the main lymphoid organ (3). Particularly, the intrathymic production of classical 
neurohonnones suggests that paracrine and autocrine interactions, mediated by these 
compounds and their respective receptors, influence both thymic lymphoid and stromal 
compartments (3,4). 
Somatostatin (55) is one of the neuropeptides implicated in neuro-imnumo-endocrine 
interaction (5). The wide spectn1m of actions of SS and the presence of SS receptor (SSR) 
expression in lymphoid organs implies a broad functional role of this peptide in the 
inunune system (2,5). 
We have recently demonstrated the expression of SS and of three clifferent SSR subtypes 
(sst) within the human thymus (6). Messenger RNAs encocling for sst" sst'A and sst, 
receptors were found in a series of normal thymic tissues. Sst, and sst2A were selectively 
expressed on cultured thymic epithelial cells (TEe) and both SS and its analog octreotide 
inhibited in vi/m TEC proliferation. No SSR subtype mRNA was detectable in 7-14 day-
cultured thymocytes (6), while recently, our preliminary data have demonstrated a low 
number of SS-bincling sites on freshly isolated human thymocytes (7). On the other hand, 
SSR are expressed on thymocytes of clifferent animal species (8-10), and in humans SS is 
known to modulate different functions of T lymphocytes, which directly derive from 
thymocytes (5). In fact, sst, mRNA has been recently demonstrated constitutively 
expressed in human resting peripheral T lymphocytes, while the mitogenic activation of 
these cells seems to induce the expression of sst, mRNA (11). Thymocytes are a 
heterogeneous cell popldation. In fact when progenitors enter the thymus from bone 
marrow they lack most of the specific T·cell markers. Most inunature human thymocytes 
are characterized by the presence of CD34 antigen (12). This antigen is highly expressed on 
the pluripotent stem cell in bone marrow and the expression climinishes through lineage 
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conunitment (13). The interactions with thymic microenvironment trigger the expression 
of T-cell specific surface molecules. Firstly CD2 is the marker of immature thymocytes 
when they do not express the TCR-CD3 complex or the coreceptors CDS and CD4 
(14,15). These cells are called "double negative" thymocytes and are a highly heterogeneous 
pool of cells that include several early stages in T-cell development (14,15). Thus, 
thymocytes undergo maturation through a series of stages that can be distinguish by the 
differential expression of the TCR-CD3 complex, CDS and CD4. CDlCD4'CDS' 
represents an intermediate thymocyte subset before the "double positive" CD4+CD8+ 
thymocytes stages (16). Finally the CD3'CD4'CDS' subset further differentiates into 
mature CD4' or CDS' single positive thymocytes (14-16). 
The current study was designed to investigate the presence and potential role of 55R in 
human thymocytes. The receptor expression partern was evaluated i",ino in freshly isolated 
thymocytes by 55R binding studies on membrane homogenate and by RT-PCR to identify 
and quantify 55R subtypes on different thymocyte subsets. In addition, the imino effect of 
55 and octreotide on cell proliferation was investigated in isolated human thymocytes. 
MATERIALS AND METHODS 
Samples. Thymic tissues were removed from 8 patients (age range between 3 months and 5 yr) to 
allow adequate exposure of the heart during cardiovascular surgery. Samples from these thymuses 
were used in the present study. The protocol was in accordance with the Helsinki Doctrine on 
Human Experimentation and infonned consent was obtained from the patients or their parents. All 
samples were histopathologically nomw and were taken fresh at the operation. 
Protaxl of the study. Thymocytes were freshly isolated from the S samples and used for binding 
studies 011 membrane homogenates with iodinated $$-14 and octreotide (nos. 1-8, Table 1), while 
thymocytes derived from 4 samples were separated in subpopulations for RT-PCR studies (nos. 
nos. 5-8, Table 1; see below). Thymocytes from 3 samples of the same series (nos. 5-7, Table 1) 
were used for the in uho primary cell cultures. 
CeI/ disp"";",, reI/ """,ali", and reI/ aJ/un:. Thymocyte, were collected using a fIlter chamber (NPBI, 
Emmer-Compascuum, The Netllerlands) and placed in RPMI-1640 (Gibco BRL, Life Technologies 
LTD, Paisley, Scotland) supplemented with 10% heat-inactivated FCS, penicillin (10; UIL) and 
fungizone (0.5 mg/L). The pH of the medium was adjusted to 7.4. Cell viability was determined 
before each study and was more than 95%. These thymic cell suspensions generally contain more 
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than 95% thymocytes, as it has been demonstrated by flow cytometty (FACS') and and-CD2 
antibodies, which selectively bind to thymocytes, in a series of nonnal pediatric thymuses (II). To 
confirm this we perfonned FACS' analysis in one case (no. 5, Table 1) using FACScan cytometer 
(Beckton Dickinson & Co., Erembodegem, Belgiwn) and anti-CD2 antibodies (Beckton Dickinson 
& Co.). Cytometty and additional fluo-conjugated antibodies were used to determine the 
proportion of the different thymocyte subsets and the monocyte-macrophage fraction (anti- CD3, 
CD34, and CDI4, alI from Beckton Dickinson & Co.). Thymic cells (10') were sorted by setting 
appropriate electronic gates with the dual-laser FACS' system {Beckton Dickinson & Co.) For RT-
PCR analysis, thymic cells were nrst depleted from the monocyte fraction (see below) and 
subsequently separated into subpopulations by using magnetic beads coated with specific antibodies 
(Dynal AS, Oslo, Norway). The cells were suspended in phosphate-buffered saline (PBS) 
containing 0.5% bovine serum albumin (BSA), and incubated with the coated beads in plastic tubes 
kept on ice for 30 min. By continuous rotation of the tubes, the cells and beads were kept in 
suspension. The tubes were then placed in a magnetic rack to separate the supematant from the 
beads-captured cells. The non-selected cells in the supernatant were used for the subsequent rounds 
of selection with appropriate antibody-coated beads. The beads-captured cells were washed 5 times 
with PBS containing 0.5% BSA, counted and evaluated for specificity by determining the 
percentage of cells rosetted by the beads, which was higher than 98% in all the cases. The 
thymocyte suspension was depleted from the monocyte fraction by using beads coated with CD14 
antibodies (CD14+). In order to isolate intennediate/mature thymocytes (CD3+), anti-CDkoated 
beads were used. The remaining cells (after a second round of depletion with anti-CDkoated 
beads) were further incubated with anti-CD2-coated beads to obtain the inuuature thymocyte 
fraction (CD2+CD3-). Very early thymocytes were isolated using anti-CD34-coated beads. 
Additional freshly isolated thymocytes, which did not undergo beads separation, (5 x 10& cells per 
well) were seeded in 1 ml culture medium in 24-well plates (Costar, Cambridge, MA). Then, test 
substances were added, and the cells were incubated for 24 h for functional experiments. Cell 
viability was constantly tested during the separation procedure as well as before and after functional 
studies, and was satisfactorily. 
SSR monhmne binding swdies. The method of membrane isolation and the reaction conditions were 
previously described (6). [I25I-Tyrll}SS-14 (Amersham, Houten, The Netherlands) and p25I-Tyr3} 
octreotide (Novartis Pharma, Basel, Switzerland) binding to the thymocyte membranes was 
analyzed. Briefly, membrane preparations (corresponding to 30-50 fIg protein) of fresh~' dispersed 
cells were incubated in a total volume of toO fI1 at room temperature for 30 min with increasing 
concentration of [t25I-Tyrll]-SS-14 or for 60 min with increasing concentrations of [WI-Tyr3} 
octreotide, with and without excess (111M) of unlabeled SS-14 or octreotide, respectively, in 
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HEPES buffer (10 m.\f HEPES, 5 mM MgCI, and 0.02 giL bacitracin, pH 7.6) containing 0.2% 
B5A. After the incubatioll, 1 ml ice-cold HEPES buffer was added to the reaction mixture, and 
membrane-bound radioactivity was separated from unbound by centrifugation during 2 min at 
14.000 rpm in an Eppendorf microcentrifuge. The remaining pellet was washed twice in ice-cold 
HEPES buffer. and the final pellet was counted in a 'i-counter (1470 \'(lizard, Wallac, Turku. 
Finland). Specific binding was taken to be total binding minus binding in the presence of 1 ~}".f 
unIabded SS·14 or ocrreotide. 
Ftmctimill studies. In all experiments 5S-14 (Bachem Inc., Hannover, Germany) and octreotide 
(Novartis Pharma) were used at a concentration of 10-13, 10-12, 10-10, 10-S, and 1(}6 M. After 24 h, 
proliferation was measured by adding I ~a of [methyPH}Thymidine (91 Cilmmol; Amersham) 
for the last 6 h in each well of the 24-well plates. Thereafter, the cell suspension was transferred to 
s-m.l tubes and precipitated with 10% trichloroacetic add and the pellet was washed once again in 
trichloroacetic acid. After solubifu.ation in 1 M NaOH, the cells were transferred to scintillation 
counting vials and incorporated radioactivity was measured, after neutralization with Hd and the 
addition of scintillation fluid, in a liquid scintillation counter (Betamatic, Packard, Downers Grove, 
IL). 
RT-PCR studies. RT-PCR was performed as previously described (6). Briefly, poly A' mRNA was 
isolated using Dynabeads Oligo (dTJ" (Dynal AS, Oslo, Norway) from cell pellets containing 0.5-
lxl()6 cells per sample. cDNA was synthesized using the poly A + mRNA captured on the 
Dynabeads Oligo (dl)25 as solid phase and ftrst strand primer. One-tenth of the eDNA was used 
for each amplification by PCR using primer sets specific for human sstl.S, S5 and hypoxantine 
guanine phosphoribosyltransferase (HPRl). Several controls were included in the RT-PCR 
experiments. To ascertain that no detectable genomic DNA was present in the poly A + mRNA 
preparation (since the 55R subtype genes are intron-Iess), the cDNA reactions were also perfonned 
without reverse transcriptase and amplified with each primer-pair. Amplification of the eDNA 
samples with the HPRT speciftc primers served as positive control for the quality of the cDNA. To 
exclude contamination of the PCR reaction mixtures, the reactions were also perfonned in the 
absence of DNA template in parallel with cDNA samples. As a positive control for the PCR 
reactions of the 55R receptor subtypes) 0.001 to 0.1 fig of human genomic DNA, representing 
approximately 300 to 30.000 copies of sst-template was amplified in parallel with the eDNA 
samples. As a positive control for the PCR of the HPRT and SS eDNA aliquots of a eDNA sanlple 
known to contain 5S and HPRT mRNA were amplified, because these primer-pairs did enclose 
introns in the genomic DNA. In the thymocyte cell preparations only sst2 and ssh mRNAs were 
detectable. In order to quantify sst2 and sst) mRNAs a quantitative RT-PCR was perfonned by 
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TaqMan ~ Gold nuclease assay (The Perkin-Elmer Corporation, Foster City, CA) and the ABI 
PRISM& 7700 Sequence Detection System (The Perkin-Elmer Corporation) for real-time 
amplification, according to the manufacturers instructions. The specific primer sequences that were 
used included: 
sst", fOlWard 5'-AT~GATGAAGACCATCAC-3', 
sst", reverse 5'-TGAACTGATTGATGCCATCCA-3' 
sst, fOlWard 5'-CTGGGTAACTCGCTGGTCATCTA-3' 
sst, reverse 5'-AGCGCCAGGTTGAGGATGRA-3' 
HPRT fOlWard 5'-TGCTTTCCTTGGTCAGGCAGTAT-3' 
HPRT reverse 5'-TCAAATcx::AACAAAGTCTGGCTT ATATC-3'. 
The probe sequences that were used included: 
sst", 5'-FAM-TGGCTCTGGTCCACTGGCCCTTTG-T AMRA-3' 
sst, 5'-FAM-CGGCCA=CTTCAGTCACCAAC-TAMRA-3' 
HPRT 5'-FAM-CAAGCITGCGACCTTGACCATCTTTGGA-TAMRA-3'. 
'The amount of SSt2 and sst) mRNA was detennined by means of a standard curve generated in each 
experiment from known amounts of human genomic DNA. For the determination of HPRT 
mRNA amoWlt, the standard curve was obtained by including dilutions of a pool of cDNAs known 
to contain HPRT. The amount of sst2 and sst) mRNA was calculated relative to the amount of 
HPRT and is given in arbitrary units. 
Statistical analysis. Data are expressed as Mean±SEM, n = 4 wells per treatment group. All data were 
analyzed by the ANOV A to detennine overall differences between treatment groups. When 
significant differences were found, a comparison between treatment groups was made using the 
Newman-Keuls test. SSR binding data were analyLed by the method of Scatchard. Receptor binding 
studies and RT -PCR experiments were performed at least twice. 
REsULTS 
SSR binding stlldy Using membrane homogenate binding, specific [mr-Tyr"}SS-14 binding 
was demonstrated on freshly isolated thymocytes in all cases examined (n-6). Binding of 
[mr-Tyr"]-SS-14 could be displaced with excess unlabeled SS-14. Scatchard analysis of the 
binding data revealed a single class of high affinity binding sites with an apparent K, 
ranging between 0.4±0.1 and 3.1± 1.0 nM and a low maximum binding capacity (Bmnl 
ranging between IO± 1.9 and 59±5.5 fmoles/mg membrane protein (fable I). As a control 
for binding, rat brain cortex membranes were used. An example of saturation binding data 
110 
with Scatchard analysis is shown in Figure 1. Using ["'I-Tyr'}ocreotide. no specific binding 
was detected on membrane preparations of thymocyte, (fable 1). 
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FIGURE 1. Binding of ['15I-Tyrll}SS-14 to a membrane homogenate preparation of human thymocytes . • , 
Specific binding (total minus non-specific binding in presence of 1 ~M of 5$·14). Inset: Scatchard analysis of 
the binding data (Kd, 0.43 nM and Bmrr. 10 fmol/mg membrane protein; no, 5, Table I). 
TABLE 1. Somatostatin receptor expression in human thymocytes detennined by Scatchard analysis of [1251_ 
Tyrl1J.somatostatin-14 and (1251_ Tyrl}octreotide binding on membrane homogenates. 
Samples (l25I-Tyrtl]-SS.14 binding 
Ko B= 
(nM) (fmoles/rug protein) 
l. 3.1±l.0 S9±S.5 
2. O.7±O.OS 1l± 1.5 
3. l.2±0.6 31±6.1 
4. n.p. n.p. 
5. 0.4±0.1 10±l.9 
6. n.p. n.p. 
7. 0.8±0.2 29±3.4 
8. 2.1±0.8 47±3.3 
rat brain l.4±0.2 469.3±89.1 
[125I-Tyr3J-octreotide binding 
n.p. 
0.8+ 1.1 
B~ 
(fmoles! mg protein) 
n.p. 
496.S±41.S 
S5-14. 50matostatin-14; KJ. dissociation constant; Baux, maximum binding capacity; -, undetectable; n.p., not 
perfomled. The data represent the Mean±sEM of at least two independent experiments. 
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FIGURE 2. Heterogeneous expression of S$ and sstl.5 mRNAs in hwnan thymocytes, Poly A + mFNA was 
reverse transcribed and eDNA was amplified by PCR. PeR products of the sst1.5 were separated on 1% 
agarose gel and stained with ethidiwn bromide. M, lOO-bp ladder; A) control; B) freshly isolated 
thymocytes; C) CD14+ cells; (no. 5, Table 1), RT·PCR analysis of each tissue was performed at least twice 
with identical results, 
TABLE 2. Heterogeneity of somatostatin and somatostatin receptor subtype mRNA expression in 
different fractions of hwnan thymocytes and CD14+ thymic cells as determined by RT·Pffi in 4 cases 
(nm. 5·8 Table 1). 
Cell subset 
Freshly isolated thymocytes 
CD)+ cells 
CD2+CD)· cells 
Cultured thymocytes 
CD14+ cells 
sst! sstlA 
+ 
+ 
+ 
+ 
RT·PCR 
sst) sst, sSt5 SS HPRT 
+ + 
+ + 
+ + 
+ 
+ 
SS, somatostatin. Each case was evaluated alieas! two tinles in independent experiments and yielded 
identical results. 
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SS and SSR SIIbt;pe "pression: By RT-PCR, sst,. and sst) mRNA expression was detected in 
freshly isolated thymocytes from 4 cases (nos. 5-8, Table I), whereas mRNA encoding for 
55, sst" sst, and sst, was absent (Fig.2B). No mRNA encoding for any 55R subtype was 
detectable in thymocytes after 7-14 days culture (data not shown), confirming our previous 
observation (6). In CD14+ cells the presence of only sst'A mRNA was detected (Fig.2e). 
RT-PCR of thymocytes after separation into immature CD2+CDJ and 
intermediate/mature CD3+ fractions revealed sst2A and sstJ mRNA expression in both 
subsets. Table 2 summarizes the results of RT-PCR analysis and an example is shown in 
Figure 2 (no. 5, Table I). Quantitative RT-PCR analysis revealed a higher number of sst) 
mRNA copies in the intermediate/mature CD3+ thymocyte fraction compared to the 
immature CD2+CD3' one (Fig.3A). Conversely, the number of sst'A mRNA copies was 
higher in the immature CDrmJ fraction compared to the mature CD3 + thymocytes in 3 
of 4 cases (Fig.3B). The sst/sst,. ratio increased with the level of thymocyte maturation 
(Fig.3e). Moreover, in one case (no. 8, Table I) we isolated the very early CD34+ 
thymocytes and we found that sst,. mRNA expression was higher (5.1 VS. 2.6 sst'A/HPR1), 
while sst) expression was lower (0.5 '<S. 12.1 sst/HPR1) compared to the immature 
CD2+CDl fraction. The method of beads separation showed that thymocytes were more 
than 95%, while CDI4+ cells were less than 5% among the filtered thymic cells, in all the 
cases examined. In order to confirm tltis finding we performed FACS~ analysis in one of 
these cases (no. 5, Table I) and the results are shown in Figure 4. Among these cells, 
thymocytes at ditterent levels of maturation yielded 95.8% (FigAA), CD14+ cells yielded 
3.4% and very early CD34 thymocytes yielded 1% (Fig.4B). 
These data are in agreement with other authors, which performed this evaluation on a 
larger series of age- and sex-matched pediatric thymuses (II). 
Effoct of SS and O(/Jrotide 01/ J H lIl)midine inrorJX!ration bl til)"IIXJ'es 55-14 significantly inhibited 
'H-Thymidine incorporation in all the 3 cnItures (nos. 5-7, Table I) of freshly isolated 
thymocytes in a dose dependent matmer. 
The inhibition was statistically significant at a concentration of 10"' (ranging between 45 
and 57%) and 10" M (ranging between 27 and 41 %) in all 3 cases, at a concentration of 10' 
10 M in 2 of 3 (21 and 41%, respectively), and at a concentration of 10'" M in I of 3 (26%) 
(Fig. SA-e). 
The 55 analog octreotide significantly inhibited )H-Thymidine incorporation only in 
culture of thymocytes at concentrations of 10" (43%) and 10' M (23%) (Fig. 5D-F). 
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CD2+CD3-, and intermedi:u:elmarure CD3'" tbymocytes calculated relative to the amount of HPRT and given in :arbitrary units. A) sst3/HPKf mRNA r:ui:; B) 
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FIGURE 4. Flow cytometric analysis of thymic squeezed cells. 1()& ceUs were labelled with fluorescein 
isothiocyanate- (FITC) and phycoerythrin- (PE) conjugated antibodies A) CD2+ and CD3+ cells were sorted 
after setting of the gates as indicated in the figure and 95.8% of cells were identified as thymocytes B) CD14+ 
and CD34+ cells were sorted after setting of the gates as indicated in the figure and 3.4% of cells were 
identified as monocytes (CD14 +), while 1% as early thymocytes (CD34 +). 
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FIGURE 5. Effects of somatostatin (A.q and octreotide (DoE) on 3H-Th)midine incorporation in thymocyte 
cultures from 3 different thymuses (nos. 5·7, Table 1). Thymocytes were incubated in RPMI-1640 supplemented 
with 10% heat-inactivated PCS, penicillin and fungizone during 24 h in quadruplicate without or with the drugs 
indicated at the concentrations of 1!}1J, 1!}12, 1!}10, 1!}S, and 1fr6 M. Values are expressed as counts per minute 
(cpm) and are Mean±SEM (n=4 well per treatment group). 
*, p<O.01 u. control; **, p<O.05 u. control. SS·14 .. and octreotide ~. 
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DISCUSSION 
TIle thymus is responsible for promoting the differentiation and maturation of lymphoid 
precursor cells into mature T lymphocytes. The developing T cells are embedded in an 
epithelial network known as the thymic stroma. Other cells of haematopoietic origin 
participate in constituting the complex architecture of this organ; these cells include 
dendritic cells and macrophages (17,18). Interactions between thymic stromal cells and 
thymocytes are mediated by direct contact and w soluble factors, and playa crucial role in 
T cell development (19,20). Among the soluble factors, neuropeptides have been 
demonstrated to be deeply involved in the regulation of thymic functions. The intrathymic 
production of classical hormones suggests that in addition to the endocrine circuits, 
paracrinel autocrine interactions may exist in the thymus, influencing both the lymphoid 
and stromal compartment of the organ (3). 
SS is a representative neuropeptide with a wide spectrum of actions (21). The biological 
effects of SS are mediated w five specific, high-affrnity, G-protein coupled receptors (22). 
The presence of the neuropeptide and its receptors has been demonstrated in the human 
thymus (6,23,24). We have recently described the expression of sst" sst" and sst, mRNAs 
in human thymic tissue. Cultured TEC selectively expressed sst, and sst'A mRNA (6). 
Conversely, in long-term cultured thymocytes SSR mRNA was undetectable (6), while SS-
binding sites were found on freshly isolated thymocytes (7). Sst, mRNA was detected in 
murine resting thymocytes (8), in contrast with the expression in the rat, where these cells 
selectively express sst, and sst, mRNAs (9). These differences poulted to species-specific 
expression of SSR subtypes in inunune cells. Moreover, another study showed the presence 
of sst, mRNA in fresh rat thymocytes, and demonstrated that the activation of these cells 
upregulates the expression of sst, (10). It should be mentioned that many extrinsic factors 
and changes in the microenwomental conditions might regulate the expression of SSR 
(25,26). SS itself could be involved in the regulation of receptor expression. SS induced an 
increase in its receptor binding and SSR subtype mRNA expression in GH3 pituitary cell 
line (27). 
In the present study, using freshly isolated thymocytes, we firstly demonstrated specific 
["'I-Tyr"}SS·14 binding on cell membrane homogenates, while [!2;I.Tyr'}octreotide 
binding was undetectable. The number of 55-binding sites was vel}' low. These thymic cells 
are a heterogeneous population mainly formed by intermediate/mature thymocytes (11-15). 
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Subsequently, we characterized the SSR subtype expression by RT-PCR. In freshly isolated 
thymocytes sstiA and sst, mRNA expression was detected, while in thymocytes after 7-14 
days culture, no mRNA encoding for SSR subtypes was detectable. Since in freshly isolated 
thymocytes are present cells at different level of maturation, we investigated whether sst2A 
and sst, mRNA could be differentially regulated and expressed in the different stages of 
maturation of human thymocytes. \VIe separated whole thymocytes into 
intermediate/mature C03+ and immature corCOl fractions, and by RT-PCR, we 
detected sstlA and sst, mRNA in both thymocyte subpopulations. However, by quantitative 
RT-PCR analysis we demonstrated the predominant expression of sst, mRNA in COl' 
thymocytes. These cells represent the subset of thymocytes, which have reached a higher 
level of maturation during the complex cascade of events occurring in the thymic network 
(28). Interestingly, sst, mRNA has been found constitutively expressed in peripheral T 
lymphocytes which directly derive from mature thymocytes (11). Conversely, a 
predominant expression of sstiA mRNA was found in the C02+COJ thymocytes, which 
are the immature fraction and, very interestingly, sst1A mRNA was also the predominant 
receptor in the vel)' early C034 + thymocytes, which belong to the most immature subset of 
lymphoid cells in human thymus. In fact, when progenitor cells enter the thymus from 
bone marrow, they lack most of the surface antigens characteristic of mature T cells. 
Thereafter the interactions with the thymic stroma trigger rapid proliferation and the 
expression of the first T-cell specific surface moleclde C02. The C02+COl thymocytes 
form in the developed thymus a small but highly heterogeneous pool of cells (29). The low 
proportion of this latter subset might explain the lack of binding of the sst,-preferring 
ligand [123I-Tyr'}octreotide at the study on thymocyte membrane homogenates. In 
addition, it should be considered that the number of SS-binding sites was vel)' low, in 
agreement with the presence of a low number of SS-binding sites on circulating human 
immune cells (11). On the other hand, the binding of the universal ligand [I2lI-Tyrtl}SS-14, 
which binds all 5 SSR subtypes, is likely due to the binding of this ligand to the sst, 
subtype, which is mainly expressed on the intermediate/mature cells, representing the 
major proportion of thymocytes. Most of these cells are destined to die as a consequence 
of failing selection (30). Cell death in the thymus occurs by a process known as 
programmed cell death or apoptosis, which is a common feature in many developmental 
pathways (30). The expression of the sst, on these cells is intriguing, since this SSR subtype 
is involved in agonist-mediated apoptosis (31). Conversely, since the immature C02+COl 
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thymocytes are intensively proliferating cells undergoing a rearrangement process, the 
predominant presence of the sstlA on this very small subset suggests the involvement of 
this SSR subtype in the early phase of thymocyte development within the thymus. These 
data provide the evidence for a strong compartmentalization of neuroendocrine peptide 
receptors in lymphoid tissue (2), as it is also shown by the expression of vasoactive 
intestinal peptide (VIP) receptors on murine and rat thymocytes (32). In fact, the two VIP 
receptors display a distinct distribution in different thymocyte subsets, suggesting that the 
expression of neuropeptide receptors could be developmentally regulated and v;rl!U?rsa (32). 
Finally, it is also noteworthy to mention that in CD 14' cells, which are cells belonging to 
the monocyte-macrophage lineage, the presence of only sst'A mRNA was detected. This 
finding is in agreement with our previous reports on the selective expression of this SSR 
subtype on human macrophages and monocytes (33,34, Lichtenauer-Kaligis EGR et al., 
unpublished observations). 
We have previously demonstrated that SS mRNA is present in human TEC (6). In the 
present study we found that SS mRNA was not detectable in thymocytes. SS has been 
shown to exert an antiproliferative effect on concanavalin A-activated rat thymocytes (35), 
while SS was inactive on human phytohaemagglutinin-activated thymocytes (36). In the 
present study, we found an inhibition of the 'H-Thymidine incorporation in early cultures 
of thymocytes during the administration of SS-14, supporting the presence of functional 
receptors on these cells. The inhibition of 'H-Thymidine incorporation by octreotide was 
statistically significant in only one out of the three cases, and only at high concentrations. 
This SS analog binds with high afftnity sst2A and with lower afftnity sst, and sst, (22). The 
possibility that at high concentration, octreotide acted vii the sst), or that a higher nwnber 
of sst2A-expressing cells were present only in the culture showing the inhibitOl), effect of 
the SS analog can not be ruled out. All together, these data suggest that SS produced by 
TEC may affect the thymocyte population in a paracrine manner. 
The heterogeneous expression of 5SR within the human thymus, together with the 
endogenous production of 5S and other neurohormones, emphasizes once more the role 
played by neuropeptide hormones in the human thymus. Finally, the maturation and 
selection of the T cell repertoire is one of the most intriguing processes and involves a 
number of factors. SS, likely produced by TEC (6), seems to affect both the lymphoid and 
microenviromental compartments of the thymus. TEe are known to drive the most 
important phases of T cell maturation and differentiation, however, thymocytes might 
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affect TEe functions as well (37). Thus, a bi·directional interaction pathway exists berween 
the rwo main cell components of the thymus, and SS might be part of this complex circuit. 
Moreover, SS is known to affect the production of immunoglobulins and interleukins 
(38,39), which are well recognized factors participating at the sophisticated and elegant 
process leading to the maturation of cellular immunity. In this light SS may represent an 
important molecule involved in the chain of events, resulting in the generation of T cell 
repertoire. 
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AGE-RELATED DECREASE OF SOMATOSTATIN RECEPTOR NUMBER 
IN THE NORMAL HUMAN THYMUS 
ABsTRACT 
a"'ptO'Il.6 
The thymus exhibits a pattern of ageing orientated towards a physiologic involution. The 
stntctural changes start with a steadily decrease of thymocytes, while no major variations 
occur in the number of thymic epithelial cells (TEe). The data concerning the role of 
hormones and neuropeptides in thymic involution are equivocal. We recently demonstrated 
the presence of somatostatin (SS) and three different SS receptors (SSR) subtypes in the 
human thymus. TEe selectively expressed SSR subtype 1 (sstJ and sst'A' In the present 
study we investigated whether SSR number is age· related in the thymus. Binding of the 
sst,-preferring ligand ['2lI-Tyr'J-ocreotide was evaluated in a large series of normal human 
thymuses of different age by SSR autoradiography and ligand binding on tissue 
homogenates. The score at autoradiography, as well as the nwnber of SSR at membrane 
homogenate binding (B.",J were inversely correlated with the thymus age (r~.O.84, 
P<O.OOl; r~-O.82, P<O.OOl, respectively). The autoradiographic score was positively 
correlated with the B~ values (r~0.74, P<O.OOl). Since TEe mUllber, in the age range 
considered, remains unchanged, the decrease of octreotide binding sites might be due to a 
reduction of sstlA receptor nwnber on TEe. The age~related expression of a receptor 
mainly involved in controlling secretive processes is in line with the evidence that the major 
changes occurring in TEe with ageing are related to their capabilities in producing thymic 
hormones. In conclusion, SS and SSR might play a role in the involution of the htuuan 
thymus. These findings underline the links between the neuroendocrine and the inunune 
systems and support the concept that neuropeptides participate in development of cellular 
inumm.ity .in hwnans. 
125 
Age-relata! e>.pression if Wl1at05ldtin nxeptor'S in tbe t),Y1lUS 
INlRODUCTION 
The thymus, the primaty lymphoid organ responsible for differentiation and maturation of 
the specific T cell repertoire, exhibits an ageing behaviour, which is unique because of its 
irreversible physiologic involution (1). This phenomenon is characterized by a progressive 
structural change of the gland, starting at an early stage of life. Lipomatous atrophy is the 
most evident age-related change in the thymus, although it represents the fmal state of the 
involution (2). The early stages of this process are essentially characterized by a steady 
decrease of the number of thymocytes, the lymphoid cellular component, and of thymic 
dendritic cells, while no major changes are found in the number of thymic epithelial cells 
(TEe), which represent the most relevant component of the thymic stroma (3). However, 
the human thymic epithelium is capable of undergoing sequential stages of maturation in 
the postnatal thymus (4). The factors regulating the involution process of the thymus have 
not been completely clatified yet. Particularly, contradicting hypotheses have been raised 
concerning the potential role of honnones and neuropeptides in this process. For instance, 
thymic involution is considered either dependent or independent from puberty (5,6). 
Because several neuropeptides are localized in lymphoid tissues, and because somatostatin 
(55) may influence cells of the immune system, we have recently searched for the presence 
of 5S and 55 receptors (5SR) in the normal human thymus (7). 55 and three different 55R 
subtypes (sst), sst!, sstllr, and sst), were expressed in the human thymic tissue, while sst! and 
sst" were selectively expressed on cultured TEC (7). Moreover, 5S and octreotide 
administration induced an in 'liau inhibition of TEC proliferation, which is presumably 
mediated by receptors of the sst" subtype (7). These data support the concept of a 
modulato'Yaction of 55 on cell functions within the thymus. In addition, a functional role 
of 55 and 5SR in the involution process of the thymus can be hypothesized as well. In 
order to evaluate whether the 5SR pattern shows an age-related change, we studied the 
binding of the sst,-preferring ligand ['''I-Tyr'}ocreotide in a large series of normal human 
thymuses of different age. SSR density was determined both by 5SR autoradiography and 
by ligand binding studies on tissue homogenates. The results were correlated with the 
chronological age of the thymuses. 
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METHODS 
SamfXes Thymic tissues were removed from 30 patients (15 males and 15 females, age ranging 
between 15 days and 21 years) to allow adequate exposure of the heart during cardiovascular 
surgery. Samples from these thymuses were used in the present study. The protocol was in 
accordance with the Helsinki Doctrine on Human Experimentation and informed consent was 
obtained from patients or their parents. All samples were histopathologically nonna! and were taken 
fresh at the operation, quickly frozen on dry ice and stored at -80°C for ligand-binding on cryostat 
sections and membrane homogenates. The 30 thymic tissue samples were divided in 5 different 
groups on the basis of an arbitrary age range: Group 1 (10 cases), 0-12 months; Group 2 (5 cases), 
13-24 months; Group 3 (5 cases), 25-72 months; Group 4 (5 cases), 73-120 months; Group 5 (S 
cases), > 120 months. 
ss roxptor binding (»2 CY)ostat sediws Receptor autoradiography was carried out as described by Visser-
Wisselaar et al., (8). Briefly, 1O-micrometer thick cryostat ijung CM3000, Leica, Gennany) sections 
of the tissue samples were mounted onto precleaned gelatine-coated microscope glass slides and 
stored at -80°C for at least 3 days before the experiment, in order to improve the adhesion of the 
tissue to the slide. As radioligand, the SS analog [I25I-Tyr3}octreotide (Novartis Pharma, Basel, 
Switzerland) was used. Specific activities of the radioligand amounted approximately 2000 
CiI mmoL To wash out endogenous 55, the sections were preincubated at room temperature for 10 
min in 170 m\1 Tris-HCI (PH 7.4). Thereafter, the sections were incubated for 60 min at room 
tempemture in binding buffer (170 mM Tris-HCl (PH 7.4), 5 mM MgCI" 1% BSA, 40 ~g/ml 
bacitracin) with [12SI-Tyrl]-octreotide (fmal concentration approximately 80-160 pmoles/litcr). Non-
specific binding was determined in a sequential section in the presence of excess unlabeled Tyr3-
octreotide (1 f1M). The incubated sections were washed twice for 5 min in binding buffer containing 
0.25% BSA and once in binding buffer without BSA. After a short wash in distilled water to 
remove salts, the sections were air dried and exposed to Kodak X-OMAT AR or Hyperfilin-3H 
(Amersham) for 3-7 days in X-ray cassettes. Histology was perfanned on hematoxylin-eosin stained 
sequential cryasectians. A sample was considered positive for [l25I-Tyrl}actreotide binding when 
the signal obtained in a control section was displaced by an excess of unlabeled actreotide by more 
than 50% (9). The binding signals obtained were analyzed densitametrically using a camputer-
assisted image processing system and quantified by calculating the ratios between the regions of 
interest delineated on the total (I) and non-specific (NS) binding sections, Using the TINS ratios, 
the amoWlt of binding in evety section was graded as negative [OJ, for TINS ranging from 0 to 1.9, 
positive [lJ, for TINS ranging from 2 to 3, and strongly positive [2J, forTIN5 greater than 3. 
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SS receptor binding on m8nbrane /xmoiPzates The method of membrane isolation and the reaction 
conditions were the same as described by Reubi (10). Briefly, membr.me preparations 
(corresponding to 30-50 ~g protein) of tissue samples were incubated in a total volume of 100 ~l at 
room temperature for 60 min with increasing concentrations of (125I-Tyr3]-octreotide without and 
with excess (1 flM) of unlabeled octreotide in HEPES buffer (10 rnM HEPES, 5 mM MgCb and 
0.02 g/liter bacitracin, pH 7.6) containing 0.2% BSA. After the incubation, 1 ml ice-cold HEPES 
buffer was added to the reaction mixture, and membrane-bound radioactivity was separated from 
tulbound by centrifugation duting 2 min at 14,000 rpm in an Eppendorf microcentrifuge. The 
remaining pellet was washed twice in ice-cold HEPES buffer, and the fmal pellet was counted in a 
v-counter (1470 \'(Iizard, Wallac, Turku, Finland). Specific binding was taken to be total binding 
minus binding in the presence of 11-'-M unlabeled octreotide. 
Statistical analysis Data are expressed as Mean±SEM. All data were analyzed by ANaVA to 
determine overall differences between groups. \'<'hen significant differences were found, a 
comparison between groups was made using the Newman-Keuls test. The comparison between 
categorical data among the groups was analysed using the Fisher exact test. The correlation study 
was performed by using non-linear or linear analysis calculating the Spearman or Pearson 
coefficients respectively, where appropriate. SSR binding data were analyzed by the method of 
Scatchard. Receptor binding studies were performed at least twice. 
REsULTS 
SSR billding on cryostat sectiolls Figure 1 shows an exemplaty case for each age group 
of the specific binding of the sst, subtype preferring ligand [125I-Tyr'}octreotide on cryostat 
sections of human thymus. At autoradiography, the binding was not homogeneously 
distributed but mainly localized in the medullaty region of the thymuses (pig. 1). Using a 
three-point-score, the amount of binding was graded as strongly positive (2) in 8/10 cases 
(80%) of group 1, in 115 cases (20%) of groups 2 and 3. The binding was graded as 
positive (1) in 2/10 (20%) of group 1, in 415 (80%) of groups 2 and 3, in 115 (20%) of 
group 4. The binding was graded as faint or negative (0) in 415 (80%) of group 4 and in 
sis (100%) of group 5 (fable 1). The percentage of cases with a grade 2 and 1 was 
significantly higher in the group 1 compared with groups 4 and 5 (1'<0.005) and in groups 
2 and 3 compared to groups 4 and 5 (1'<0.05). The mean values of total-to-non specific 
ratio (fINS) displayed a progressive decrease with the increasing age range in the 5 groups 
(pig. 3A). The mean TINS values were significantly higher in group 1 than in group 4 and 
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5 (1'<0.05). The decrease in the TINS values with the increasing age of the cases in the 5 
'fABLE 1. Somatostatin receptors in human thymic tissues as detennincd by somatostatin receptor-
autoradiography using (1251_ T yr3}octreotide. 
Age range groups 
(months) 
Score 
number of cases (%) 
1. (0-12) 0/10 (0%) 2/10 (20%) 8/10 (80%) 
2. (13-24) 0/5 (0%) 4/5 (80%) 1/5 (20%) 
3. (25.72) 0/5 (0%) 4/5 (80%) 115 (20%) 
4. (73.102) 4/5 (80%) 1/5 (20%) 0/5 (0%) 
5. (> 102) 5/5 (100%) 0/5 (0%) 0/5 (0%) 
a) 0, negative (fINS ranging from 0 to 1.9); 1, positive (TINS ranging from 1.9 to 3); 2, strongly 
positive (fINS greater than 3). 
different groups shows an exponential rather than a linear trend (Fig. 3A). Histology was 
normal in all the samples and no major structural differences were found between the 
different groups. 
SSR billdillg 011 membralle bomogellates Using [mI-Tyr'J-octreotide, specific binding 
was detectable on membrane preparations of all thymic tissues, except in 4 cases of group 4 
and 3 cases of group 5. Scatchard analysis of the binding data revealed a single class of high 
affinity binding sites with an average apparent K, of 0.6±0.1 nM. The maximum binding 
capacity (B""J was low with an average of 18.5±3.6 fmoles/mg membrane protein, in the 
cases with detectable [1251_ Tyr'J-octreotide binding. An example for each group of 
saturation curve with Scatchard analysis of the binding data is shown in Fig. 2. The mean 
values of B!Illl displayed a progressive decrease with the increasing age range in the 5 groups 
(Fig. 3B). The mean B~ values were significantly higher in group 1 than in group 4 and 5 
(1'<0.001). The decrease in the B= values with the increasing age of the cases in the 5 
different groups shows an exponential rather than a linear trend (Fig. 3B). As a positive 
control for ligand binding, SSR-positive mouse AtT-20 pituitary tumor cell membranes 
were used (K, of 0.19±0.03 nM; B= 705±64 fmoles/mg membrane protein). No specific 
binding was detectable on a proven SSR negative cell line and tissue (8). 
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FIGURE 1. SSR expression in human thymuses of different age. Exemplary cases. Photomicrograph of SSR·autoradiography: Group 1 (age range 
1~12 months); Group 2 (.age range 13·24 months); Group 3 (age range 25~72 months); Group 4 (age range 73"120 months); Group 5 (age range 
>120 months). A) hematoxylin-eosin stained section; B) autoradiogram showing total binding of [125I.TyrJ}octreotide; C) autoradiogr.un showing 
oon-soecific bindinQ" 6n the oresence ofl t.tM of TvrJ-octreotide). Bar. 2 mm. 
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FIGURE 2. SSR expression in hwnan thymuses of different age. Exemplary cases. Binding of {'25I_Tyr3} 
octreotide to a membrane homogenate preparation of hwnan thymuses: A) Group 1 (age, 3 months; Brrwr, 
54; Kd, 0.8); B) Group 2 (age, 14 months; BJ:Ij.J.~) 18; Kd. 0.3); C) Group 3 (age, 35 months; Bm .. ~, 8; KJ. OJ); 
D) Group 4 (age, 97 months; BJllll(, 2.7; Kd, 0.1); £) Group 5 (age, 144 months; BmlX, 1.1; K:!. 0.1). 
Saturation curves indicate the specific binding (total minus non-specific binding in presence of 1 11M of 
Tyr3-octreotide); In.m Scatchard analysis of the binding data; 11 Summary of the Scatchard analysis data. 
A, Group 1; X, Group 2;., Group 3;., Group 4; 0, Group 5. 
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Corre/atiolls A significant correlation was found between ligand binding studies on 
cryostat sections or on membrane homogenates and age of the thymus. In detail, the TINS 
ratios at autoradiography (r~.O.84; P<O.OOI) and the Bm~ values at membraue homogenate 
binding study (r~-O.82; P <Qool) were inversely correlated with the age of the thymus (pig. 
4 A and B). In addition, the TINS ratios at autoradiography were positive~' correlated 
with the B= values at membrane homogenate binding study (r~0.74; P<O.ool) (pig. 4 c). 
Conversely no correlation was found between the estimated Kd values aud the age of the 
thymuses aud between gender aud both TINS and B~, values (data not shown). 
A 
B 
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FIGURE 3. SSR expression in hwnan thymuses of different age. A) Total·to.non.specific (fINS) binding 
ratios values calculated at autoradiographic binding study on cryostat sections; B) Bm>:< values detected at 
binding studies on membrane homogenates of thymic tissues in the 5 groups_ Bars represent the value of 
TINS ratios and Bnu:< (fmoles/rug protein) and are expressed as Mean±SEMj *, P<O.05 and P<O.OOl vs. 
Group 1, respectively. Lines represent the exponential trend of the changes in TINS ratios and Brn.u with 
the increasing age in the 5 different groups of thymuses. 
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FIGURE 4. SSR expression in human thymuses of different age, A) Correlation between age and total·{O·non-
specific ratios values (fINS). B) Correlation between age and B= values; C) Correlation between TINS and BJ:lll..< 
values. TINS ratios and B= (fmoles/rug protein) values detected at binding studies on cry-ostat sections and 
membrane homogenates of thymic tissues of the 30 cases distributed per age (months), 
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DISCUSSION 
The involution of the human thymus with age is a complex phenomenon and remains 
poorly understood. The human thymus interacts with products of endocrine glands 
throughout life and although conflicting results have been reported, thymic involution 
seems in part dependent to age-related alterations in the interaction between the 
neuroendocrine activity and the thymus itself (5,6). Moreover, the intrathymic production 
of hormones and neuropeptides and the presence of specific receptors represent an 
autocrine/paracrine pathway, which, in addition to classical endocrine circuits, might 
modulate the activities of both the lymphoid and stromal components of tllls organ (11). In 
fact, TEC produce thymic peptides and other factors known to modulate the main 
function of the gland, namely the development of the T cell repertoire, and many 
hormones and neuropeptides may participate to this function by interacting vu specific 
receptors with both developing inunune cells and with TEC (12). However, the role of 
neuropeptides and their receptors in thymic involution is still debated. 
SS is a well-characterized neuropeptide with a wide spectnun of action and recent insights 
have strongly suggested that the thymus nilght belong to the list of its target organs (7,13-
15). The five different SSR subtypes recently cloned and characterized (16,17), show a 
tissue specific distribution. The majority of SS-target tissues express multiple SSR, making 
it difficult to understand the functional role(s) of the individual SSR subtypes. The most 
well known SS analog, the octapeptide octreotide, binds with high affinity to the sst, 
subtype (18). In the endocrine system, where they have been better characterized, SSR 
subtypes are involved in the control of hormone secretion and cell proliferation, exerting 
mainly inhibitOlY effects via distinct mechanisms (19,20). The sst, subtype plays a major 
role in this system. \XIhile in the endocrine system SSR activation leads to inhibitol)' effects, 
in the inunune system both stimulatol)' and inhibitory effects have been reported (21). 
Moreover, very little is know with the respect to the cellular signalling mechanisms coupled 
to SSR activation in inunune cells (22). 
In normal human thymus, we recently demonstrated the presence of three different SSR 
subtypes, sst,) sstlA and sst} (7). In TEC, sst l and sstZA were selectively expressed, and TEC 
seemed to produce SS, since SS mRNA was present in these cells (7). All together, these 
findings pointed towards an important role of the sst'A receptor in the human thymus, 
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which seems to be confirmed by the heterogeneity of the expression of this subtype among 
thymic cells (7). 
In the present study, we have found additional evidence for a functional role of the sst,. 
receptor in the thymus. This SSR subtype may be involved in the processes linked to the 
thymic age-related changes, since its expression undergoes significant changes with 
increasing age. In fact, using two different techniques, we observed an inverse relationship 
between the number of binding sites for the sst,-preferring ligand, [!2;I-Tyr'}octreotide, 
and the age of the thymus, the number of [1251_ Tyr'}octreotide-binding sites were 
sigrtificantly !Ugher in the younger subjects. T!Us fmding is in line with the recently reported 
evidence of an in vim thymic uptake of [IllIn-DTPA-D-Phe1}octreotide in the 3 youngest 
patients (ages, 4, 5 and 16 months) out of 11 underwent SSR scintigraphy to evaluate 
abdominal or pelvic neuroblastoma (23). Conversely, no thymic concentration of ellln-
DTPA-D-Phe1}octreotide was documented in the relatively older children of the same 
series and in a series of adult patients with thymic hyperplasia (24). In the present study, the 
ages of the thymus were inversely conelated with both the results of the autoradiograp!Uc 
studies on thymic ctyostat sections and the B= values measured at the ligand binding 
studies on tissue homogenates of the corresponding cases. Moreover, the score of the 
autoradiography was positively correlated with the values of the B=. While 
autoradiography is a semiquantitative method for the evaluation of the ligand binding, the 
B= value directly indicates the density of binding sites for a specific ligand expressed on 
cell membranes. Moreover, it should be pointed out that, at the ligand binding on 
membrane homogenates, the estimated Kd values were not correlated with the thymus age. 
T!Us suggests that the change in the number of SSR binding sites is not related to changes 
in receptor affInity. Considering that sst,. is mainly expressed on TEC in the medullaty 
compartment of the human thymus (7,13,15), it might appear that the reduction of the 
number of binding sites is related to the decrease in the number of sst1A -expressing cells. 
However, this seems unlikely, since the number of TEe, in the age range considered in our 
study, remains almost unchanged (2,3). In fact, little or no decrease in the number of 
keratin-positive cells has been demonstrated, while especially thymocytes, and to a much 
lesser extent, dendritic cells dranlatica1ly decrease in number during the ageing process (3). 
During postnatal development, the thymic epithelium displays a pathway of differentiation 
similar to that observed in other epithelial organs throughout the human body, rather than 
a real change in the number of its cellular elements (4). T!Us observation supports the 
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concept that the thymic epithelium is capable of undergoing sequential stages of 
maturation during fetal and postnatal thymic development. Moreover, even considering 
that at a certain point the number of TEe declines, contributing to the significant 
reduction of the octreotide-binding sites, we have obsetved a progressive decrease of the 
number of octreotide-binding sites starting after the ftrst years of life, when the number of 
TEC is still unchanged. Since two different techniques gave a comparable result, it is 
suggested that the decrease in the number of sst" occurs on TEe. Although in cultured 
thymocytes no mRNA encoding for SSR subtypes was detectable (7), we have recently 
demonstrated SSR binding on freshly isolated thymocytes (25). Preliminary RT-PCR data 
have shown the expression of sstlA and sstJ mRNAs in resting thymocytes. However, sstJ 
seems to be the SSR subtype predominantly expressed in the heterogeneous pool of T 
lymphoid cell precursors, whereas sstlA mRNA expression is limited to a very small subset 
of immature cortical thymocytes (unpublished observations). The recent evidence of a 
selective expression of sst, mRNA in peripheral human T lymphocytes (26) is in line with 
our obsenration in thymocytes, which are the natural precursors of circulating T cells. 
Although the inuuature thymocytes are localized in the cortical region of the human 
thymus, a contribution of their loss to the decline of octreotide-binding sites can not be 
fully mled out. However, it should play a minor role in this phenomenon because, 
according to the autoradiographic pattern, the decline of octreotide-binding sites occurs 
mainly in the medullary region of the thymus, where TEC are the predominant cell type 
displaying sst2A -binding. 
sstlA is the SSR subtype involved in controlling secretive processes in SS target cells. Thus, 
the reduction of sst" receptor on TEC might be in line with the evidence that the major 
changes occurring in these cells during ageing are related more to their functional 
capabilities in producing thymic honnones, rather than to modification in their number (3). 
The decrease in sstlA receptor numbers might be related to the production of substances 
modulating the thymus involution, as well as the maturation of T cells. Which is the 
factor(s) involved in regulating receptor expression needs to be further investigated. 
However, in the light of studies in which stimulation of neuropeptide receptors by their 
own ligand was shown to result in receptor internalization (27,28), it is possible that a 
downregulation of sstlA receptors might occur, as consequence of ligand-induced 
internalization. In fact, the sstlA receptor has been demonstrated to efficiently internalize 
bound ligand in many cell systems (29-31). Furthermore, it has been demonstrated in rat 
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brain that endogenous SS regulates cell surface sst" receptors (32). The presence of 
endogenous SS within the human thymus (7,33-37) might account for a regulation of sst'A 
receptor expression on TEC by this mechanism. Conformational changes and! or chemical 
alterations of the internalized receptor might explain why the exogenous ligand does not 
recognize its specific receptor (30). However, the influence of additional factors, like 
cytokines or other neuropepticles, can not be ruled out either in such a complex organ. It is 
known that hormones and neuropeptides can modulate TEC physiology exerting a 
pleiotropic action on thymic stroma. In fact, glucocorticoid, thyroid, and pituitary 
hormones can modulate extracellular matrix ligands and receptors (11). Moreover, the 
expression of receptors for neuropeptides, such as vasoactive intestinal polypeptide, 
appears to be developmentally regulated in several systems, including the thymus (38,39). 
In conclusion, the expression of sstlA is inversely correlated with the age of the human 
thymus. The receptor itself and, obviously SS, might playa role in the involution of the 
thymus, consequently affecting the main function of this organ. Although further studies 
are required to clarify this complex, but fascinating network between the neuroendocrine 
and the immune systems within the human thymus, our findings raise the possibility that 
neuropeptides may participate in the intrathymic maturation and differentiation of T cell 
repertoire, which leads to the development of cellular immunity in humans. 
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CHAPTER III 
SOMATOSTATIN RECEPTORS 
IN THYMIC TUMORS 
SWza/ostatiJl1£t:eptfJr sOlItigrapby 
SOMATOSTATIN RECEPTOR SCINTIGRAPHY 
In the last two decades increasing efforts have been undertaken to introduce peptide 
receptor scintigraphy for in vim application in patients bearing tumorS. The visualization of 
the tumor occurs after the intravenous injection of a radioactive peptide (ligand), which 
binds the receptor expressed on the membrane of cells. In general, the higher density of 
receptors on tumor cells compared with the normal tissues, or the high number of cells 
expressing the targeted receptor allows to discriminate between positive lesions and 
surrounding tissue. A gamma camera is used to visualize the accumulated radioisotope. 
Planar images can already depict a clear localization of the tumor, whereas tridimensional 
reconstruction of planar acquisitions by single-photon emission computed tomography 
(SPECI) may provide real maps of radioactivity within the target organ or tumor tissue. 
SSR have been demonstrated in a large number of hwnan tumors, mainly neuroendocrine 
tumors, which may express the receptors over l00-fold compared to the tissue of origin (1-
5). Since native SS in unstable and has a short half-life, synthetic analogs have been 
developed for clinical applications (6). Human SSR positive tumors show a high uptake of 
['IIIn-DTPA.D.Phe[j-octreotide at SSR scintigraphy (1). SSR scintigraphy using [[IIIn_ 
DTPA.D·Phe[j-octreotide has become a standard procedure in the work-up of patients 
with neuroendocrine tumors to obtain an accurate estimate of the spread of tumors. 
Besides that, SSR scintigraphy has been proposed to select candidates responsive to 
specific peptide treatment (3,7). Physiological accumulation of the radiopharmaceutical 
occurs in the spleen, kidneys, urinary bladder, liver, thyroid, salivary glands and pituitary 
gland (5). Of particular interest is the accumulation in normal organs that are known to 
express SSR, like spleen, pituitaI}' and to a lesser extent thyroid. Later in tills chapter, tills 
issue will be further discussed concerning the role of specific SSR subtypes in determining 
the uptake of the radioligand. 
[[IIIn-DTPA.D.Phe[j-octreotide is considered as a sst,-preferring ligand, which suggests a 
crucial role of sst2 receptor in determining the accumulation of radioactivity in tumor cells 
following internalization of the radioligand-receptor complex. Radiolabeled octapeptide SS-
analogs are internalized in a high amount by SSR-positive mouse and human tumor cells 
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(8-10). Evidence for a predominant importance of the sst, receptor in determining the 
uptake of the radiopharmaceutical ['"In-DTPA-O-Phe']-octreotide by SSR positive tumors 
is presented from studies showing that sst,-expressing cells internalize SS (11), as well as 
octreotide (1). However, on the basis of the high SS-internalization rates of the sst, and sst, 
subtypes, it cannot be excluded that sst, and sst, receptors might playa role as well (11). 
Apart from [IIIIn-DTPA-o-Phe']-octreotide other radiolabeled SS analogs, suitable for 
diagnostic or therapeutic applications as well, have been synthesized (5,12,13). Moreover, 
radiotherapy, as well as targeted chemotherapy, using S5 analogs is considered as a future 
effective and feasible approach to treat patients with advanced, metastatic SSR-positive 
neuroendocrine tumors (3,14,15). SSR scintigraphy has been successfully used to visualize 
sites of disease in patients with abnormalities of the immune system (16.20). Neoplastic 
and inflammatOlY lesions have been clearly visualized in lymphomas, granulomatous 
diseases and autoimmune diseases. The in vim evidence of SS binding sites using S5R 
scintigraphy opened a new field of interest for the role of SSR in the immune system. 
Moreover, the presence of SSR has been demonstrated inVltm in tissues belonging to the 
heterogeneous group of tissues and cells, which are formed the organs of the inumme 
system (21.23). An additional observation is the visualization of thymic epithelial tumors 
using ['"In-DTPA-o-Phe']-octreotide scintigraphy (24,25). This seems to have relevance 
for selecting patients, which may benefit from treatment with SS analogs (26). However, as 
previously discussed for the normal thymus (chapter II), these complex pathologic entities 
have not been accurately investigated so far. In the coming paragraphs, after an overview 
on the most recent clinicopathological findings on thymoma (chapter 111.2), the results of 
investigations on the distribution and relevance of SS and its receptors in this rather 
unexplored category of tumors will be presented. These studies start from the in uW 
evaluation of S5 binding sites in a large series of human thymoma by [IIIIn-DTPA-O-
Phet]-octreotide scintigraphy, followed by in vitro studies evaluating the expression and 
functional significance of SSRs in these tumors. 
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THYMIC EPITHELIAL TUMORS 
In the past, various types of neoplasms have been included in the spectnun of thymoma. 
These include the thymic localization of Hodgkin's disease and other categories of 
lymphomas, seminoma, thyrnolipoma, carcinoid and carcinoma (1~3). However, thymomas 
are a highly heterogeneous categol}' of epithelial thymic tumors. A strict definition of 
thymoma describes tllls entity as a tumor composed of cytologically bland, neoplastic 
thymic epithelial cells accompanied by variable admixture of benign lymphocytes. 
ClASSIFICATION 
In the beginning of the sixties, thymomas were histologically divided in 4 categories, based 
on the predominance and shape of the the specific thymic cell type, as well as on the basis 
of the lymphocyte/epithelial cell ratio. These four categories comprise spindle cell, 
lymphocytic thymoma, predominantly lymphocytic and predominantly mixed lymphoC)~ic 
and epithelial thymoma. However, these criteria generated considerable confusion. 
Therefore, thymic epithelial tumors have been recently classified by the World Health 
Organization (WHO) (4). Since several controversies occurred in the past concerning the 
classification and nomenclature of thymic epithelial tumors, the WHO based its own 
classification on a combination of letters and numbers (fable 1). However, it is useful to 
mention two other world~wide classifications that are still in use, i.e. the Levine & Rosai 
classification, and the more recent Marino, Miiller~HennelinkJ Kirchner & coworkers 
classification (5-8). The three classifications of thymic epithelial tumor are summarized in 
Table 1. According to Levine and Rosai classification, thymic tumors were grouped 
considering their invasiveness (stage) and the occurrence of cytological atypia. This first 
step was helpful for a better clinical prognostic relevance of the system (5). In 1985, 
Marino, Miiller-Hermelink, Kirchner & coworkers proposed an uillovative and interesting 
classification based on the morphological resemblance of neoplastic epithelial cells to 
subsets of normal TEC (6.8). The histogenetic classification of Marino, Miiller-Hermelink, 
Kirchner has been shown to be an independent prognostic factor. Medullary and mixed 
146 
thymomas were considered benign tumors with no risk of recurrence, even in the presence 
of capsular mvaSlOn. \Vhile organoid and cortical thymoma showed intermediate 
mvaSlVeness and low but significant risk of late relapse, well·differentiated thymic 
carcinomas were always invasive and displayed the highest risk of relapse and death (9). 
The WHO classified these tumors following different criteria. The two major categories 
included tumors dependiug on whether the cells show spindle or oval shape (type A), and 
dendritic or epithelioid feafures (type B). Tumor displaying a combination of these 
appearances were classified separately (type AB). The type B categoty is further divided in 
subgroups accordiug to the increasing epithelial/lymphocyte ratio and occurrence of atypia. 
Separately were considered the nonorganotypic carcinomas (type C), which included a large 
group of tumors arising outside the thymus (4). 
TABLE 1. The WHO classification of thymic epithelial tumors compared with the dinicopathologcal and to 
the histologic classifications. 
WHO 
A 
AB 
B1 
B2 
B3 
C 
Clinicopathological classification 
Benign thymoma 
Malignant thymoma 
Category I 
Malignant Thymoma 
Category II 
CLINICAL CHARACTERISITCS AND MANAGEMENT 
Histologic classification 
Medullary thymoma 
Mixed thymoma 
Predominantly cortical thymoma 
Cortical thymoma 
Well differentiated carcinoma 
Epidermoid (squamous cell) carcinoma 
Epidermoid nonkeratiniz.ing carcinoma 
Lymphoepithelioma-like carcinoma 
Sarcomatoid carcinoma 
dear cell carcinoma 
Basaloid carcinoma 
Mucoepidermoid carcinoma 
Undifferentiated carcinoma 
Thymoma is the most common tumor occurring in the anterior.superior mediastinwn. In 
general it is a benign tumor, but occasionally it shows a serious clinical aggressiveness. 
Although metastases are rare outside the thoracic cavity, these tumors may behave in a 
local aggressive fashion, infiltrating the lung, pleural and pericardial space. Many studies 
revealed that the tumor stage is the most relevant prognostic factor (8,10·12), although it 
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has been shown that histology is another important marker in predicting relapsing 
behaviour of these tumors (10-12). 
Only one third of patients bearing thymoma present symptoms of local compression, such 
as dyspnoea, dysphagia, cough and "na cam superior syndrome. In another third the 
diagnosis is usually made via the accidental detection of a mass at chest X-ray. Thymomas 
are frequently associated with paraneoplastic syndromes. Among these, mytSlf:enia [7fWis 
(MG) is the most common one (13). MG occurs as typical complication of \VHO type A, 
AB and BI-3 thymoma, but not of C. MG-associated thymomas are tumors able to 
produce maturation of immature precursors of T cells (14). Moreover, they display 
disturbances of lympho-epithelial interactions, but generally do not express autoantigens, 
which is a common feature in MG not associated with thymoma (13). MG is associated 
with other thymic pathologies as well, including thymitis and thymic hyperplasia. (15). 
Other thymoma-associated syndromes include agammaglobulinemia, pure red cell aplasia, 
Cushing's syndrome, thyroid autoimmunity and more rarely other autoimmune diseases. 
The surgical resection of the tumor is unpredictable for the development of the 
paraneoplastic syndromes. 
Surgety is considered the treatment of choice, while it is still discussed whether there is a 
role for adjuvant radiotherapy hI a resectable stage. Radiotherapy may be the primary 
treatment in lUuesectable stages. However, there are some arguments in favour of a 
surgical debulking in lmresectable stages as well (16). Moreover, the results of current 
oncological approaches to inoperable thymomas are rather disappointing. An overall 
response rate of about 50% with a median survival time of 3-5 years is achieved with 
aggressive and expensive chemotherapy (16,17). 
NEW INSIGHTS 
Two very new important aspects about these tumors recently emerged. Firstly, an original 
study demonstrated the presence of neuroendocrine differentiation in non-neuroendocrine 
thymic epithelial tumors (18). \Vhile uclassic" neuroendocrine markers or cells are conunon 
features in thymic carcinoids, the presence of focal or dispersed neuroendocrine cells in 
thymic carcinoma and atypical thymoma may reflect multidirectional differentiation within 
the ttunor. The neuroendocrine differentiation may represent an additional marker of these 
thymic tumors, next to cell atypia, expression of specific epithelial cell clusters and lack of 
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immature T cell infiltration, (18). Moreover, detection of endocrine products in thymoma is 
intriguing, particularly in the light of the second new finding regarding this class of 
neoplasms. In fact, it has recently been shown that thymoma can be visualized by a 
raclionuclide-coupled SS analog, currently in use as diagnostic procedure for several 
neuroendocrine tumors, as well as experimentally for other pathological entities involving 
the immune system (19-25). As already discussed in the previous paragraph, [IIIIn_DTPA_ 
D-Phe1]-octreotide scintigraphy allows the visualization in viw of tumors and tissues 
expressing SSR. Tumor visualization was positive in most thymomas, but not in thymic 
hyperplasia. This can be considered as an innovative approach for this procedure to 
distinguish tumoral from non-tumoral thymic mass (19), which was rather difficult with 
other traditional imaging techniques (26). 
In the next paragraphs, studies will be presented on the characterization and significance of 
SSR in thymic tumors. 
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SOMATOSTATIN RECEPTOR SUBTYPES IN HUMAN THYMOMA 
AND INHIBITION OF CELL PROLIFERATION BY OCfREOTIDE IN VITRO 
ABsTRACT 
Somatostatin (SS) and SS receptor (SSR) subtypes, codenamed sst l .5> are heterogeneously 
expressed in the normal human thymus. This suggests their involvement in controlling the 
immune and/or neuroendocrine functions in this organ. Moreover, recently a high in 7.iw 
uptake of [1I'In-DTPA-D-Phe'J-octreotide has been reported in patients bearing thymoma. 
The present study characterizes in vim and in vitm, functional SS binding sites in a human 
thymoma. A high uptake of ["'In-DTPA-D-Phe lJ-octreotide was observed in the chest of a 
patient with m)mthmia gravis due to a cortical thymoma. Specific binding of [12SI-Tyr"J-SS-
14 was found on a membrane preparation of the surgically removed thymoma. Scatchard 
analysis showed high affmity binding sites [Kd' 47.5 ±2.5 pM] with low maximum binding 
capacity [B=<> 23.5±2.5 fmoles/mg membrane protein]. RT-PCR analysis showed the 
presence of sstH sstlA and a predominant sst) mRNA expression in the Ulmor tissue. 
Primruy cultured tumor cells expressed sst) rnRNA only. In contrast to the normal thymus, 
SS mRNA was not expressed. By inununohistochemisuy, the tumor cells highly expressed 
sst) receptors, weakly expressed sst) receptors, and showed no imnnmostaining for sst1A 
receptors. sstlA immunoreactivity Was found in the stromal compartment of the Ulmor, 
particularly on the endothelium of small intratumoral blood vessels. In primary cultured 
tumor cells, both SS and octreotide (10 nM) significantly inhibited 'H-thymidine 
incorporation by 40.6 and 43.2%, respectively. The following conclusions were reached. 1) 
As this tumor displayed a high inununoreactivity for sst, and the cultured nrmor cells 
expressed the sst, mRNA only, this SSR may be the subtype involved in the inhibition of 
epithelial tumor cell proliferation by octreotide in vitro. 2) A bss of endogenous SS 
production in this thymoma might be implicated in the uncontrolled cell growth. 3) In this 
case, the sst, may playa role in determining the uptake of ['"In-DTPA-D-Phe'J-octreotide 
at in vim SS receptor scintigraphy. 
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INTRODUCTION 
The thymus is the primaty lymphoid organ where cytokines and thymic hormones 
participate in regulating the proliferation and differentiation of T cells (1). These factors are 
produced by the thymic stroma. The preponderant cell type in the stroma is of epithelial 
origin, consisting of at least two distinct subsets, cortical and medullaty thymic epithelial 
cells (TEe) (2). Recently, attention has been drawn to the presence of neuroendocrine and 
peripheral hormones, which seem to participate in an autocrine and paracrine manner to 
the functioning of TEC (3). Some of these hormones have well·characterized actions on 
immune cell differentiation and proliferation, whereas others, such as somatostatin (55), 
have been identified, but not investigated for their function within the thymus (4). 
The biological effects of S5, including the inhibition of hormone and exocrine secretion, as 
well as the modulation of neurotransmission and cell proliferation, are mediated through 
five different G protein·coupled, high affinity, membrane receptor subtypes (sst,.,) (5,6). SS 
receptors (S5R) have been demonstrated in nonnal tissues and in many tumors at the 
protein and mRNA levels by receptor binding studies on tissue homogenatesJ by in'Liw and 
in vitm S5R autoradiography, by in sitll hybridization as well as by RT·PCR (7,8). 
Furthermore, S5R subtypes have been localized at the cellular level by 
immunohistochemistry using a specific anti-peptide antibody in a series of human tumors 
and in normal human pancreas as well (9.13). Localization studies of S5R on specific cell 
types within S5R.positive tissues demonstrated heterogeneity of receptor distribution (14). 
Octreotide, an octapeptide S5 analog, binds with high affInity to sst, and with a relatively 
lower affInity to sst) and sst, (15). Imaging techniques with ['"In.DTPA.D.Phe'Joctreotide 
have visualized S5R in various human neoplasms in vim. In many cases, a positive scan 
predicts a good response to treatment with octreotide (16,17). 
We have recently characterized the 55 and S5R subtype distribution pattern within the 
normal human thymus (18). S5, and sst" sst" and sst) mRNAs were found in thymic tissue, 
whereas enriched cultured TEC selectively express sst, and sst'M as well as S5 mRNA (18). 
Moreover, successful treatments with octreotide have been reported in two patients with 
thymoma (19,20). To unravel the functional significance of S5R in human thymomas, we 
investigated in the present study the expression and functional role of S5 and S5R subtypes 
in a cortical thymoma. In vim 55R scintigraphy was performed in a patient admitted for 
nTj:1stbmia grmis. 55R expression on the tumor tissue was investigated using in vitro SSR 
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binding studies, RT-PCR and inummohistochemistry. Moreover, the effect of 55 and 
octreotide on cell proliferation were evaluated in a primary cell culture of the thymoma. 
METHODS 
In vivo swdy. Scintigraphy with [ttlIn-DTPA-D-Phe1]-octreotide was performed as previously 
reported (21). Briefly, planar and single photon emission tomography (SPECI) images of the chest 
were obtained 24 h after the injection of 228 Mbq [ll1In-D1PA.D-Phe l J.octreotide (Mallinkrodt. 
Petten, The Netherlands). Imaging studies were perfonned using a two-headed gamma camera 
(picker 2000, Picker Instruments., Cleveland, Ohio, USA) for planar imlging and a three-headed 
gamma camera (picker 3000) for SPECT studies, both equipped with a medium-energy-collimator. 
Acquisition time for planar spot images was 15 min. 
Samples. TIle thymoma was surgically removed from a female patient (age 55 yr). Samples from 
this tumor and from three nonnal thymuses (from children undergoing cardiac surgery) were used 
in the present study. The protocol was in accordance with the Helsinki Doctrine on Human 
Experimentation. Infonned consent was obtained from the patients or their parents. Samples were 
taken directly at the operation, quickly frozen on city ice and stored at -80°C for autoracliographic 
and RT-PCR studies, or fixed in 10% paraformadehyde overnight for immunohistochemistry. An 
additional specimen of the tumor was used for the establishment of a primary culture. 
SS receptor autoradiography alld RT-PCR. Receptor autoradiography was carried out on 10-
micrometer thick cryostat sections using ['HI-Tyrll}SS-14 and [125I-Tyr3]-octreotide as radioligands 
(SA -2000 Ciinullol) as previously described (18). RT-PCR was performed as previously reported 
(18). The size of PCR products were 318, 332,651,221, 323, 223, 349, and 762 bp, for sstl. sst'A. 
sst2B, SSt3, sst. and sst5, SS, and ~-actin, respectively. 
SS receptor billdt'llg studies. The method of membrane isolation and the reaction conditions 
were described previously (18). (!25I-Tyrll]-SS-14 and (!25I-Tyr3]-octreotide were used as 
radioligands. 
Immll1lOht'stocbemt'cal 10caUzatt'01l of sstl, sstlA atld sstJ receptors. Paraffm-embedded 
sections (5 ~) were deparafinized, rehydrated, exposed to microwave heating (in citric acid buffer) 
at 100°C for 15 min, rinsed in tap water followed by phosphate-buffered saline and subsequently 
incubated for 15 min in normal goat serum (1:10 dilution in phosphate-buffered saline + 5% BSA). 
The sections were then incubated overnight at 4°C with the sstl (R1-201) and SS12A (R.2-88) 
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antibodies (gift from Dr. A. Schonbrunn) (22,23) in a dilution of 1:500 (12) and with the sst, 
antibodies (Biotrend, Cologne, Gennany) in a dilution of 1:3000. Finally, a standard streptaviclin-
biotinylated alkaline phosphatase or peroxidase complex (ABC kit, Biogenix, San Ramon, CA) was 
used according to the manufacturer's reconunendation to visualize the bound antibodies. Negative 
controls for inununohistochemisuy included 1) omission of the primal}' antibody and 2) 
preabsorbtion of the antibodies with the respective immunizing receptor peptides (at a 
concentration of 100 nM). 
Cell dispersion alld cell culture. Nonna! and neoplastic TEC were isolated as previously 
described (18). Briefly, the thymoma tissue was enzymatically dissociated with collagenase (Sigma 
Chemical Co., St. Louis, MO; 2 mg/mL) for 1 h at 37°c' TIle dispersed cells were precultured for 
5·7 days in 15 mg/cm' collagen type I (Collagen S, type I, Roche Molecular, MannheinJ, Germany)-
precoated 75-cm2 flasks (Costar, Cambridge, MA) at a density of 5x1()6 cells/flask in 10 mL culture 
medium.. The culture medium, the same as that used during the experiments, was MEM D-valine 
(Gibco BRL, Life Technologies LTD, Paisley, Scotland) supplemented with 10% FCS, penicillin 
(105 UlL), fungizone (0.5 mg/mI), L-glutanaine (2 mmoVL). The pH of the medium was adjusted 
to 7.4. The cells were cultured at 37°C in a humid COrincubator. After tltis period, cell viability 
detected by trypan blue exclusion was 90%, and the cells that had not attached to the flasks, mainly 
thymocytes, were harvested. 
The isolation of epithelial cells was indirectly perfonned using sheep antimouse IgG·coated 
magnetic beads and an AS02 antillUman fibroblast primary antibody kit (Dianova GmbH, 
Hamburg. Germany). This mouse monoclonal antibody reacts specifically with membrane·bound 
protein of human fibroblasts of different origin. The magnetic beads were coated with the specific 
primary antibody and mixed with the target cell suspension to fonn bead-rosetted cells (fibroblasts) 
which were collected at the tube wall and isolated using a magnetic separator rack. For a complete 
negative selection, the supernatant, containing the epithelial cells that were not bO\md to the beads, 
was treated once again with the coated beads. This remaining suspension containing isolated 
epithelial cells was used for the experiments. The cells (20,OOO/well) were seeded in 1 mL culture 
medium in 24·well collagen type I·precoated plates (Costar), and allowed to attach for 24 h. 
111ereafter, test substances were added, and the cells were incubated for 72 h_ Cell proliferation was 
measured by adding 1 f-lCj of (mtl~/.JH}-thymidine (91 Cilmmol; Amersharn, Pharmacia Biotech, 
Houten, The Netherlands)/well dwing the last 24 h, as described in detail previously (18). For RT-
PCR studies, neoplastic TEe were seeded in collagen-coated flasks (see above) and grown to 
confluence. Thereafter, the cells were harvested and mRNA was isolated as described previously 
(18). For keratin staining, cells were cultured on collagen-coated glass coverslips. The cells were 
fixed for 10 min with methanol at the end of the incubation period. Cytokeratin staining was 
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perfonned with a PAP Kit S)"tem (code K518, DAKO, Glostrup, Del1!11alk). Cultured thymocytes 
were collected and processed for mRNA analysis by RT·PCR as previously described (18). 
Test substallces. 55-14 (Bachem Inc.) Harmover, Germany) and octreotide (Novartis, Basel, 
Switzerland) were used at a concentration of 10 rlM. 
Statistical analysis. Data are expressed as mean ± SEM. Binding experiments were perfonned at 
least twice, and the data shown for the displacement study are derived from triplicate values. In 
functional studies, there were four wells per treatment group. The data were analyzed by ANaVA 
to determine overall differences between treatment groups. \'?'hen significant differences were 
found, a comparison between treatment groups was made using the Newman-Keuis test. SSR 
binding data were analyzed by the method of Scatchard. 
REsULTS 
Scimigrapby with 1II1n-DTPA-IJ.Pbe1-octreotide. A high uptake of [IIIIn-DTPA-D-
Phe1]-octreotide was detected after 24 h in the mediastinum (pig. lA-B). Computed 
tomographic scanning of the chest confirmed the diagnosis of thymic enlargement (Fig. 
Ie). 
SS and SSR (subtype) expressioll. At autoradiography, no specific binding of [125j_Tyr"]-
SS-14 or [125j-Tyr']-octreotide was found in the thymoma (data not shown). However, 
Scatchard analysis of [125j_ Tyr"]-SS-14 binding on an enriched- membrane preparation of 
the thymoma tissue revealed high affinity binding sites with an apparent Kd of 47.5±2.5 pM 
and a low maximum binding capacity (Bmul of 23.5±2.5 fmoles/mg membrane protein. 
Figure 2A shows a representative experiment. No specific binding was detectable on the 
tumor-derived cultured thymocytes. In addition, octreotide (100 nM) displaced [125j_Tyr"]-
SS-14 binding on membrane preparations of the thymoma tissue significantly less 
compared with SS-14 (49.5% u. 90.8%, respectively; Fig. 2B). On normal human thymus 
membranes high affinity binding sites for [125j_Tyr']-octreotide were detected [Kd 200±70 
pM; B= 4.7 ±O.3 fmoles/ mg membrane protein (Mean±sEM)]. 
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FIGURE 1. A, Planar images of the chest 24 h after injection of [lIIIn-D1PA-D.Phe l}octreotide. Anterior 
Qeft) and posterior (right) views. There is normal uptake in the thyroid, and some accumulation in the nose 
region due to common cold. An abnormal uptake in the region of the left hilum is seen. B, Transversal 
SPECT images of the chest 24 h post-injection. Images are from cranial to caudal. The left side of the 
images represents the right side of the patient. In the upper row, the accumulation at the site of the 
thymoma is seen, located left-sided in the anterior mediastinum. The last two images in the lower row show 
uptake in the liver. C, Computed tomographic scan of the chest. The arrows indicate the extent of the 
thymic mass. 
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FIGURE 2. Expression of SSR in a membrane preparation of the human thymoma. A, Saturation curves 
indicate total, (a), non-specific (+) and specific (e) binding of [l15I-Tyrll}SS-14.lnset: Scatchard analysis 
of [llSI-Tyrll}SS-14 binding to thymoma tissue membranes [Kd, 50 pMj Brn%'<. 21 fmoles/mg membrane 
protein]. B. Displacement of [125I-Tyrl1}SS.14 binding by 55-14 (100 rut) and octreotide (100 nM). ", 
p<O.Ol 'V5. control; H, p<O.Ol 'liS. 55-14. Control, 922.3±3.2 cpm; 55-14, 84.7±4.7 cpmj octreotidc, 
465.7 ± 14 cpm. Data are derived from triplicate values and are the mean±SEM. 
By RT·PCR, sst" sst2A and a predominant sst) mRNA expression was detected in the 
thymoma tissue (fable 1). Conversely, mRNAs encoding for SS, sst2B1 sst4 and ssts were 
absent (fable 1). In the cultured neoplastic TEC, RT·PCR analysis showed the presence of 
sst} mRNA only (fable 1). In cultured thymocytes only mRNA for ~-actin was detected 
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(Table 1). As previously described (18), the normal thymus expressed 55, sst" sstlA , and sstJ 
mRNAs, whereas cultured TEe expressed 55, sst" and sst'A mRNAs (Table 1). By 
immunohistochemistry, a high immunoreactivity for sst) receptors and a vel)' weak 
immunostaining for 55tu but not for sstlA receptors was observed on the tumor cells (Fig. 
3A and C). sst2A was weakly expressed in the stroma, mainly on endothelium of few small 
intratumoral vessels (pig. 3B). In all the cases the immunostaining could be completely 
abolished by preabsorption with 100 nM of the respective antigen peptides (pig. 3D, E, and 
F) 
TABLE 1. Somatostatin and somatostatin receptor subtype mRNA expression in nonnal human thymus and in 
a cortical thymoma as determined by RT·PCR 
Samples RT·PCR 
sstm sst, 
Nanna! human thymus + + + + + 
Normal TEe + + + + 
Thymocyte>" (nannal thymus) + 
Thymoma ± ± + + 
Neoplastic TEe + + 
Thymocytel (thymoma) + 
~ somatostatin receptor subtypes 1-5; Z somatostatin; < thymic epithelial cells; J cultured thymocvtes. 
In vitro effect of SS alld oclreolide all J H-Ibymidille illcorporatioll of clllillred 
lIeoplastic TEe. 55-14 (10 nM) and the 55 analog octreotide (10 nM) significantly 
inhibited JH-thymidine incorporation by 40.6% and 43.2%, respectively, in the cultured 
tumor cells (pig. 4). The epithelial origin of the cultured tumor cells was confirmed by 
immunocytochemical staining for cytokeratin that revealed a 100% pure epithelial cell 
culture. S 
'p g 
100 ~ 
u 
* .S * ~"O' ~~ . 
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FIGURE 4. Effects of SS and octreotide on JH-thymidine incorporation in a primruy culture of the thymoma. 
Neoplastic thymic epithelial cells were incubated in MEM and 10% FCS for 72 h in quadruplicate without or 
with 10 nM of the drugs indicated. Values are expressed as a percenJ$e of JH-th)midine incorporation by 
control cells and are the mean±SEM (n = 4 wells). *, p<O.Ol 'lS. control.£2a SS-14, .octreotide. 
The control value of 3H-thymidine incorporation was 182.3± 15.9 cpm. 
160 
aMpler [[lJ 
FIGURE 3. Immunohistochemical detection of ssth sstlA and SSt3 receptors in the thymoma. Left p.vui: A, We"" 
diffuse sst, immunoreactivity within the tumor. Section developed with 3,31 diaminobenzidine; B, SShA 
immunoreactivity located on the endothelium of an intratumoral vessel. Section developed with 3,3' 
diaminohenzidinc; C, High diffuse sst) immunoreactivity within the tumor. Section developed with New 
FuchsinelNaphtol AS·MX. Rig/x p.mel: D·P, Acijacent sections showing displacement of inununostaining after the 
preabsorption of the antibodies with 100 nM of the respective peptide antigens. The sections are slightly 
counterstained with hematoxylin. Magnification X400j &r 25 11m. 
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DISCUSSION 
Human thymoma is the most conunon tumor of the anterio-superior mediastinum and is 
composed of cytologically bland, neoplastic TEC accompanied by a variable admixture of 
benign lymphocytes (24). This tumor is frequently associated with paraneoplastic 
phenomena, such as u'1)ttstlxnia gravis, and/or other autoimmune-related disorders and 
hematological abnormalities (24). The microenvironment is abnormal in thymoma and it 
differs from the normal thymus in the prevalence of cortical areas and the deficiency of 
medullary ones (25). 
A high "I vim uptake of [1l!In-DTPA.D.Phe!Joctreotide has been detected in patients 
bearing thymoma or thymic carcinoid, whereas the normal or hyperplastic thymus is not 
visualized (20,26). Moreover, successful treatments with octreotide and prednisone and 
with octreotide alone have been reported in two patients with thymoma (19,20). In one 
case the treatment resulted in both tumor size reduction and an improvement of the 
autoimmune·related disease (19). The precise mechanisms involved in this effect are 
\Ulclear, however. In a previous study, using in uno SSR autoradiography, Reubi et aI. did 
not find SS-binding sites in four thymomas of undefined histological subtype, whereas SSR 
receptors were detectable in the normal thymus (27). The lack of im';ho detection of SSR in 
human thymoma seems in contrast with the compelling evidence that tumors originating 
from SSR·positive tissues generally express SSR (8,28). 
We have recently characterized SSR subtype expression in the normal human thymus (18). 
sstl and sstZA mRNAs were expressed in the thymic tissue and isolated TEe, whereas sst) 
mRNA was detectable in thymic tissue only and not on enriched cultured TEC or cultured 
thymocytes (18). As several different subsets of epithelial cells and thymocytes have been 
described within the human thymus, the sst, receptor might be expressed on another cell 
subset or might undergo rapid downregulation during culturing. In fact, it is well known 
that the expression of neuropeptide receptors on immune cells is dynamically regulated and 
depends on the traffic of these cells through and within lymphoid compartments and 
homing in the tissues (29,30). Moreover, preliminaty data show sst1A immunoreactivity on 
stromal cells in the medullary compartment of normal human thymus (31). All of these 
findings are in agreement with the evidence of a strong compartmentalization of 
neuroendocrine peptide receptors in lymphoid tissue (32). 
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In the present report, we found a high uptake of [II1In-DTIA-D-Phel)-octreotide in a 
patient with cortical thymoma and, in agreement with the study by Reubi et ai. (27), a lack 
of SSR-binding sites by autoradiography performed on cIYostat sections from the !tunor 
tissue. However, we were able to detect a vel)' low density of specific high affinity binding 
sites of [IBI-Tyrl1)-SS-14 on an enriched membrane preparation from the thymoma tissue. 
By RT-PCR, we found mRNAs encoding for sst,) sst2A and sst3 in the thymoma tissue, 
whereas mRNA encoding for sst, was detectable in primary cultured neoplastic cells. 
Conversely, no binding was detectable and no mRNAs encoding for SSR subtypes were 
found on the ttunor-derived cultured thymocytes. Consonant with the presence of sst l 
mRNA and the low affmiIY of octreotide for sst, receptors, we found that octreotide only 
partially displaced [115I_Tyrl1)-SS_14 binding on cell membrane from this tumor. To further 
characterize the heterogeneous expression of SSR subtypes in this twnor, we used three 
recently developed polyclonal SSR antibodies, highly specific for sst l, sst" and sst, 
receptors (11,22,23). By immunohistochemistIY, we observed a high inununoreactivity for 
sst] receptors and a very weak expression of sst, receptors on the tumor tissue. Conversely, 
the tumor cells did not express sst2A receptors, whereas sst1A immunoreactivity was 
localized in the stroma, mainly on the endotheliwn of scattered small intratumoral vessels. 
These ftndings confirm the predominant presence of sst, in this !tunor. In fact, the mRNA 
encoding for this protein has been detected by RT-PCR on both ttunor tissue and cultured 
tumor cells and our hypothesis is that this cortical thymoma might have arisen from a 
subset of thymic sst3-expressing cells. However, the diffuse immunoreactivity for sst) in the 
twnor tissue suggests the presence of this SSR subtype on reactive thymocytes as well. 
Although mRNA encoding for sst, was undetectable in cultured thymocytes from both 
thymoma and normal thymus, our recent observation showed the presence of SS-binding 
sites on freshly isolated thymocytes (31). This finding might explain the diffuse 
immunoreactivity for sst} in the thymoma and confirm the evidence that neuropeptide 
receptor expression in lymphoid tissues might rapidly change in conditions different from 
those in the natural microenvironment (33). 
sst, receptors have been shown to display the highest amount of agonist-dependent 
receptor internalization compared to the other SSR subtypes (34). Although the affmity of 
octapeptide 5S analogs for sst) is lower compared with that for sst2, the high internalization 
of sst, receptors might be the possible mechanism regulating the in viw uptake of CI1In-
DTIA-D-Phel}octreotide within thymomas. Indeed, the present S!tldy demonstrates that 
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sst, is the subtype predominantly expressed in this tumor displaying a significant in Uw 
uptake of p"ln-DTPA-D-Phel]-octreotide. Another suggestive hypothesis, which can not 
be completely excluded, is the presence of a novel unidentified 55R involved in 
determining the m Uw uptake of the radiotracer. 
Cell subsets containing neuropeptide honnones are present in the cortical areas of normal 
thymus as well as in thymoma (35). The identification of 55 and its receptors in the nonnal 
thymus strongly supports the paracrine actions of the peptide in modulating the irrununo-
and/or neuroendocrine functions in this organ (18,27). The pattern of distribution of 55-
binding sites observed in normal thymus seems to be still preserved in thymic hyperplasia 
associated with m)ustJ.w,;, gram, but seems to be lost in thymoma (27). Furthermore, in the 
present case, SS mRNA was not detectable in either thymoma tissue or the primruy 
cultured tumor cells, whereas it was detected in normal human thymic tissue and in normal 
cultured TEe (18). This finding suggests that the loss of local 55 production might be 
implicated in the uncontrolled cell growth and! or the tumor autoimmune·related diseases 
and possible tumor pathogenesis. In support of this hypothesis, we found that the in-dtm 
administration of 55-14 and the 55 analog octreotide at high concentration (10 nM) 
significantly inhibited 'H-thymidine incorporation in the cultured tumor cells. Both 
compotmds displayed a comparable ability in inhibiting 'H-th}'Ttlidine incorporation by 
cultured cells. As 55-14 binds sst, with higher affinity than octreotide, a difference in the 
percentage of inhibition should have been observed. However, taking into consideration 
that we measured the uptake of 'H-thymidine after 72 h, we might have underestimated the 
true inhibition degree by 55-14, due to a lower stability of the latter compound. The 
inhibition of cell proliferation by 55-14 and octreotide, and the predominant expression of 
sst, in the thymoma, are in line with emerging data regarding signal transduction pathways 
linked to 55R that show a cell cycle-dependent induction of apoptosis by octreotide (36). 
Octreotide·induced apoptosis seems signaled through the sst) and associated with 
dephosphorylation-dependent conformational change in wild-type p53 (37). Although 
controversial data about alterations of p53 expression have been reported in thymic 
epithelial tumors (38,39), 55-induced apoptosis might represent an additional mechanism 
involved in the regulation of cell proliferation in human thymus. Futthennore, tills finding 
may form the basis for the inhibition of tumor growth in patients with thymoma treated 
with octreotide. As octreotide binds to sstlA1 sst) and sstSI but not to sstll and considering 
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that in the present case sstlA and sst.s are not expressed in the tumor cells, the inutm effect 
of SS and octreotide seems to be mediated directly by sst). 
In conclusion, although further investigations are required, the loss of SS production in 
combination with a predominant expression of sstJ receptor in this thymoma might be 
implicated in uncontrolled cell growth and tumor pathogenesis. These data support the 
physiological paracrine/autocrine role of SS in the human thymic microenvironment and 
indicate that a disturbance in this system might be involved in the pathogenesis of thymic 
neoplasms. Furthermore, SSRs are localized in different complementary cell compartments 
in the normal and neoplastic human thymus. At least three SSR subtypes seem to control 
neuroendocrine function as well as the cell growth in this organ. Moreover, the sst,} subtype 
may play an important role in determining the uptake of [1IlIn-DTPA-D-Phe'J-octreotide 
during in viw SSR scintigraphy. The inhibition of cell proliferation by octreotide through 
sst) may explain the reported successful treatment of thymoma with this SS analog. Finally, 
SSR scintigraphy and SS analog treatment of thymomas may represent a new diagnostic 
and therapeutic approach to these tumors. 
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IN VIVO DETECTION AND IN VITRO LOCALIZATION OF SOMATOSTATIN 
RECEPTORS IN HUMAN THYMIC TUMORS: PRELIMINARY STIJDY ON 14 
CASES 
ABSTRACT 
We have previously shown that most thymic tumors can be visualized in humans by 
scintigraphy with ['"In-DTPA-D-Phe'J-octreotide, and that therapy with somatostatin (SS) 
analogs exert antineoplastic effects. These findings suggest that SS receptors (SSR) are 
expressed on these ttunors. However, previous studies did not present evidence of the 
presence of such receptors in tissue specimens. Therefore we have utilized two polyclonal 
antibodies raised against a synthetic peptide fragment of SSR subtype 2A (sst,.J and sst,. 
Immunohistochemical analysis was performed on tissue specimens of 14 surgically 
removed thymic tumors from patients previously studied by SSR scintigraphy. 
By scintigraphy, 13 out of 14 thymic tumors showed detectable uptake of ['"in-DTPA-D-
Phe'J-octreotide with tumor to backgound ratios ranging between 1.4 to 6.3 fold. One 
tumor was not visualized. By immunohistochemisuy, 4 tumors demonstrated positive 
immonostaining for both sstlA and sst); 2 were positive for sst2A and 5 for sst) only; 3 tumor 
samples stained completely negative. The staining was highly heterogeneous and sst" and 
sst) expression was associated with different cell types. In particular, sst2A expression was 
clearly associated with thymic epithelial cells in 2 cases; sst, expression was frequently 
found associated with thymocytes; sst) immunoreactivity was weakly present on tumor cells 
in most cases, however. The staining was specific in all the cases examined. 
This study clearly demonstrates the in vitro expression of at least two of five SSR subtypes 
in a series of human thymic tmnors. FlUthermore, the discrete concordance of 
scintigraphic and immunohistochemical results, demonstrates that specific receptor-
mediated binding of ['"In-DTPA-D-Phe'J-octreotide occurs in most thymic tumors. 
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INTRODUCTION 
The clinical implications of high peptide receptor expression by htunan tumors for imaging 
and therapy have been clearly demonstrated for somatostatin (SS) receptors (SSR) (1-4). 
Imaging by [IIIIn-DTPA-D-Phe']-octreotide as radioligand is a well-established in'liw 
method to visualize SSR-expressing tumors (4). Therapy with SS analogs has been 
demonstrated to be effective in some SSR positive neuroendocrine twnors (3,5). Both 
diagnostic and therapeutic applications of SS analogs follow the irl'vitIV identification of 
these tumoral receptors by ligand techniques (6-8). 
The development of antibodies specific for different SSR subtypes may be used to study 
their expression in tissue sections by immunohistochemistry (9,10). Preliminary reports 
indicated that immunohistochemist,y is a reliable method to evaluate the expression of SSR 
subtypes either in carcinoids or other SSR positive ttunors (11-1S). Immunohistochemistry 
is also easier to perform and more practical for clinical use than reverse transcriptase 
polymerase chain reaction (RT-PCR) or ill sit1l hybridization methods. Furthermore, 
immunohistochemistry can be applied on fixed materials; thus, it is mandatory when frozen 
material lacks. 
We have found that htunan thymic tumors are detectable by SSR scintigraphy (SRS) using 
P"In-DTPA-D-Phe']-octreotide, showing very high tumor-to-background (f-to-B) ratios 
(16). It has also been shown that patients with thymic tumors may successfully respond to 
SS-analog based therapy (17,18). Besides this evidence, SSR expression was not found in 
thymic tumors by in vitm autoradiographic techniques, while a high content was found in 
thymic carcinoids, as well as in normal young or adult normal thymuses (19). Recently, 
using combined evaluation by in vitm techniques, we demonstrated the expression of sst!, 
sst2A and sst, in a cortical thymoma, which was detected by SRS (20). 
The aim of the present study-was to verify the expression of sst2A and sst} in a series of 14 
thymic tumors, which had been pre-operatively imaged by SRS scintigraphy. This 
preliminary study was designed in order to evaluate whether the presence of these SSR 
might be related to the in 'liw scintigraphic results. 
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MATERIALS AND METHODS 
Patients Fourteen patients (6 females and 8 males, age-range 19-74 yr) with a diagnosis of thymic 
ttunor entered the study. Three patients were untreated, 4 had received only chemotherapy and the 
remaining patients underwent different combinations of chemotherapy, surgery and radiothenlPY. 
Myasthenia gravis was the most common associated paraneoplastic syndrome observed in the 
group of patients. Pure red cell aplasia was present in two patients, The patients' profile at study 
entry is reported in Table 1. 
TABLR 1. Patients' £rofJe at stu~ ent!!. 
Case Sex/age WHO Previous Sites of disease Associated 
classification theraer srndrome 
1. F/G8 C CHT mediastinum, lung 
2. F/s7 B2 CHT mediastinum, pleural PRCA 
3. F/G7 C None mediastinum, pleural 
4. F/so B3 None mediastinum, pleural 
S. Ml2G B2 CHT·S mediastinum MG 
6. FISO C CHT·RT·S mediastinum, pleural, lung 
7. MlS8 B2 CHT mediastinum PRCA 
8. FIN BI S·CHT·RT mediastinum MG 
9. F/GI C None mediastinum, pericardium 
10. MlI9 C CHT mediastinum, cervical 
I!. MlS3 B2 S·CHT mediastinum 
12. MlS2 B2 S·CHT mediastinum MG 
13. Ml4G B3 S·CHT pleural 
14. Mill B2 S·CHT mediastinum 
a-rr, chemotherapy; S, surgery; RT, radiotherapy; PRCA, pure red cell aplasia; MG, myasthenia gravis. 
TI$SJfe samples The samples of 14 histologically proven thymomas were collected and used for 
immunohistochemical evaluation in this study. All samples were fonnalin-fixed and paraffm-
embedded. Fixation was perfonned for 24-36 hours. The ttunors were classified according to the 
new WHO classification of thymic epithelial tumors (21) and the results are reported in Table 1. 
Santigmpbic studies Scintigraphy with [lllln-DTPA-D-PhelJ-octreotide (lvfallinkrodt, Petten, 'TIle 
Netherlands) was performed as previously reported (16). Briefly, planar and tomographic images 
were collected 24 h after the Lv. injection of 180-222 1vIBq of radioligand. Labeling was perfonned 
according to the manufacturer instructions; injected preparations had <2% of uncoupled IIIIndium. 
Images were obtained by gamma·camera (Siemens, Erlagen, Germany) equipped with a medium 
energy collimator (photopeaks were set at 172 and 242 keV, 10% window). T-to-B ratios were 
obtained by using the regions of interest (ROJs) method. A ROJ was manually drawn around the 
area(s) of radioligand uptake; similar one was placed in chest where no uptake was detectable. In 
each patient, the T-to-B ratio was obtained in the planar or tomographic images of the chest 
obtained 24 h p.i., dividing the counts in the thymic ttunor by those in the background area. 
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ImmHllchistwxmiml kxaiizaticn ofSSt2A and sst) nxeptors Paraffiu-embedded sections (5 !-ffi1 of tickness) 
were deparafinized, rehydrated, and heated in microwave (in citric acid buffer, pH 6.0) at 100°C for 
IS min, rinsed in tap water followed by phosphate-buffered saline (PBS) and subsequently 
incubated for 15 min in normal goat senun (1:10 dilution in PBS + 5% bovine serum albumin, 
BSA). The sections were then incubated overnight at 4°C with sst2A and sst3 antibodies (Biotrend, 
Cologne, Germany) in a dilution of 1:3000. Finally, a standard streptavidin-biotinylated·alkaline 
phosphatase complex (ABC kit, Biogenix, San Ramon, CA) was used according to the nunufacturer 
recommendations to visualize the bound antibodies. Negative controls for immunohistochemistry 
included: a) omission of the primary antibody; b) preabsorbtion of the antibodies with the 
respective inununizing receptor peptides (at a concentration of 100 nM). 
RESULTS 
SW/IIIOsta/in Ilxeptar scitlti[7atilY resliits SRS was positive in 13 out of 14 patients included in 
this study. In 4 cases at least two sites of abnonnal radioligand uptake were seen in the 
chest, while in 9 other patients a single area of uptake was recognized. The degree of ['ItIn. 
DTPA-D-Phe'Joctreotide uptake was vel)' heterogeneous, as documented in Figure 1. The 
values of T·to-B ratios ranged from 1.4 to 6.3 fold. The SRS results and T-to·B ratios are 
shown, case by case in Table 2. 
TABLE 2. Summary of somatostatin receptor scintigraphy results and immunohistochemical localization of 
SStlA and SSt3 receptors. 
Case Somatostatin receptor Classification Inununohistochemistry 
scintigraphy 
sites of uptake T-to-B ratios sst2A Sst3 
1. mcdiastinum, lung 
2. mediastinum 
3. mediastinum 
4. mediastinum 
5. mediastinum 
6. mediastinum, lung 
7. mediastinum, pleural 
8. mediastinum 
9. mediastinum 
10. mediastinum, cervical 
ll. mediastinum 
12. mediastinum 
13. negative 
14. mediastinunl 
n.e" not evaluable. 
4.2/3.3 
3.1 
3.4 
6.2 
1.4 
6.3 
2.1/1.4 
2.6 
2.1 
1.5/1.5 
3.2/1.7 
3.3 
1.4 
C 
B2 
C 
B3 
B2 
C 
B2 
BI 
C 
C 
B2 
B2 
B3 
B2 
scattered cells 
scattered cells 
+ 
+ 
+ 
+ 
n.e. 
+ 
n.e. 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
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FIGURE 1. Somatostatin receptor scintigraphy in patient with inva.sive thymoma. Planar images of the chest 24 h after injection of [lllIn-DTP A-D-Phe1} 
cx;creotide. Anterior Qeft) and posterior (right) views. There is abnotn'lal. uptake in the mediastinum and in the left lung (no. 1 Table 2). The physiologic uptake or 
the radioln.cer in the thyroid, pituitary, as well as in the liver is also evident. 
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Immlfn<:J;istooxmitai deta:tion of sstlA mm sst] Expression of sst1A and sst) receptors or their co-
expression was clearly detectable by immunohistochemistry in 11 out of 14 thymic tumors, 
while 3 thymomas were completely negative. In 12 biopsies inuuunohistochemistry was 
complete for both subtypes. In 2 cases immunohistochemistty results were evaluable for 1 
subrype only. These results are summarized in Table 2. The immunostaining was usually 
weak to moderate. However, for both subtypes a wide heterogeneity of distribution was 
found. Immunohistochemistry provided a unique opportunity to exactly localize the 
cellular distribution of SSR within thymic tumors. The expression of sst,. was diffuse 
within the tmnor in 2 cases only, while in the remaining sections immunoreactivity was 
highly heterogeneous and confined to limited areas in the tissue samples. The expression of 
sst, was found diffuse within the tumor on both cell types, but mainly associated with 
thymocytes. The specificity of sstlA and sstJ immunostaining was confumed in all biopsies. 
In fact, on adjacent sections, after absorption with specific peptide antigen (100 nM:), the 
immunostaining of these antisera was completely prevented. 
In 4 thymic tumor biopsies (nos. 2,5,6,7; Table 2), both sst,. and sst, receptors were 
localized. In details, in 2 cases (nos. 6 and 7; Table 2) sst'A immunoreactivity was present 
on tumor cells, while in the other 2 samples (nos. 2 and 5; Table 2) immWloreactivity was 
detected on few scattered cells in one case and on the stroma in the remaining case. In one 
of the two cases with immunohistochemical co-expression of sst2A and sst), the tumor 
displayed the highest level of [IIIIn-DTPA-D-Phe'Joctreotide uptake in 'Iiw. 111e diffuse 
sstlA inuutu10reactivity in the tumor sample from tlus case is shown in Figure 2A (no. 6, 
Table 2). In Figure 2B an example of sst, immunoreactivity is shown (no. 5, Table 2). 
In 5 cases the expression of sst, receptor only was detectable (nos. 4,10,11,12,14; Table 2). 
Co-expression of sstlA receptors was not detectable in 4 biopsies and not evaluable in the 
remaining one (no. 14; Table 2). 
In 2 cases, the expression of only sstlA receptors was demonstrated (nos. 1,3; Table 2). 
Among these 2 cases sst, receptor was undetectable in one (no. 1; Table 2) and not 
evaluable in the remaining case. 
In 3 cases the expression of both sstlA and sst) receptors was undetectable (nos. 8,9,13; 
Table 2). 
Prribnbwy crmj>1ratiw analysis of in vivo and in vitro resliitS We compared the results of 
immunohistochemistry for sstlA and sst) receptors with T~to-B ratios measured at SRS. 
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Beside the relatively small number of cases we have analyzed, a positive trend between the 
T-to-B ratios and immunostaining seems evident. In particular, the expression of both 
subtypes and sst", alone has been observed within thymic tumors with higher radioligand 
concentration (Table 2). 
A B 
FIGURE 2. Immunohistochemical detection of SShA and sst) receptors in the two different thymomas, A) 
Diffuse moderate SShA immunoreactivity localized on tumor cells (no. 6, Table 2); B) Weak diffuse sst) 
immunoreactivity within the tumor, moderate immunoreactivity localized on reactive thymocytes (no.S, Table 
2). Sections developed with New FucsinelNaphtol AS-11X. The sections are slightly counterstained with 
hematoxylin. Ma~nification 400 X; 8.1r 25 ~Ill. 
DISCUSSION 
In this study we systematically analyzed and compared the scintigraphic results from ['"In_ 
DTPA-D·Phe'Joctreotide scans and the immunohistochemical results on their surgical 
biopsies in the same patients with thymic twnors, The immunohistochemical identification 
of sst", and sst, in 11 of 14 thymic tumors confirms that these SSR are expressed in these 
rare human malignancies. We previously demonstrated that ['"In-DTPA-D.Phe'J 
octreotide visualized the majority of thymic hUnor deposits greater than 15 mm (16). 
Moreover, therapy with SS analogs plus prednisone was effective in a patient unresponsive 
to other conventional treatments (17). Lately, another case of a patient with a thymoma 
visualized with ['"In-DTP A-D-Phe'Joctreotide scintigraphy and successfully treated with 
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SS analog therapy has been reported (18). However, there was no in vi'm evidence that 
these tumors may express SSR, with the exception of one case (19,20). Thus, the possible 
mechanisms involved which might explain these results remained unclear. Furthermore, by 
autoradiography Reubi et al. demonstrated SSR in normal human thymuses with a lack of 
binding sites in 4 epithelial thymic tlUnors (19). Tlus was the only example of ttunors 
originating from SSR positive tissues not expressing such receptors. 
Thymomas consist of thynlic epithelial cells mixed to benign lymphocytes and stromal cells 
(21-23). The nlicroenvironment in these thymic tumors differs from the normal adult 
thymus for the prevalence of cortical areas and deficiency of medullary ones (24). In 
normal thymus sst, and sst", mRNAs have been found to be expressed in thymic tissues 
and isolated thymic epithelial cells, while sst) mRNA was found in thymic tissue only (25). 
However, preliminaty data have demonstrated the presence of 5S-binding sites on normal 
freshly isolated thymocytes (26). 
In thymic tumors we frequently found the expression of sst)) prevalently associated with 
thymocytes and sst", expression confined to malignant epithelial cells or within stromal 
structures. Such differentiated cellular distribution reqnires further comments. SSR 
distribution within the normal human thymus seems to display a strong 
compartmentalization (19,25). This observation had been already previously made for other 
neuropeptide receptors within this primary lymphoid organ (27). However, the distribution 
of receptors for neuropeptides and hormones within the thymus underlines the important 
role exerted by these substances, which are often locally produced, in modulating the 
physiologic processes occurring in this organ (28). In the thymus lymphoid or accesso!), 
cells at different stages of maturation might differentially express neuropeptide receptors 
(26). Moreover, a dynamic traffic of cells occurs in thymic lobules and different cell subsets 
interact with each other (29). The intense cell activity is mainly orientated to drive 
thymocytes migration and differentiation in order to complete normal T cell maturation, 
which is the main function of this primary lymphoid organ (30,31). Thymic epithelial cells 
are supposed to be the major cell type involved in this process (29). Different subsets of 
epithelial cells are present in the normal thymus. At least three principal phenotypes are 
recognizable: a subcapsular, cortical and medullary epithelimn. Within the thymic 
microenvironment, these cells are exposed to various substances and stimuli. A tumor 
originated from the hmnan thymus nlight derive from each cell type, which belongs to 
these subsets. Different SSR have been described to be selectively expressed in different 
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regions and perhaps on specific epithelial cell types in the human thymus (25,26). This 
might partially explain the considerable heterogeneity of receptor expression between 
thymomas and within the same tumor. Further studies orientated to identified adjunctive 
markers within the neoplastic cells are mandatoty to better understand whether the 
distribution of SSR might have a rationale or whether the presence of a specific SSR might 
act as a marker itself. 
The analysis of scintigraphic results compared to the presence of SSR expression at 
inununohistochemistty indicate that in general the higher T-to-B ratios inviw correspond 
to the expression of at least one of the two SSR subtypes in'litro. In particular, the highest 
ratio has been detected in one patient with a diffuse co-expression of both receptors in the 
tumor. Moreover, in one of the three tumors, which were negative at SRS, 
inununohistochemistty failed to detect SSR in the tumor tissue. However, rather high T-to-
B ratios were calculated in the two other patients with tumor lacking SSR subtype 
expression invitro. Although, the sensitivity of the technique or the procedure of ftxation of 
the samples might account for this discrepancy, the presence of another SSR subtype 
cannot be ruled out. 
['"In-DTPA-D-Phe'J-octreotide binds with high affinity to sst, and with lower affinity to 
sstJ and ssts. Two of these SSR subtypes have been evaluated invitm in the present series of 
human thymomas, and both these receptors might parricipate in determining the uptake of 
the radiopharmaceutical. However, in three cases a high uptake in'liw corresponded to the 
selective expression of sstJ receptors within the tumor, suggesting that despite the lower 
affinity for [IIIIn-DTPA-D-Phe'J-octreotide of this subtype compared with sst'A' it may 
play an important role in the uptake during SRS. On the other hand, since apart from the 
affinity, additional biological events related to receptor turnover might play a role in 
displaying the in vim uptake of radiolabeled SS analogs, sst, may account for the occurrence 
of [IIIIn-DTPA-D-Phe'J-octreotide uptake in thymomas. In fact, recently a high rate of 
agonist-dependent internalization has been described in cells transfected with this SSR 
subtype (32). Moreover, sst, has been found to be involved in a cell cycle dependent 
induction of apoptosis by octreotide (33). Apoptosis signaled through the sst, could 
represent an important mechanism in regulating cell survival in the human thymus, and 
might he related to the successful therapy with octreotide in patients with thymomas 
(17,18). 
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In conclusion, although further studies are required to better characterize these rare but 
intriguing tumors, two SSR subtypes, i.e. sst2A and sst), are heterogeneously expressed in 
thymomas. Both receptors might be involved in determining the in Uw uptake of [IllIn_ 
DTPA-D-Phe'J-octreotide in patients with thymic tumors. 
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IMMuNOHISTOCHEMICAL LOCALIZATION AND QUANTITATIVE 
EXPRESSION OF SOMATOSTATIN RECEPTORS IN NORMAL HUMAN SPLEEN, 
THYMUS, AND THYMOMA 
ABSTRACT 
We have recently characterized somatostatin (SS) receptor (SSR) expression pattern in the 
normal human thymus. Three different SSR subtypes, 55tH sst2AJ and sst] were expressed in 
thymic tissue. Although, this lymphoid organ is not visualized during in '1iw SSR 
scintigraphy, thymic tumors can be often detected. ["'In-DTPA-D-Pheloctreotide 
scintigraphy allows the visualization of several types of SSR-expressing tumors, as well as 
normal SS target tissues. Among these, the spleen is clearly depicted. Since both the human 
spleen and thymus contain SS-binding sites, we evaluated whether the heterogeneity of 
distribution, he type of SSR, as well as the arnOtmt of the different SSR subtypes might 
explain the apparent contrasting findings in these lymphoid organs. By membrane 
homogenate binding studies we found [I15I-Tyr'J-octreotide binding-sites both in the spleen 
and in the normal and hyperplastic thymus, but not in thymomas. On the other hand, ['251_ 
Tyr"J-SS-14 binding was detectable in all cases. Reverse transcriptase polymerase chain 
reaction (RT-PCR) analysis demonstrated sst" sst" and sst) mRNAs in the thymus and 
thymoma, while the spleen selectively expressed sstlA and sst] mRNAs. SSt2B) sst-4 and ssts 
mRNAs were not detected in any of the tissues. Quantitative evaluation of SSR subtype 
mRNAs showed a high and almost selective expression of sst'A mRNA in the spleen 
whereas a higher expression of sst) mRNA was present in the thymus. The highest 
expression of sst) mRNA was detected in thymic hyperplasia and in thymomas. The 
highest density of sst" receptors in the spleen is in line with the in'1iw uptake of ['"In_ 
DTPA-D-Phe'J-octreotide, which is considered a sst,-preferring ligand. However, although 
octreotide displays a lower affinity for sst) receptors, the relatively high expression of sst) 
mRNA in thymic tissues suggests that this SSR subtype might playa role in determining 
the uptake of the radiopharmaceutical at in '1iw SSR scintigraphy in patients with thymoma. 
Apart from the affinity of the radioligand for the receptor, also the efficicacy of the 
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interna1ization of the radioligand.receptor complex might play an important role III 
determining the radioactivity uptake during in'1iw 5SR scintigraphy. 
Finally, the cellular loca1ization of these two 5SR subtypes, determined by 
inununohistochemistry, showed a preferential expression of sst1A receptors on 
microenvironmental cells and of sst) receptors on lymphoid cells in both these organs. In 
thymomas sst) receptor was mainly expressed on reactive lymphoid cells, and to lesser 
extent on nunor cells. This distribution pattern might explain the different effects of 55 on 
immune cell functions. 
184 
aMpler /I/. 5 
INTRODUCTION 
The effects of somatostatin (SS) are mediated 'lid a family of high affinity G-protein-
coupled membrane receptors (SSR) with five known subtypes, codenamed sst,., (1,2). In SS 
target tissues, SSR are expressed in a tissue- and subtype-selective manner (3). Like other 
modulatoty neuropeptides, SS acts on cells of the inunune system (4-6). Vatiable effects of 
SS and its octapeptide-selective analogs have been reported on immune cell functions, both 
in animals and man (4,5,10,11). These observations might be related to a heterogeneous 
expression of SSR on inunune cells (7-9). The expression of SSR in lymphoid tissues has 
been investigated in 'lilm by binding studies, using fluorescent and/or iodinated SS and SS 
analogs, and by reverse transcriptase polymerase chain reaction (RT-PCR) method 
(4,5,10,11,12). In addition, using radiolabeled SS analogs, several scintigraphic studies have 
shown the in vim localization of SSR in lymphoid tissues, either in normal or pathological 
conditions (5,13-16). In particular, the normal human spleen usually displays a high in'1iw 
uptake of ['ItIn-DTPA.D.Phe']-octreotide (14). This strong inviw uptake seems to be due 
to the presence of specific SS binding sites in this lymphoid organ. In fact, high affinity 
SSR, preferentially located in the red pulp, have been demonstrated by in'lilm SS binding 
studies using ['25I-Leu', D.Trp", Tyr"]-SS.28 and [12SI-Tyr']-octreotide (15). Moreover, the 
presence of specific SSR in the spleen is supported by the fact that the in vim labeling is 
significantly reduced in patients treated with the octapeptide SS analog octreotide (15). 
Conversely, although SSR have been clearly demonstrated in 'lilm in the normal human 
thymus (15,17), this organ is not visualized during scintigraphy with [IIIIn.DTPA-D.Phe']-
octreotide, while a high in Uw uptake of the radiotracer has been detected in patients with 
thymic epithelial tumors (18.21). 
In order to investigate whether the heterogeneity of expression and differences in the 
density of SSR might explain this apparent contrast, we have characterized in the present 
study SS and SSR subtype expression in the normal human spleen and thymus, in thymic 
hyperplasia and in thymomas by classical binding studies, by RT-PCR, and by 
inununohistochemistty. Using a quantitative RT-PCR method, we analyzed the amount of 
sstlA and sst) mRNAs in these lymphoid tissues. Since immunohistochemistry, which 
allows the localization of the receptor proteins at cellular level (22-25), has been recently 
successfully employed in human lymphoid tissues (26.28), we used two polyclonal 
antibodies raised against specific peptide fragments of sst2A and sst) receptors to further 
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investigate the expression pattern of these subtypes on frozen and/ or formalin~fixed 
sections of human spleen, thymus and thymoma. 
MATERIALS AND METHODS 
Somatostatill receptor scilltigrapby. Scintigraphy with [111In-DTPA-D-Phe1}octreotide was 
performed as previously reported (29). Briefly, planar inuges were obtained 24 h after the injection 
of 228 Mbq PIlIn·DTPA-D-Phel}octreotide (Mallinkrodt, Petten, The Netherlands). Imaging 
studies were performed using a two-headed gamma camera (picker 2000, Picker Instruments, 
develand, Ohio, USA) equipped with a medium-energy-collinutor_ Acquisition time for planar 
spot images was 15 min. 
Samples. Two samples of splenic tissue were obtained from patients operated for pancreatic 
disorders (1 female, age 25 yr and 1 male, age 47 yr) and were histologically normal. Normal th)IDic 
tissues (n=2j 1 female, age 9 yr and 1 male, age 12 yr) were obtained from children undergoing 
cardiac surgery. The hyperplastic thymic tissue and the two thymomas (one B2 and one A, 
according to the \'{!HO classification) were surgically removed from patients with my5tlxnl.a gtads (2 
females, age 55 and 40 yr and 1 male, age 35 yr). The protocol was in accordance with the Helsinki 
Doctrine on Human Experimentation. Informed consent was obtained from the patients or their 
parents. Samples were taken directly at operation, quickly frozen on dry ice and stored at -80°C for 
ligand binding and RT-PCR studies and for immunohistochemistry_ Additional samples were ftxed 
in 10% paraformaldehyde overnight for immunohistochemistry. 
SSR binding studies. Receptor autoradiography was carried out on 10-micrometer thick cryostat 
sections almg CMJOOO, Leica, Germany) using (125I-Tyr3]-octreotide and [i25I_Tyrl1}SS_14 as 
radioligands (specific activity approximately 2000 Cilmmo~ as previously described (17). The 
method of membrane isolation and the reaction conditions were described elsewhere (17). Briefly, 
membrane preparations (corresponding to 30~50 flg protein) of tissue samples were incubated in a 
total volume of 100 fll at room temperature for 60 min with increasing concentrations of [1251-
Tyr3]-octreotide or [l25I-TyrllJ-SS-14 without and with excess (1 J.lM) of unlabeled octreotide and 
SS-14 in HEPES buffer (10 mM HEPES, 5 mM MgCI, and 0.02 g/liter bacitracin, pH 7.6] 
containing 0.2% bovine serum albumin (BSA). After the incubation, 1 m1 ice-cold HEPES buffer 
was added to the reaction mixture, and membrane-bound radioactivity was separated from 
unbound by centrifugation during 2 min at 14,000 rpm in an Eppendorf microcentrifuge. TIle 
remaining pellet was washed twice in ice-cold HEPES buffer, and the final pellet was counted in a 
y-counter (1470 Wizard, Wallac, Turku, Finland]. Specific binding was taken to be total binding 
minus binding in the presence of 1 11M unlabeled ligands. 
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RT-PCR stlldies_ RT-PCR was perfonned as previously described (17)_ Briefly, poly A + mRNA 
was isolated using Dynabeads Oligo (dT)" (Dynal AS, Oslo, Norway) from tissue samples_ eDNA 
was synthesized using the poly A + mRNA captured on the Dynabeads Oligo (dT)2S as solid phase 
and first strand primer. One-tenth of the cDNA was used for each amplification by PCR using 
primer sets specific for hwnan sst\.5, SS, and HPRT (21). Several controls were included in the RT-
PCR experiments. To ascertain that no detectable genomic DNA was present in the poly A + 
mRNA preparation (since the SSR subtype genes are intron-Iess), the cDNA reactions were also 
performed without reverse transcriptase and amplified with each primer-pair. Amplification of the 
cDNA samples with the HPRT-specific primers served as a positive control for the quality of the 
eDNA. To exclude contamination of the PCR reaction mixtures, the reactions were also performed 
in the absence of DNA template in parallel with cDNA samples. As a positive control for the PCR 
reactions of the SSR receptor subt),pes. 0.001 to 0.1 fig of human genomic DNA, representing 
approximately 300 to 30.000 copies of sst-template was amplified in parallel with the cDNA 
samples. As a positive control for the PeR of HPRT and SS, aliquots of a cDNA sample known to 
contain SS and HPRT mRNA were amplified, because these primer-pairs did enclose introns in the 
genomic DNA. In order to quantify sst2 and sst] mRNAs a quantitative RT-PCR. was performed by 
TaqMan' Gold nuclease assay (The Perkin-Elmer Corporation, Foster City, CA) and the ABI 
PruSMs 7700 Sequence Detection System (rhe Perkin-Elmer Corporation) for real-time 
amplification, according to the manufacturers instructions. The specific primer sequences that were 
used for the quantitative RT-PCR included: 
sst,. forward 5'-ATGCCAAGATGAAGACCATCAC-3', 
sst,. reverse 5'-TGAACTGATIGATGCCATCCA-3' 
sst, forward 5'-CTGGGTAACTCGCTGGTCATCTA-3' 
sst, reverse 5'-AGCGCCAGGTIGAGGATGRA-3' 
HPRT forward 5'-TGCTITa::rTGGTCAGGCAGTAT-3' 
HPRT reverse 5'-TCAAATCCAACAAAGTCTGGCITATATC-3'. 
The probe sequences that were used included: 
sst2A 5'-FAM-TGGCTCTGGTCCACTGGCCCTITG-T AMRA-3' 
sst,5'-FAM-CGGCCA=CITCAGTCACCAAC-TAMRA-3' 
HPRT 5'-FAM-CAAGCITGCGAa::rTGACCATCITIGGA-T AMRA-3'_ 
TIle amount of $st2 and sst] mRNA was detennined by means of a standard curve generated in each 
experiment from known amounts of hwnan genomic DNA. For the determination of the amount 
of HPRT mRNA, the standard curve was obtained by including dilutions of a pool of eDNAs 
known to contain HPRT. The amowlt of sst2 and sst] mRNA was calculated relative to the amount 
of HPRT and is given in arbitrary units. 
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Immtmobistochemical localization of sst2A alld sstJ receptors. Immunohistochemistry was 
perfonned on 5-micrometer thick sections cut on a cryostat Gung CM3000). TIle sections were 
fixed for 10 min in 4% pamfonnaldehyde, washed in tap water and phosphate buffered saline (PBS) 
and incubated for 15 min in nomW goat serum (1:10 dilution in PBS + S% BSA). Then, the 
sections were incubated with antibodies against sstM (R2-88, gift from Dr. A. Schonbrunn) and sst) 
(Biotrend, Cologne, Gennany) overnight at 4°C. The antibodies were used at a dilution of 1:1000 
and 1:3000, respectively in PBS + 5% BSA. A standard streptavidin-biotinylated-alkaline 
phosphatase complex (ABC kit, Biogenix, San Ramon, CA) was used according to the 
manufacturers recommendation to visualize the bound antibodies. Finally, the sections were 
developed with New Fuchsine/Naphtol AS-MX, slightly counterstained with hematoxylin and 
mounted. Paraffin-cmbedded sections (5 IJ-Ill) were deparaffinized. rehydrated, exposed to 
microwave heating em citric acid buffer, pH 6.0) at 100°C for 15 min, rinsed in tap water followed 
by PBS. The subsequent steps were perfonned exactly as in the protocol for frozen sections. The 
sstM and sst) antibodies were used at a dilution of 1:500 and 1:2000 in PBS + 5% BSA and the 
sections were incubated at overnight at 4°C. Negative controls for immunohistochemistry included: 
a) omission of the primaty antibody; b) preabsorbtion of the antibodies with the respective 
immunizing receptor peptides (at a concentration of 100 nM). A tissue was considered positive 
when the immunostaining was abolished by pre-absorption of the antibody with the respective 
peptide antigen. 
Statistical analysis. Data are expressed as Mean ± SEM. Binding experiments were perfonned at 
least twice. SSR binding data on membrane homogenates were analyzed by the method of 
Scatchard. 
RESULTS 
Somatostatin receptor binding stlldies. At SSR scintigraphy a high uptake of ['UIn_ 
DTPA-D-Phe']-octreotide was detected after 24 h in the mediastinum of the patient with 
thymoma B2, whereas no uptake was measured in the patient with thymoma A (data not 
shown). Vel)' high physiologic uptake was detected in the spleen (Fig.1A) of a patient with 
carcinoid syndrome whom underwent SSR scintigraphy for the localization of the tumor. 
The diagnosis of carcinoid tumor was confirmed later on. No sites of the disease were 
present in the spleen and this patient was chosen as exemplruy case for studying the inUw 
uptake of ["'In-DTPA-D-Phe']-octreotide in the spleen_ SSR scintigraphy was perfonned 
in this latter patient after 6 months during therapy with octreotide {500 (.lg three times a 
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day). The uptake of the radiopharmaceutical was virtually abolished in the splenic region, 
while not in the kidneys (Fig.lB). 
A B 
FIGURE 1. SSR scintigraphy in a patient with carcinoid syndrome. Planar images of the abdomen 24 h after 
injection of (II1In-DTPA-D-Phe1J.octreotide. Potenor-anterior views. A) Scan performed before starting 
octreotide therapy. There is normal uptake in the spleen (arrow) and kidneys. B) The same patient 6 
months after continuous octreotide therapy. The physiologic uptake of the radiopharmaceutical is abolished 
in the spleen, while not in the kidneys. 
At autoradiography, specific bindiug of [l25j.Tyr']-octreotide was found in all splenic and 
thymic tissues, while no specific bindiug was detected in the thymomas. The bindiug was 
heterogeneous and mainly distributed in the red pulp of the spleen and in the medulla>y 
region of the normal thymuses. The bindiug was specific, since an excess of unlabeled 
[Tyr'J-<>ctreotide (I ~M) displaced it. Scatchard analysis of [125j-Tyr']-octreotide bindiug on 
an enriched membrane preparation of the splenic and thymic tissues revealed high-affinity 
bindiug sites in all cases. For the spleen membranes the estimated K. values were O.8±OA 
nM, with a maximum binding capacity of B~ 163.5 ±24.5 fmoles/ mg membrane protein, 
for the thymus the values Kd were OA±O.I nM, B~ 22±4 fmoles/mg membrane protein 
(Mean±sEM). Figure 2 shows representative experiments. Although no specific binding of 
[mj-Tyr']-octreotide was found in the thymomas, specific binding of [mj_Tyrll]-SS-14 was 
found on enriched- membrane preparation of one thymoma tissue (data not shown). 
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FIGURE 2. SSR expression of in a membrane preparation of human spleen and thymus. Saturation curves 
indicate specific. binding of rl25I.TyrJ}octreotide. hlrets: Scatchard analysis of [mI.Tyr}octreotide binding 
to splenic and thymic membranes A) spleen [Kd, 0.4 nM, maximum binding capacity (Bm...), 139 fmoles! mg 
membrane protein]; B) thymus [Kd, OJ n..\1, Bmu, 18 fmoles! mg membrane protein]. 
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RT·PCR stlldies. By RT·PCR, mRNAs encoding for sstlA and sst, were detectable in the 
spleen, while not 5S, 55tH sst" and ssts mRNAs. (Fig.3). In addition, 55, sst" sst2A and sst3 
mRNA expression was found in the normal and hyperplastic thymic tissues. In the 
thymoma tissue sst j ) sst2A and sst3 mRNA expression was present) whereas sst" and ssts 
mRNA was undetectable (Fig.3). SS mRNA was undetectable in the B2 thymoma tissue 
and sst1ll mRNA was undetectable in all the samples of the present series. Quantitative 
analysis of the sstlA and sst) mRNA content showed a much higher expression of sst2A 
compared to sst, mRNA in the spleen (FigAA). TIlls is also evident from Figure 3B, which 
shows the ratio of sst2A/ sst3 mRNA copies. Conversely, the number of sstJ mRNA copies 
was higher compared to sstlA in the normal, hyperplastic and in one of the thymomas 
(thymoma B2; FigAA). Moreover, the amount of sst'A mRNA was significantly higher in 
the spleen compared to the normal thymic tissues and thymoma. The number of sst) 
mRNA copies was higher in the hyperplastic thymus and in the thymoma B2 compared 
with that in the normal thymic tissue (FigAA). 
1000 bp"-+ 
500 bp 
1000 
500 .... -
B 
FIGURE 3. Heterogeneous expression of 55 and sstj_5 mRNAs in nomlal human spleen, normal thymus and 
thymoma. Poly A + mRNA was reverse transcribed and eDNA was amplified by PeR. PCR products of the 
sstl_5 were separated on 1% agarose gel and stained with ethidium bromide. M, 100·bp ladder; A) spleen; B) 
normal thymus; C) thymoma; D) control. RT-PCR analysis of each tissue was performed at least twice with 
identical results. 
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FIGURE 3. Quantitative analysis of RT·PCR data showing the different relative amount of sstlA and sstj mRNAs 
in human spleen, nonnal and hyperplastic thymus and thymoma tissues calculated relative to the amount of 
HPRT and given in arbitrary units. 
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FIGURE 5. Immunohistochemical detection of Sst2A and sst) receptors in nonnal. spleen, thymus and in thymoma. Upper panel (paraffin.-embedded sections of 
spleen). A) Sst2A~i.mmunoreactivity localized on microevironmental cells in the marginal zone and in the red pulp. C) sst3~immunoreactivity on lymphoid cells 
localized in the outer regions of the periarteriolar lymphatic sheaths. B.D) adjacent sections showing displacement of iromunostainlng after preabsorption of the 
antibodies with 100 nM of the respective peptide antigens. Magnification 200 X; Bar 25 Ilm.Central panel (cryost:tt: sections of thymus). A) sstzKimromoreactivity 
localized on microevlronrnental cells in the thymic medulla. C) sst)-immunoreactivity on thymocytes., mainly at the corticomedullary junction. B,D) adjacent sections 
showing displacement of immunostaining after preabsorption of the antibodies with 100 DM of the respective peptide antigens. Magnification 400 X; Bar 25 /lm. 
Bottom. panel (paraffin-embedded sections of thymoma). A) SS!2A·imrnunoreactivity localized on the endothelium of an intratumoral vessel. C) sst)·im.m.unoreactivity 
within the thymocytes and tumor cells. B,D) adjacent sections showing displacement of immunOstaining after preabsorption of the mcibodies with 100 nM of the 
respective peptide antigens. Magnification 400 X; Bar 25 ).lIIl. 
Sections developed with Ne.v Fuchsine!Naphtol AS-lYDC. The sections are slightly counterstained with hematoxylin. 
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Immunohistochemistry. All the samples, except for the thymomas, were histologically 
normal. In the spleen sstlA immunoreactivity was localized in the marginal zone and 
diffusely in the red pulp, while sst, immunoreactivity was observed in lymphoid-appearing 
cell clusters in the white pulp, patticularly localized in the outer regions of the periatteriolar 
lymphatic sheaths. No sst, immunoreactivity was observed in the red pulp (Fig.5, upper 
panel). In the thymus, immunoreactivity for sstlA receptors was predominantly localized in 
the medulla, particularly around Hassal's corpuscles, while sst] receptor inu11lffioreactivity 
was observed mainly at the corrico·medullary junction, but in the medulla as well (Fig.5, 
central panel). In one of the thymomas, weak sst2A immunoreactivity was found on the 
endothelium of some small intratumoral vessels, while clear sst] inununoreactivity was 
observed on the tumor cells and reactive thymocytes (Fig.5, bottom panel). In all cases, 
immunostaining could be completely abolished by pre.absorption with 100 nM of the 
respective peptide antigens (FigAB,D). 
DISCUSSION 
Based on the higher amount of SSR on tumor cells when compared to normal tissuesJ in 
'liw SSR scintigraphy using [llIIn-DTPA·D·Phe'J-octreotide has become a highly sensitive 
method in detecting SSR·positive tumors (13,14). However, the visualization of normal 
organs, namely pituitary gland, thyroid, spleen, liver, and kidney occurs as well. In the 
spleen it has been demonstrated that the in viw radiolabeled SS analog uptake is due to the 
presence of SS-binding sites within the tissue (15). Conversely, the normal and hyperplastic 
thymus, which is known to contain SSR as well, is generally not visualized during SSR 
scintigraphy (8,15,17). Thymic visualization barely occurred in a few vel}' young children 
(30), while rumors originating from this organ were successfully localized (18.21). ['"In_ 
DTPA-D.Phe'J-octreotide accumulation in sst,·expressing cells may be determined by the 
internalization of the radioligand-receptor complex. Several authors have shown this 
mechanism, demonstrating the internalization of SS, octreotide and radiolabeled 5S analogs 
into sst,.expressing cells in,,;/>v (31-35). The majority of human SSR-positive rumors, which 
display a significant .,viw uptake of ["'In-DTPA-D-Phe'J-octreotide, express multiple SSR 
subl)'pes (36). It has recently been shown that among several SSR scintigraphy-positive 
rumors, 3 thyroid tumors lacked the expression of sst, receptor (37), suggesting that tissue 
expression of sst2J which has the highest affinity for octreotide, is not a prerequisite for 
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positive imaging. An additional important observation is the absent or only faint expression 
of sst, mRNA in normal thyroid tissue (37,38), since the thyroid gland, as well as the 
kidneys are constatly visualized during [IIIIn-DTPA-D-Phe1]-octreotide scintigraphy, and 
the uptake may be slightly decreased but not abolished during continuous treatment with 
"cold" octreotide. Conversely, the uptake in the spleen is markedly reduced or even 
abolished during octreotide therapy (39). In agreement with this, in our representative case 
shown in figure 1 who underwent SSR scintigraphy during long-term treatment with 
octreotide, the uptake of the radiopharmaceutical was aholished in the splenic region, while 
not in the kidneys (Fig.1B). Thus, the heterogeneity of SSR subtype expression might playa 
significant role in determining the uptake of [lllIn-DTPA-D-Phe1]-octreotide, accounting 
for the differential behaviour of SSR-expressing tissue during administration of competitive 
"cold" octreotide. 
In order to evaluate whether the level of different SSR subtypes might be involved in the 
heterogeneity of inviw[ItIIn-DTPA-D-Phel]-octreotide uptake as well, we used quantitative 
RT-PCR analysis, which allows examining the relative amount of mRNA expression. This 
technique has been recently successfully employed for the quantification of SSR subtype 
proftIes in human pituitary tumors (40). We found a predominant expression of sst" 
mRNA in normal human spleen, while normal or hyperplastic thymus and one of the 
thymomas expressed relatively higher sst, receptor mRNA compared to the spleen. The 
high and almost selective expression of sst" mRNA in the human spleen is in line with the 
evidence of high ul'viw uptake of [lllIn-DTPA-D-Phe1]-octreotide as well as the decreased 
accumulation of the radiopharmaceutical occurring during octreotide therapy. In fact, 
treatment with octreotide may saturate sstlA receptors, which have the highest affinity for 
tlus octapeptide SS analog. However, in thymic tissue and especially in the hyperplastic 
state and in the B2 thymoma, sst, mRNA is predominantly expressed. Indeed, this 
thymoma (E2) was clearly visualized during SSR scintigraphy, suggesting that the 
involvement of sst, receptors in the uptake of ellIn-DTPA-D-Phe1]-octreotide can not be 
ruled out. In vitro studies revealed a low expression of sst1A, the absence of ssts and high 
expression of sst) receptor in the B2 thymoma. Cons{dering the highest agonist-dependent 
internalization rates demonstrated for sst, receptor (31), this SSR subtype might be 
involved in the in viw uptake of["'In-DTPA-D-Phe1]-octreotide as well. Conversely, in the 
second tumor, classified thymoma A and not visualized during ellIn-DTPA-D-Phe1]-
octreotide scintigraphy, the expression of sst) mRNA was lower than that in the normal 
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thymic tissue. Interestingly, the highest amount of sst2A and sst) receptors, but with a 
sstlA/ sst) ratio comparable to the normal thymus, has been found in the single case of 
thymic hyperplasia that was studied. FlUther studies on a larger number of hyperplastic and 
tumorous thymuses are needed, however, to confinn this observation. 
The above-described in vitro techniques do not allow to distinguish which cell type 
expresses a distinct SSR subtype. Moreover, lymphoid tissues are rather complex both in 
their structure and in the heterogeneity of cell content. In the last few years much progress 
has been made in the cellular localization of SSR, due to the development of antisera 
against specific peptide sequences of SSR subtypes. Immunohistochemistty allowed 
documenting the distribution at the cellular level of the receptor proteins in normal and 
abnormal tissues (22-25). SSR subtypes have been recently evaluated by 
immunohistochemistty in lymphoid tissues as well, where the receptor expression is much 
lower compared to neuroendocrine tissues (26.28). Using two specific antibodies for sst2A 
and sst3 receptors, respectively, we found sstlA inununoreactivity mainly located in areas 
where microenvironmental cells are prevalent, while sst) inununoreactivity was 
preferentially observed on cells that have recognizable lymphoid morphology, in bod, 
spleen and thymus. In fact, sstlA inununoreactivity was preferentially located in the medulla 
of the thymus, where epithelial cells, dendtitic cells, and macrophages are predominant cell 
types, and in the marginal zone and red pulp of the spleen, where monocytes and 
macrophages are predominant. These data are in agreement with the binding of the sst,-
preferring ligand, [ '25I-Tyr'J-octreotide, detected at SSR autoradiography. Conversely, sst, 
immunoreactivity was preferentially observed in the deep cortex of the thymus, as well as 
in the border areas with the medulla, which are regions containing highly and densely 
packed developing thymocytes. In the spleen, sst, immunoreactivity was detected in the 
periarteriolar lymphoid sheaths of the white pulp, which are densely packed of T 
lymphocytes. Finally, immunohistochemistty confirmed the predominant expression of sst, 
in the B2 thymoma tissue, which is a tumor with a predominance of lymphocytes (41). 
These observations confirm previous data showing a strong compartmentalization of 
neuropeptide receptors in lymphoid tissues (8). The distribution of SSR in these lymphoid 
organs suggests that distinct receptor subtypes might be expressed at specific 
differentiation stages of lymphoid or accessory- cells. Moreover, in the spleen the detection 
of immunoreactive cells near the marginal zone might be related to their antigenic 
stimulation. The marginal zone is populated by a mixture of macrophages having a COllb 
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and COl4 phenotype and many pale endothelioid ceUs, plus few T and B lymphocytes (42). 
These findings are in agreement with the recent obsetvation of sst2A immunoreactivity in 
endothelial ceUs of venules and capillaries, as weU in a subset of ceUs of the 
monocyte/macrophage lineage in tissue biopsies from patients with hwnan immWle-
mediated diseases, such as rheumatoid arthritis (26). Moreover, sst2A immunoreactivity has 
been observed in biopsies from patients suffering from granulomatous diseases, such as 
sarcoidosis and \'(i'egener's granulomatosis, again associated with cells of the mononuclear 
phagocyte lineage, including epithelioid ceUs and multinucleated giant ceUs within the 
granulomas (27). Finally, the predominant inununoreactivity for sst, receptor in areas rich 
of thymocytes in the thymus and in areas rich of T ceUs in the spleen is in line with the 
recent data showing the selective expression of sstJ mRNA in human resting peripheral T 
lymphocytes (43). 
In conclusion, the sstlA receptor determines the uptake of [11IIn-DTPA-D-Phe1}octreotide 
in the spleen. However, since ["'In.OTPA.D.Phe'}octreotide binds with high affinity to 
sst2 receptors, but with lower affinity to sst) as well, and because uptake of this 
radiopharmaceutical is observed in a sst)-expressing tumor lacking sst2A and ssts receptors, 
the sst, may he involved in the &1 viw uptake of [!!'In.OTPA.D.Phe'}octreotide. The 
affinity of the radioligand for the receptor, as weU as the efficiency of internalizarion of the 
radioligand.receptor complex might playa concomitant role in determining the uptake in 
receptor-positive tissues during in vim SSR scintigraphy. However, the heterogeneity of 
expression and the level of SSR subtypes may contribute in determining the uptake as weU. 
Indeed, most of the data on agonist·induced internalization of the 5 SSR subtypes are 
derived from studies using transfected ceU lines. Further data on the internalization of SSR 
ligands by ceUs which express SSR subtypes endogenously are mandatoty in order to 
elucidate several remaining questions regarding human SSR.positive ceUs. Although in 
lymphoid tissues SSR subtype distribution needs to be further investigated, the present data 
indicate that specific SSR subtypes are expressed on distinct ceU subsets within inunune 
tissues. Such a distribution might explain the heterogeneity of the effects exerted by S5 in 
the immune system. 
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GENERAL DISCUSSION 
GENERAL DISCUSSION 
In the second half of the last centuty, a large number of studies have demonstrated the 
existence of tonic control of the irnmWle system by honnones and neuropeptides, as well 
as the influence of immune-derived products on neura-endocrine mechanisms (1). Virtually 
all tissues throughout the human body may contain resident immune cells. During certain 
physiologic or pathophysiologic conditions, these cells are recruited and are involved in 
immwlOlogical and inflammatory processes. However, resident immune cells and their 
products coexist with hormones and neuropeptides, which reach the interstitial space or are 
locally produced by the diffuse neuroendocrine system, or are even generated by llrunWle 
cells themselves, and interact with them (2,3). The result of this integrated system displays 
the final responses of the organism in order to preserve its own homeostasis (1-3). 
Specialized primary lymphoid organs, apart from being the organs where immune cells 
develop, may be considered preferential sites where the above-described immune-neuro-
endocrine interactions mainly occur. In support of this concept, lymphoid organs are 
extensively innervated by autonomic and peptidergic fibres. Furthermore, neuropeptides 
are actively produced in the microenvironment of these organs (1). 
SS is a neuropeptide that has been extensively investigated for its well-known inhibitoty 
actions in the nervous and endocrine systems. However, the immunomodulatory role of SS 
has gained interest since SSR were described in sites of immunological and inflannnatoty 
activity, as well as directly on immune cells (4). Although the expression of the five SSR 
subtypes on endocrine and neural cells has been extensively investigated, the data on 
immune cells remain contradictory. For example, conflicting results have been obtained in 
cell lines from different species (animal and human cell lines), as well as primary cultured 
cells (from animals and humans). This points to a differential expression of SSR on 
immune cells between animal and human models (5). The situation becomes even more 
complex as SSR subtype expression in immune cells seems to be dependent on the 
activation state of cells or on the localization of immune cells (homing in tissues or 
circulating cells) (1,5). Finally, SS may exert a "biphasic" effect on immune cells, with 
inhibition at low (nanomolar) concentrations and absence of an effect at higher 
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(micromolar) concentrations. The reasons for these observations are unclear, but may 
involve receptor internalization and subsequent down-regulation, uncoupling from second 
messenger activation, and/or activation of different intracellular second messenger 
pathways via distinct SSR subtypes (6). However, although there are differences between 
neuroendocrine and immune cells, some basic aspects are comparable between these 
different cell populations, considering also that these cells closely collaborate and share 
specific signalling molecules. 
The focus of this thesis is the human thymus. This choice was made because this primaty 
lymphoid organ represents a paradigmatic case of integration between the neuroendocrine 
and immune systems. Complex intrathymic circuits involving the local production of 
neuropeptides and hormones participate in the primruy "lymphoid" function of this organ, 
namely the development of T-cell repertoire, as well as in the less explored "endocrine 
function" of the human thymus (7). The main aim of tillS thesis was to evaluate whether SS 
and its receptors playa role in this system. Recently, it was demonstrated that thymic 
epithelial tumors could be visualized ill tiw by SSR scintigraphy using radiolabeled SS 
analogs (8,9). Since rather scarce and conflicting data on SSR expression and their 
significance in the normal and neoplastic thymus were present in the literature, the first 
step was to characterize the SS and SSR subtype expression in the normal hwnan thymus. 
Emphasis was given to the specific cellular localization of SSR subtypes and to the 
potential significance of such distribution (chapter Il). 
SS alld SSR slIbtypes characterizatioll, distriblltioll alld fllllctiollal role ill llorlllal 
hl/Illatt t"YIllIIS 
Mainly binding studies and RT-PCR were used to characterize SS and SSR subtype 
expression in normal human thymus. SS and three SSR subtypes, sst l and sst1A and sst) 
were found in the tissue (chapter IIA) (10). No expression of the splicing variant sst" was 
found in any of the tissues and cells studied. The expression of these different subtypes 
appeared to be heterogeneous within the tissue and to be localized on different cell subsets. 
A selective expression of sst, and sstlA was found on TEe, in line with the evidence of 
[!1;I-Tyr'J-octreotide binding in the thymic medulla, where TEC is the prevalent cell type 
(chapter IIA). In fact, [125I-Tyr'J-octreotide is considered a sst,-preferring ligand. TEC were 
found also to be a potential source of SS production witllin the thymus, since SS mRNA 
was found to be expressed in these cells (chapter 11.4) (10). Conversely, SS mRNA was 
undetectable in thymocytes and the distribution of SSR subtypes on this heterogeneous cell 
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population appeared complex (11). In fact, in freshly isolated thymocytes sstlA and sst, 
mRNA expression was detected, while in long-term cultured thymocytes no mRNA 
encoding for 55R subtypes was detectable (chapter U.s), suggesting a relatively rapid down-
regulation of SSRs on thymocytes during culture. Moreover, sst3 rnRNA expression was 
higher in intermediate/mature thymocytes, whereas sst'A mRNA was highly expressed in 
the more immature fractions. In addition, sst2A was the predominant receptor in the early 
CD34' thymocytes, which belong to the most immature subset of lymphoid cells in human 
thymus (chapter U.S). The low fraction of the latter cell subsets of the total thymocyte 
population might explain the lack of binding of the sst,-preferring ligand [ml_Tyr']_ 
octreotide in the study of thymocyte membrane homogenates (chapter U.s). Therefore, the 
binding of the universal ligand [l15l.Tyr"]-5S-14, which binds to all 5 5SR subtypes with 
high affinity, was likely due to the binding of this ligand to sst, receptors on the 
intermediate/mature cells. These cells represent the major population of thymocytes. In 
general, the number of SS~binding sites was low, in agreement with the presence of a low 
nwnber of SS.binding sites on circulating human T lymphocytes (12), which derive from 
thymocytes. Finally, on macrophages, the third thymic cell component examined, the 
presence of only sst" mRNA was detected (chapter U.s). This finding is in agreement with 
previous reports showing the selective expression of this SSR subtype on human 
macrophages and monocytes (13,14, Lichtenauer-Kaligis EGR et al., unpublished 
observations). The presence of functional SSR subtypes on both TEC and thymocytes was 
demonstrated by in viao studies on isolated cell cultures using SS and the SS analog 
octreotide (chapters 11.4 and 11.5). 
The first consideration is that the expression pattern of SSR subtypes in the thymus shows 
a species-specific distribution. There are substantial differences between man (chapter U.s) 
and the two more extensively studied animal models, i.e. the rat and mouse (15.18). These 
differences make both these two models rather unsuitable for studying the effects of 5S on 
human thymic cells. Also the local production of 5S seems to have a different source in 
mouse and human. In fact SS mRNA was found in human TEC (chapter 11.4), but not in 
thymocytes or monocyte/macrophage lineage cells, whereas in mouse the peptide is mainly 
present in macrophages (10,19). 
Taking into consideration the peculiar hwnan thymic microenvironment, its architecture 
and the specific pattern of SSR distribution, the existence of specialized areas where 5S and 
its receptors might exert differential activities may be hypothesized. 
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On microenvrronmental cells, sst.2A seems to be the receptor predominantly expressed and 
an autocrine or paracrine activity of 55 could be involved in controlling the different 
functions of these cells. A potential role for the neuropeptide in controlling TEC growth is 
suggested by the inhibitory effect of both 55 and its octapeptide analog octreotide on 
unstimulated and growth factor·stimulated proliferation of cultured TEC (10) (chapter 
11.4). Interestingly, pituitary hormones, which are under hypothalamic 55 control, such as 
GH and PRL, as well as IGP·I enhance TEC proliferation (20.23). However, since sst'A is 
the SSR subtype mainly involved in controlling secretion processes by neuroendocrine 
cells, further studies should investigate this possibility for thymic cells as well. In fact, TEC 
and macrophages produce a significant number of thymic hormones and cytokines, and 
these thymic secretory substances have previously been demonstrated to be influenced by 
other neuroendocrine factors (7). Both TEC and macrophages drive the maturation of 
thymocytes and are actively implicated in the positive and negative selection of the future T 
lymphocytes. In addition, macrophages are classical antigen·presenting cells and may play 
this role in the thymus as well. The presence of specific 55R on these cells suggests the 
involvement of the neuropeptide in regulating such highly specialized cell activities in the 
thymus. On the other hand, 55 and other neuropeptides have been reported to effectively 
modulate proliferation, cytokine production and antigen presentation by macrophages in 
the skin under physiological and pathophysiological conditions (24). 
However, sstlA receptors are expressed on a subset of htunan thymocytes as well (chapter 
U.s). The pattern of 5SR subtype expression on thymocytes seems to follow a predisposed 
order related to the different stage of maturation of the lymphoid cells (chapter U.s). The 
most inunature cortical thymocytes preferentially express sst2A, while moving towards the 
medulla, where thymocytes are more mature, sstJ becomes the SSR subtype predominantly 
expressed on these cells (chapter U.s). TIns pattern of expression is particularly interesting 
considering that sstlA has been indicated as the main 5SR subtype expressed by progenitor 
cells in murine bone marrow (Oomen S, unpublished observations). The higher expression 
of this subtype on CD34+ early thymocytes (chapter U.s) seems in line with this evidence. 
Precursors from bone marrow reaching the thymic cortex might keep the expression of 
sstlA until a certain phase of their intrathymic maturation. It is important to underline that 
inunature thymocytes are actively proliferating cells, Wldergoing a rearrangement process of 
surface antigen molecules, which will constitute the future phenotype and commitment of 
the developing thymocyte. The presence of sstlA receptors in this phase nlight be related to 
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the necessity of a modulatory action on these processes, which may be exerted by SS via 
this receptor subtype. 
Conversely, sst, is expressed mainly on thymocytes that have reached a higher level of 
maturation dw-ing the complex cascade of events occuning in the thymic network (chapter 
II.5). Interestingly, this SSR subtype seems to be selectively expressed on peripheral resting 
T lymphocytes, which directly derive from mature thymocytes (12). In the thymus, the 
majority of thymocytes are destined to die as a consequence of failing selection (25). Since 
cell death in the thymus occurs by apoptosis, the expression of the sst) on these cells is 
intriguing. In fact, this SSR subtype may be involved in agonist-mediated apoptosis (26). 
The presence of a receptor involved in this sophisticated process is highly suggestive for a 
modulatory activity of SS in thymocyte deletion. However, further studies should elucidate 
whether SS might have an inductive or protective effect on progranuned cell death in the 
hwnan thymus. Recently, potent inducers of apoptosis in thymocytes, such as 
glucocorticoids, have also been shown to be implicated in the rescue of thymocytes from 
activation-induced cell death (27). 
Emerging data have shown that adhesion molecules, extracellular mattix ligands and 
receptors drive thymocyte traffic, in terms of entrance of precursors, migration within the 
thymus, as well as exit of mature cells from the organ. This process seems to be influenced 
by neuroendocrine products as well (28-32). Since SS and other neuropeptides are involved 
in regulating the migration of immune cells in other compartments throughout the human 
body (33-35), and considering the peculiar distribution of SSR within the thymus, SS 
probably plays a role in the modulation of this mechanism. This modulation may be 
important considering that a disturbance in tlus process may favour traffic of immature or 
wrongly selected cells towards peripheral lymphoid organs, enabling the development of 
autoinunune diseases. 
The recent availability of the antibodies specific for sst1A and sst) receptors made it possible 
to further investigate the cellular localization of these receptor subtypes by 
immunohistochemistry in human lymphoid tissues (chapter IIl.5). Apart from the thymus, 
the normal human spleen has been investigated as well. As already discussed, these tissues 
are highly complex both in their structure and in the heterogeneity of cell content. 
However, in general, sstlA immunoreactivity was mainly located in areas where stromal, 
non-lymphoid cells were prevalent, while sst) inununoreactivity occurred preferentially on 
cells with lymphoid morphology, both in the spleen and in the thymus (chapter III.5). The 
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sstlA inununoreactivity, preferentially located in the medulla of the thymus and in the 
marginal zone and red pulp of the spleen, is in agreement with the binding of the sst,-
preferring ligand, [125I-T~}octreotide, detected by SSR autoradiography, and with the 
expression of sst" mRNA in isolated TEe (10). Conversely, sst, immunoreactivity 
preferentially observed in the deep cortex of the thymus as well as in the border areas of 
cortex and medulla, and in the periarteriolar lymphoid sheaths of the white pulp of the 
spleen, points to a clear lymphoid cell localization of this SSR subtype. Again, these results 
were in line with those of ligand-binding studies and RT-PCR Thus, with tlus techrllque, it 
might be concluded that distinct SSR subtypes are expressed at specific differentiation 
stages or states of lymphoid and accessory cells. 
A novel finding in the spleen is the detection of sstlAwimmunoreactive cells near the 
marginal zone, which might be related to the antigenic stimulation of these cells as well as 
their activity as antigen-presenting cells (chapter III.5). In general, SSR distribution within 
these lymphoid tissues might offer an explanation for the variety of effects exerted by 
stimulation with SS of heterogeneous populations of immune cells. 
A final, but not less important, potential activity of SS within the thymus might be its 
involvement in the control of the physiologic involutive process which occurs in this 
lymphoid organ with ageing (chapter II.6). The human thymus undergoes involution and 
decreases its activity in producing mature T cells. However, recent evidence points at the 
maintenance of an "endocrine" activity of this organ, which might need a differential 
regulation during ageing (36). Further studies are necessary to clarify whether the decrease 
of SSR in the human thymus during ageing is a programmed step during the involution or 
whether it is a consequence of the process in itself. 
The local production of SS in the human thymus seems to be extremely relevant since the 
neuropeptide might act at different levels, on different thymic cells and vii different 
receptor subtypes. SS within the human thymus might be considered as a potential 
modulator of the homeostasis of various cell components as well as a regulator of their 
specialized activities. Moreover, S5 seems to directly participate in the main thymic 
function, namely the manlration of the human T cell repertoire. The hypothesis of a 
multiple role of S5 in the thymus is in line with the similar observation for another well-
known neuropeptide, Vo'. In fact, both 55 and Vo' are produced within this organ and a 
strong compartmentalization of their respective receptors has been shown on human 
thymic cells (37). Like S5R, the two Vo' receptor subtypes display a distinct distribution in 
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different thymocyte subsets, at least on munne and rat thymus, confirming that the 
expression of neuropeptide receptors could be differentially regulated during development 
(38). Finally, VIP may also affect multiple aspects of thymic cell functions (37,38). An 
integrated role for these two neuropeptides, possibly together with SP, has been already 
hypothesized (39). However, the exact parameters regularing a hypothetical intrathymic 
circuit between these three substances have not been established yet. In general, in 
different pathophysiological conditions SS and VIP seem to "counteract" the effect of SP 
on immune cells (40.42). However, in other situations, SS and VIP may have opposite 
effects on specific cell subsets, while acting synergistically on others (42). 
A summarized and suggestive scheme of SSR distribution and SS activities within the 
normal human thymus in reported in Figure 1. 
Somatostatin 
FIGURE 1. Hypothetiat\ scheme for the principal actions of SS within the nonna! human thymus. S5 is 
locally produced and multiple receptor subtypes are expressed on different cell subsets or are differentially 
expressed on the same cell type. SS might act at different levels, modulating several processes within the 
organ. Since SSR are expressed on TEe and thymocytes, cell proliferation and perhaps production of 
specific factors may be controlled by the neuropeptide. Traffic, maturation, selection and deletion of 
thymocytes might be influenced by 5S as well. Finally, the activities of cells belonging to the 
monocyte/macrophage lineage might also be targets of 55. 
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The hypothesis on the relevance of SS and SSR in thymus physiology discussed above form 
the basis for a better understanding of some mechanisms, which may occur in pathological 
conditions of this organ. 
Distriblltioll and significance of SS alld SSR ill hllmall tbYlllic tlllllors 
Like other tumors originating from SS-target tissues, human thymic epithelial tumors may 
express SSR. These neoplasms are visualized in vim during SSR scintigraphy using [IIIIn_ 
DTPA-D-Phe')-octreotide (8,9) (chapter IlIA). Although preliminary ligand-binding studies 
failed to detect SSR on cryostat sections of human thymomas (39), at least three SSR 
subtypes have been detected by inununohistochemistty using polyclonal antibodies specific 
for sstl, sstlA and sst) receptors (chapters IlL3 and lIlA). Moreover, in one case the 
expression of SSR subtypes was confinned at rnRNA level by RT-PCR analysis (43) 
(chapter III.3). Since the number of receptors in normal thymic tissue as weD as in 
thymoma is rather low, a different sensitivity of the two methods might in part explain this 
discrepancy. SstlA and sst) receptor expression was found in 7.itm in a series of human 
thymic tumors that were visua1ized by in vim SSR scintigraphy as weD. Considerable 
heterogeneity of SSR inununoreactivity was found within and among the tumors (chapter 
IlIA). Although both receptors were expressed within the tumor tissue, overall sst) showed 
higher expression compared to sstlA and displayed a preferential localization on reactive 
thymocytes. However, human thymomas are a heterogeneous class of tumors (44). 
Moreover, sstM and sst) receptors are expressed in the normal thymus as well, whereas this 
organ can not be visua1ized by SSR scintigraphy. Therefore, the density and the 
heterogeneity of such distribution have been further investigated (chapter m.5). The 
nonnal human spleen was also included in this study, as a paradigmatic case of a nonnal 
lymphoid organ, which is in fact visua1ized during SSR scintigraphy (chapter Ill.5). The 
study conducted in the human spleen, the normal and hyperplastic thymus as weD as 
various thymomas revealed a peculiar density and distribution of sst2A and sst) receptors in 
these lymphoid tissues (chapter Ill.S). Both receptor subtypes were heterogeneously 
expressed in all tissues, but with a predominant, almost selective expression of sst2A 
receptors in the spleen, and a prevalent expression of sst) receptors in the normal and 
hyperplastic thymus as weD as in one thymoma. Analyzed in detail, these results were useful 
to clarify some apparently equivocal data. Firstly, the heterogeneity of SSR expression and 
the density of different receptor subtypes might playa crucial role in determining the in'liw 
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uptake of radiolabeled 55 analogs, at least in lymphoid tissues. The data from this study 
suggested that the presence of sst] receptors is not an essential prerequisite for the 
visualization of 55R-positive tissues during ['"In-DTPA-D-Phe'J-octreotide scintigraphy. 
The accumulation of this radiopharmaceutical in sstiA-expressing cells is determined by the 
internalization of the radioligand-re<:eptor complex. The high and almost selective 
expression of sstlA receptors in the human spleen is in line with the evidence of high inmo 
uptake of ['"In-DTPA-D-Phe'J-octreotide as well as with the decreased accumulation of 
the radiotracer occurring during "cold" octreotide therapy. In fact, treatment with 
octreotide may saturate sst" receptors, which have the highest affmity for this octapeptide 
55 analog. In one of the two thymomas, sst, mRNA was predominantly expressed, 
suggesting that the involvement of sst, receptors in the uptake of ['"In-DTPA-D-Phe'J-
octreotide in thymomas cannot be ruled out (chapter IlLS). The high agonist-dependent 
internalization rates that were demonstrated for sst3 receptors may support this hypothesis 
(45). Further investigations are necessary to establish if this concept might be valid for 
other 55R-expressing tissues as well. The possibility that other factors may influence the 
mechanisms involved in regulating the in viw uptake of radiolabeled 55 analogs in lymphoid 
tissues cannot be ruled out. Receptor turnover and bindiug properties might be regulated 
differently in lymphoid cells compared to neuroendocrine cells. In fact, the activation of 
55R subtypes on lymphoid cells may induce opposite responses compared with endocrine 
cells (4-6). Taking into consideration that bl viw several factors may interact and influence 
each other, the target cell system might play its own part in determining the amount and 
the quality of the radiotracer uptake as well. It has been demonstrated that thymocytes, 
which are the major cell population in the human thymus, can rapid~' down-regulate the 
expression of their 55R when cultured in villV (chapter II.5). Apparently, thymocytes are 
cells with a wide plasticity in terms of modulation and expression of surface molecules. 
From this point of view it would be interesting to investigate what occurs in reactive 
thymocytes in thymomas. Perhaps in viw 55R expression on these cells may be rapidly 
regulated and the affinity of receptors for their own natural and synthetic ligands might be 
differently modldated, dependiug on factors intrinsic to the tumor as well. 
In general, in light of these new findiugs it may be hypothesized that, on the basis of its 
bindiug properties and receptor affinity, [I15I-Tyr'J-octreotide may be considered as a dear 
sst,-preferring ligand for in ""'0 bindiug studies. In uw several exogenous fattors may 
influence these properties and may playa role in determining the uptake of [IIIIn-DTPA-D-
211 
Gmerd doolSSiQtl 
Phel]·octreotide within 55R.expressing tissues and tumors as well. This is a point that may 
have important consequences for future applications of the currently available 55 analog 
for systemic radiotherapy as well as for the development and use of novel subtype.selective 
analogs and antagonists. In addition, tillS knowledge may open new perspectives in the 
clinical application of SS and its analogs in autoimnUUle and neoplastic diseases involving 
the immune system. Literature data point to a certain efficacy of treatment with SS analogs 
in this respect. Of particular interest is the reported successful treatment of patients bearing 
thymomas associated with paraneoplastic syndromes with the 55 analog octreotide or with 
the combination of octreotide and corticosteroids (9,46). In one of these patients, a clear 
reduction of tumor size was observed after longMterm treatment with octreotide and 
prednisone. However, a significant improvement was observed in the thymoma-associated 
red cell aplasia as well (46). As far as the effect on the autoimImme disease is concerned, 
further studies should investigate whether the effect of therapy with 55 analogs may have a 
rationale in the treatment of the severe autoinunune diseases which are frequently 
associated with thymic disturbances. 
As for their role in determining the VI viw uptake of labeled 55 analogs, 55R expression in 
these tumors is with high probability connected to the effects on the tumor mass exerted 
by therapy with 55 analogs (chapter III.4). A point in favour of this may be extrapolated 
from the analysis of one paradigmatic case displaying a significant inviw uptake of [IIIIn· 
DTPA.D.Phelj-octreotide and a preferential expression of sst, receptors in 'lilm (chapter 
IIU). In viM, this cortical thymoma showed a significant inhibition of cell proliferation 
when 55 and octreotide were administered. The two intriguing findings from this tumor 
were the selective expression of sst,} on cultured neoplastic cells, which candidate this 
receptor as a mediator of the blvitm inhibitory effects of 55 and octreotide, and the lack of 
endogenous 55 in tumor tissue (chapter IIU) (44). As aheatly discussed in the first section, 
55 is endogenously produced in the nonnal thymus and a wide spectrum of activities has 
been suggested for this neuroeptide on the thymic microenvironment, especially with 
regard to T cell maturation and more general, on cell homeostasis (chapter II). Although 
very preliminary, the loss of 55 in a tumor arising from this organ might be involved in the 
pathogenesis of the neoplastic transfOlmation as well as in the pathogenesis of the 
autoimmune diseases often associated with these complex tumors. A disturbance in the 
network of SS and its receptors in the thymus may be suggestive for its implication in the 
occurrence of hwnan autoimmune diseases. In this respect it would be interesting to 
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further investigate the mechanisms of the significant up-regulation of SSR observed in one 
case of thymic hyperplasia associated with m)nstlxnia g;uvis (chapter III.5). However, as 
previously underlined, thymomas represent a highly heterogeneous class of tumors and 
further investigations are mandato!)' to elucidate the significance of the specific SSR 
subtype expression in these tumors. 
SSR on target cells can be actively up- or down-regulated by the exposure to several 
heterologous agents as well as to its own ligand. In general, changes in the density, quality 
and activity of local regulato!)' factors might alter the distribution and concentration of 
neuropeptide receptors and their ligands. This may also apply to the human thymus, where 
the global activity of the organ is based on the balance of several regulating factors locally 
produced. Disturbances in this delicate equilibrium may lead to the induction of 
inappropriate immune responses and to the occurrence of diverse diseases. 
FUTURE PERSPECTIVES 
The data presented and discussed in this thesis indicate that SS is involved in the complex 
neuroendocrine control of human thymus physiology. The presence of specific and distinct 
SSRs on both lymphoid and microenvironmental cells suggests that the neuropeptide 
might be necessary to maintain various biological functions of this organ. Further studies 
should be designed to establish the functional significance of such a receptor distribution 
pattern and to elucidate the role of SS in the interactions occurring between thymocytes 
and microenviromental cells. 
The use of foetal thymus organ cultures and in viw experiments will certainly be useful to 
defme the extent and the importance of the autocrine and paracrine circuits involving S5 
and other mediators within the human thymus, including their role in thymic development. 
Moreover, the use of different knockout mice, as well as genetically engineered animals in 
which the receptor gene can be activated may represent additional experimental models 
highly useful in better determining the relative significance of a given receptor and the 
respective ligand in such a complex system. However, it should be emphasized that caution 
must be taken in extrapolating data from animal models, considering the apparent 
differences existing in neuropeptide receptor distribution between different species. 
Taking into account the peculiar distribution of SSR receptor subtypes within the human 
thymus, multiple targets for the activity of SS may be identify in this primary lymphoid 
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organ. Several honnones and neuropeptides are known to exert a control on the secretion 
of different intrathymic factors, such as thymic hormones and cytokines, as well as other 
"classical" hormones and neuropeptides produced by either stromal or lymphoid elements. 
This is a rather unexplored field, especially concerning the role played by SS. FurthemlOre, 
the presence of different SSR subtypes on antigen-presenting cells and on specific 
thymocyte subsets warrant further investigations. In fact, the potential involvement of SS 
in controlling specialized activities of these cells, as well as the traffic of lymphoid cells 
within the thymus might be important to develop new therapeutic strategies based on the 
selection and manipulation of lymphoid cells during their intrathymic differentiation. This 
point might become extremely relevant in light of the new advances in transplantation of 
postnatal cultured thymic tissue in patients with severe immunodeficiency syndrome (47). 
Finally, a further in 'vitm characterization and more controlled in tiw studies including a 
larger number of cases are required to better understand the functional and clinical 
significance of SSR in human thymic neoplasms and to clarify the mechanism of action of 
55 analogs in the treatment of these tumors. 
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SUMMARY 
Specialized primaty lymphoid organs are the preferential sites of immune-neuro-endocrine 
interactions. 5S exerts mainly inhibitory actions in the nervous and endocrine systems. 
However, it has an immunomodulatory role as well, and the study of its activities in the 
immune system has opened a new stimulating area of research. Dta on the expression of 
the five SSR subtypes on immune cells is still conflicting. Results obtained in cell lines as 
well as primary cultured cells point to a differential expression of 55R on immune cells in 
animal and human models. In contrast to neuroendocrine cells, 5S exerts a "biphasic'l 
effect on immune cells, via tmclear mechanisms. Although there are differences between 
neuroendocrine and immune cells, some basic aspects are comparable. 
In tillS thesis the attention has been focused on the htunan thymus, since this lymphoid 
organ represents a paradigmatic case of integration between the neuroendocrine and 
immune systems, where the role of SS and SSR have been poorly explored so far. 
Two main questions have been addressed. First, the identification of the 5SR subtypes 
expressed in the normal htunan thymus and the impact of the system SS/SSR in the 
physiology of this primaI)' lymphoid organ; secondly their role in the pathological 
conditions of this organ was investigated. The answers to these questions might have 
important consequences for the diagnosis and therapy of disturbances involving the 
immune system. 
Chapter I gives a comprehensive introduction to the most recent knowledge on the 
significance of neuropeptides and their receptors within the immune system, with special 
emphasis to SS and SSR. In chapter II, the first two paragraphs introduce the structure 
and function of the nonnal human thymus and its neuroendocrine circuits, followed by the 
characterization of SS and 55R subtype expression, with special attention to the specific 
cellular localization of SSR subtypes and to the potential significance of such distribution in 
thymus physiology and pathophysiology (chapter 11.3, 4 and 5). 
5S, sstl and sstM and sst} were found heterogeneously expressed within the tissue and in 
different cell subsets. A selective expression of sst) and sst2A was found on TEe, which 
also revealed to be a potential source of endogenous SS (chapter 11.4). Conversely, SS was 
219 
Stnnm:ny 
undetectable in freshly isolated thymocytes. These cells expressed sst2A and sst) receptors as 
well. However, differently from TEe, after long·term culture thymocytes rapidly down-
regulated their SSR expression (chapter 11.5). While sst'A was progressively higher 
expressed in the most immature fractions, sst) expression was higher' in 
intermediate/mature thymocytes. The nwnber of 55-binding sites was low, in agreement 
with the same finding on thymocyte-derived circulating T lymphocytes. On thymic 
macrophages, the third component examined, only the presence of sst2A was found 
(chapter 11.5). The species-specific distribution of SSR and the different source of S5 in 
humans makes it diffiCl~t to find a model for studying the activity of 55 on thymic cells. 
The presence of functional 55R subtypes on both TEe and thymocytes was demonstrared 
by in viM studies on primaty cl~tured human thymic cells, using 55 and octreotide 
(chapters 11.4 and 11.5). 
Taking into consideration the peculiar microenvironment, the architecture and the specific 
pattern of 55R distribution in the human thymus, specialized areas were found where 55 
and its receptors exert differential activities. 
Sst2A is the receptor predominantly expressed on microenvirorunental cells, where it could 
be involved in mediating autocrine or paracrine activity of S5. The neuropeptide may 
control unstimulated and growth factor-stimulated TEe growth (chapter 11.4). However, 
TEe and macrophage production of thymic hormones and cytokines might be under 
influence of SS as well. In addition, the presence of sst1A on macrophages suggests the 
involvement of SS in the regulation of the antigen presentation activity by these cells. 
55R receptors were expressed on human thymocytes, apparently linked to rhe level of 
maturation of the lymphoid cells (chapter 11.5). The most immature cortical thymocytes 
preferentially express sstlA, while more mature thymocytes express sst)' TIle expression of 
sst" on immature early thymocytes is in line with the presence of this subtype in their 
progenitors in the bone marrow. This receptor might modulate the high proliferation rate 
of immature thymocytes. Sst, is mainly expressed on thymocytes at a higher level of 
maturation, as well as on peripheral T lymphocytes, which directly derive from mature 
thymocytes. Many of these cells are destined to die byapoptosis as a consequence of the 
selection process in the thymus. Sst) is involved in agonist-mediated apoptosis and its 
presence is highly suggestive for a modulatoty activity of SS in thymocyte deletion (chapter 
11.5). Neuroendocrine products influence thymocyte traffic. Considering the peculiar 
distribution of 55R, S5 might be involved in modulating this process as well. 
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The availability of antibodies specific for sst" and sst, receptors made it possible to further 
investigate the cellular localization of these receptor subtypes by immunohistochemistty in 
human lymphoid tissues (chapter IU.5). Sst", immunoreactivity was mainly located in 
areas with prevalent microenvirorunental cells) while sst} immunoreactivity occurred 
preferentially on cells with lymphoid morphology, both in the spleen and the thymus 
(chapter 1I1.5). The localization of SSR immunoreactivity was is in agreement with the 
fmdings by binding studies and RT-PCR Thus, it was concluded that distinct SSR subtypes 
are expressed on particular cell types and at specific differentiation stages or state of both 
lymphoid and accessory cells. In general, SSR distribution within these lymphoid tissues 
offered an explanation for the variety of effects exerted by SS. 
Finally, the potential involvement of SS in controlling the physiologic involutive process 
occurring in the thymus w.ith ageing is discussed in chapter 11.6. However) further studies 
are necessary to clarify whether the decrease of SSR in this lymphoid organ with ageing is a 
programmed step during the involution) or whether it is a consequence of this process. 
In the human thymus, SS seems to act at different levels, on different thymic cells and Vid 
different receptor subtypes, and might be considered as a potential modulator of the 
homeostasis of various cell components as well as a regulator of their specialized activities 
including the maturation of the human T cell repertoire. This is in line with similar 
observations for other neuropetides, such as Vll' and SP. Although not yet established, an 
intrathymic circuit between these three substances might exist. 
Like other twnors originating from SS-target tissues, human thymic epithelial twnors may 
express SSR. Thymomas are visualized inviw during SSR scintigraphy using [lIlln-DTPA_ 
D-PhelJ-octreotide (chapter UIA), and at least three SSR subtypes have been detected by 
immunohistochemistry in these tumors (chapters UI.3 and UlA). Expression of sst'A and 
sst} receptors was found in vitm with considerable heterogeneity in a series of human 
thymic tumors that were visualized by SSR scintigraphy inviw (chapter UIA). Overall sst, 
showed a higher expression compared to sst", and displayed a preferential localization on 
reactive thymocytes. Since) sstlA and sst) receptors are also expressed in the normal thymus) 
while this organ is not visualized during SSR scintigraphy, the spleen, the normal and 
hyperplastic thymus, as well as thymomas were further investigated in order to find out 
whether the density and the heterogeneity of receptor distribution may playa role (chapter 
III.5). The data suggested that the presence of sst2 receptors is not an essential prerequisite 
for the visualization of SSR·positive tissues during [lIlln.DTPA-D.PheIJ-octreotide 
221 
Summary 
scintigraphy, and that sst, receptors might be involved in determining the uptake, at least in 
some lymphoid tissues. In light of these new fmdings, it seems that [l151-Tyr'}octreotide 
may be considered as a clear sst,-preferring ligand for in'litm binding studies, while in'1iw 
['"In-DTPA-D-Phe'J.octreotide might be less selective in this respect. This may have 
important consequences for the applications of 55 analogs for systemic radiotherapy. The 
introduction of new subtype-selective analogs and antagonists may shed more light on this 
issue. New potential clinical applications of 55 and its analogs in autoimmune and 
neoplastic diseases involving the Urunune system are under investigation. Of particular 
interest is the treatment with octreotide of patients bearing thymomas associated with 
paraneoplastic syndromes. Although further studies should investigate the mechanisms 
underlying these effects, therapy with 55 analogs may have a rationale in the treatment of 
autoimmune diseases, whether or not associated wit thymic tumor associated or not to to 
thymic twnors. Moreover, in one thymoma studied both in vim and in vitro) 55 and 
octreotide inhibited the growth of the tumor cells in 'liho. Interestingly, sst, was selectively 
expressed on cultured neoplastic cells (chapter 111.3). In addition, the lack of endogenous 
55 mRNA in tumor tissue and in tumor cell was found. Although vel}' prelimioary, this 
might be involved in the pathogenesis of neoplastic transformation, as well as in the 
occurrence of autoimmune diseases often associated with these tumors (chapter 111.3). In 
this respect it will be interesting to further investigate the mechanisms of the significant up· 
regulation of 55R observed in one case of thymic hyperplasia associated with myadX21w 
grmis (chapter III,S), 
We concluded that 55 and a set of 55R are expressed in the human thymus in both 
microenvironmental and lymphoid cells, but apparently &lective. A highly specialized 
intrathymic circuit seems to integrate 55 in the main function of this organ as well as in 
other activities, which needs further investigations. However, these preliminary results 
point out the important role of this neuropeptide and its receptors in thymic homeostasis. 
The overall activity of the thymus is based on the balance of several regulating factors, 
which are produced locally. Disturbances in this equilibrium may lead to the induction of 
umbalanced immune responses, This might be associated with thymic tumors and 
autoIDunune diseases. Alterations in the circuit involving 55 might be implicated in the 
pathogenesis of these diseases, and therapy with 55 analogs might have an application in 
particular immune disorders. 
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Lymfoide organen vormen een belangrijke plaats van imn1Ullo-neuro-endocriene 
interacties. Somatostatine (S5) heeft een voornamelijk remmende werking in het centrale 
zenuwstelsel en het endocriene systeem. Daarnaast heeft het peptide tevens een 
immunomodulerende rol. Studies met betrekking tot de activiteit van S5 in het 
immuunsysteem vormen een belangrijk meuw onderzoeksterrein. Het is nog ruet 
opgehelderd welke van de vijf op dit moment bekende somatostatine receptor (SSR) 
subtypen tot expressie komen in immmmcellen. Resultaten verkregen door middel van 
studies in cellijnen en primaire kweken van immuuncellen laten duidelijke verschillen zien 
tussen modelsystemen van dier en mens. In tegenstelling tot neuroendocriene cellen, heek 
SS op de funktie van immuuncellen een bifasisch effekt. Her mechanisme hierachter is nog 
niet opgehelderd. Naast cen aanta! duidelijke verschillen tussen neuroendocrienecellen en 
immuuncellen wat betreft de funktie van SS en SSR, zijn er ook overeenkomsten tussen 
beide ce!typen. 
Het in dit proefschrift beschreven onderzoek heeft zich met name gericht op de thymus 
van de mens, aangezien dit lymfoide orgaan een uitgesproken voorbeeld is van de integratie 
tussen het neuroendocnene systeem en het immuWlsysteem. Bovendien is er nog vrijwel 
niets bekend wat betreft de expressie en rol van SS en SSR in dit orgaan. 
Twee belangrijke aspekten zijn in dit proefschrift onderzocht. Ten eerste is de expressie 
van SSR en van het peptide SS zelf in de normale menselijke thymus vastgesteld en is de 
functionele betekenis van het SS/SSR systeem in dit primaire Iymfoide orgaan onderwcht 
en bediscussieerd. Ten tweede is de rol van het SS/SSR systeem in de pathologie van de 
thymus onderzocht. De resultaten en conclusies van deze studies kwmen belangrijke 
consequenties hebben voor diagnose en therapeutische mogelijkheden bij stoornissen van 
het immuWlsysteem. 
Hoofdstuk I geeft een uitgebreide inIeiding omtrent de huidige kennis van de rol van 
neuropeptiden en hun receptoren in het immuunsysteem. Speciale aandacht wordt besteed 
aan SS en SSR. De eerste twee paragrafen van hoofdstuk II geven een introduktie in de 
struktuur en funktie van de normale menseIijke thymus en de neuroendocriene netwerken. 
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VelVolgens wordt de expressie van SS en SSR in de thymus beschreven, waarbij speciale 
aandacht is besteed aan de specilieke cellulaire lokalisatie van SSR subtypen en aan de 
potenti;;le betekenis van de celspecifieke distributie in de fysiologie en pathofysiologie van 
de thymus (hoofdstuk II.3, 4 en S). 
SS, sst!, sstlA en sstJ vertonen een heterogene expressie in de thymus en komen differentieel 
tot expressie in de verschillende celtypen. Sst! en sst1A komen selektief tot expressie in de 
epitheliale cellen van de thymus (TEe). Bovendien blijken deze cellen zelf de endogene 
bron van SS produktie te zijn (hoofdstuk II.4). Daarentegen blijken thymocyten niet in 
staat te zijn SS te producren. Thymocyten brengen sst2A en sstJ receptoren tot expressie. In 
tegenstelling tot TEe vertoont de expressie van sstlA en sst3 receptoren op thymocyten een 
snelle downregul.tie wanneer zij in kweek gebracht worden (hoofdstuk II.S). Tevens 
worden verschillen in de expressie van sstlA en sstJ receptoren tussen verschillende 
thymocytpopulaties aangetoond. SstlA receptoren komen met name tot expressie in de 
immature populatie, tenvijl sstJ receptor expressie hoger is in de meer mature thymocyten. 
Het aantal SSR bleek erg laag te zijn, hetgeen in overeenstemming is met bevindingen in T-
lym£ocyten. Deze cellen zijn afkomstig van thyrnocyten. Op een andere 
thymuscelpopulatie, de macrofaag, werd aileen expressie gevonden van de sst1A receptor 
(hoofdstuk II.S). De soort-specilieke verdeling van SSR in immuuncellen, alsmede de 
verschillen in de endogene bron van SS produktie tussen mens en dier, maakt het moeilijk 
om een geschikt modelsysteem te vinden waarbij het mogelijk is om de eHekten van SS op 
thymuscellen te bestuderen. Het voorkomen van functlonele SSR subtypen op zowel 
menselijke TEC als thymocyten is onderzocht middels in Uno studies waarbij remmende 
effekten van SS en het SS analogon octreotide op de celproliferatie van primaire kweken 
van deze cellen werden gevonden (hoofdstuk II.4 en II.S). 
Sst" is het receptor subtype dat met name tot expressie komt in de thymocyt·omringende 
cellen, waarbij het betrokken kan zijn bij de autocriene en paracriene aktiviteit van SS. Het 
neuropeptide remt zowel de ongestimuleerde als de groeifactor gestimuleerde groei van 
TEC (hoofdstuk II.4). De productie en secretie van thymushormonen en cytokinen kan 
mogelijk eveneens door SS worden belnvloed. Daarna.st best.at de mogelijkheid dat de op 
de macrofaag aanwezige sstlA receptor betrokken is bij de regulatie van de antigeell-
presenterende funktie van deze cellen. 
Zoals hierboven genoemd, lijkt de expressie van SSR op thymocyten gekoppeld te zijn aan 
de mate van m.turatie van deze cellen (hoofdstuk II.S). De meest immature corticale 
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thymocyten brengen met name sstlA receptoren tot expressie, tenvijl de meer mature 
thymocyten preferentieel de sst) receptor expresseren. De expressie van sst2A receptoren op 
de zeer vroege thymocyt lijkt in overeenstemmillg te zijn met de aanwezigheid van dit 
receptor subtype op de voorlopercellen in beenmerg. Dit receptor subtype zou betrokken 
kunnen zijn bij de modulatie van de hoge proliferatiesnelheid van immature thymocyten. 
De sst) receptor komt met name voor op de meer mature thymocyten, evenals op in het 
bloed circulerende T·cellen, die direkt afkomstig zijn van de mature thymocyt. De meeste 
mature thymocyten zijn gedoemd te sterven via een praces van gepragrammeerde celdood 
(apoptose) ten gevolge van het selekrie proces in de thymus. De sst) receptor lijkt 
betrokken te zijn bij agonist·gei·nduceerde apoptose. De aanwezigheid van dit receptor 
subtype suggereert de betrokkenheid van SS bij het proces van deletie van thymocyten 
(hoofdstuk II.S). Produkten van neuroendocriene cellen be'Ihvloeden de migratie van 
thymocyten. De karakteristieke distributie van SSR in de thymus beschouwend, zou tevens 
verondersteld ktmnen worden dat SS een regulerende rol speelt in dit proces. 
De beschikbaarheid van antilichamen specifiek voor sst2A en sst) receptoren maakte het 
mogelijk om tevens de cellulaire lokalisatie van deze receptor subtypen in menselijke 
lymfoide weefsels in detail te bestuderen met behulp van immunohistochemische 
technieken (hoofdtsuk III.S). Sst" immunoreaktiviteit bleek met name gelokaliseerd te 
zijn in cellen die Iymfoide cellen omgeveu, tenvijl sst) receptoren immunohistochemisch 
werden aangetoond op met name cellen met een Iymfoide morfologie, in zowel de thymus 
als de milt (hoofdstuk III.S). Deze lokalisatie van SSR is in overeenstemming met 
bevindingen op basis van ligand.bindingsstudies en RT·PCR. Wij concluderen daarom dat 
bepaalde SSR subtypen selelcrief tot expressie komen op bepaalde celtypen, afhankelijk van 
de differentiatiestadia van deze cellen. De verdeling van SSRs in deze Iymfoide weefsels kan 
een verklaring zijn voor de verschillende ellekten die door SS geYnduceerd kunnen wordell. 
Tenslotte wordt in hoofdstuk II.6 de potentiele betrokkenheid van SS in de regulatie van 
de thymusinvolutie beschreveu en bediscussieerd. Deze involutie treedt normal iter op bij 
het ouder worden. Er zijn echter aanvullende studies nodig om vast te stellen of de 
gevonden afname van het aantal SSR in de menselijke thymus bij het ouder worden een rol 
speelt bij dit proces van involutie, of dat het simpelweg een gevolg is van het proces. 
In de menselijke thymus lijkt SS een ellekt te kunnen hebben op verschillende niveaus, op 
verschillende celtypen van de thymus en via verscltillende receptor subtypen. Het peptide 
kan daarom beschouwd worden als een mogelijke modulator van de homeostase van de 
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verschillende celtypen en tevens als een regulator van hun gespecialiseerde aktiviteiten, 
waaronder de maturatie van het menselijke T-eel repertoire. Een dergelijke hypothese is in 
overeenstemming met de funktie van andere neuropeptiden, zoals VIP en SP. Hoewel rut 
nog niet definitief is vastgesteld, zouden deze drie neuropeptiden elkaar in de thymus 
onderling kunnen beihvloeden. 
Evenals andere tumoren die hun oorsprong hebben in SS-doelwit weefsels, kunnen 
menselijke epitheliale tumoren van de thymus SSR reeeptoren bevatten. Deze thymomen 
worden gevisualiseerd met behulp van SSR scintigrafie, gebruik makend van het r.dioligand 
["IIn-DTPA-o-Phel]-oetreotide (hoofdstuk lIlA). Er konden drie SSR subtypen (sstl' 
sst2A and sst]) door middel van immunohistochemie worden aangetoond in dit type tumor 
(hoofdstuk IIl.3 en lIlA). In-vioo werd een sterk heterogene expressie gevonden van sst'A 
en sst) receptoren in een serie thymomen. Deze receptoren kunnen tevens gevisualiseerd 
worden met behulp van SSR scintigrafie inviw (hoofdstuk lIlA). In het algemeen was de 
expressie van sst] receptoren hoger dan die van sst2A receptoren. Sst] receptoren bleken met 
name voor te komen op reaktieve thymocyten. Aangezien sst2A en sst) receptoren tevens 
aanwezig zijn in de normale thymus, en omdat rut orgaan niet gevisualiseerd kan worden 
met SSR scintigrafie, terwijl de milt door SSR scintigmfie wel duidelijk zichtbaar kan 
worden gemaakt, is er verder onderzoek gedaan Ilaar de mate van expressie en de 
distributie van SSR in de nonnale milt, de normale en hyperplastische thymus en in 
thymomen (hoofdstuk ilLS). De resultaten van deze studies suggereren dat de expressie 
van sst" receptoren niet altijd bepalend is voor de mogelijkheid om SSR positieve weefsels 
te visualiseren met behulp van SSR scintigrafie. Sst) receptoren lijken tevens een rol te 
kunnen spelen in de opname van [IIIIn-DTPA-o-Phel]-octreotide in lymfoide weefsels. In 
het licht van deze nieuwe bevindingen moet vastgesteld worden d.t [125I-Tyr']octreotide 
een duidelijk sst,-selektief ligand is voor in vioa bindingsstudies, terwijl ["IIn_DTPA_o_ 
Phe']-octreotide in viw in dit opzicht minder selektief lijkt te zijn. Dit gegeven kan 
belangrijke eonsequenties hebben voor het gebmik van radioaktieve SS-analogen bij 
systemische radiotherapie. De ontwikkeling van nieuwe SSR subtype-selektieve analoga is 
van groot belang voor verder onderroek op dit gebied. 
De mogelijkheid van het gebruik van SS en SS-analoga bij de behandeling van 
autoimmuunziekten en tumoren van het immuwlsyteem wordt gesuggereerd in de 
literatuur. Met name van belang is de behandeling met octreotide van patienten met een 
thymoom en een gerel.teerd paraneoplastisch syndroom. Hoewel aanvullende studies 
226 
Samonuuing 
noodzakelijk zijn om het werkingsmechanisme te onderzoeken, lijkt het erop dat oct reo tide 
therapie een plaats kan hebben bij de behandeling van autoimmuunziekten, al dan niet 
geassocieerd met thymustwnoren. Bovendien is er in een bepaald thymoom dat wij zowe1 
in vim en in vitm hebben bestudeerd, gevonden dat de graei van de tumorcellen in Utro 
geremd kan worden met 55 of octreotide. In dit bepaalde thymoom bleken de tumorcellen 
aileen sst, receptoren te bevatten (hoofdstuk 111.3). Een andere belangrijke bevinding is 
dat dit thymoom niet in staat was tot endogene 55 produktie. Hoewel preliminair, kan 
gesuggereerd worden dat het verlies van de mogelijkheid om 55 te produceren een rol 
speelt bij de pathogenese van dit type tumoren, alsmede in het optreden van 
autoimmuunziekten die vaak geassocieerd zijn met deze tumoren (hoofdstuk 111.3). In dit 
kader is het van belang om het mechanisme van de gevonden verhoogde SSR expressie bij 
thymushyperplasie geassocieerd met myastenia gravis, (hoofdstuk 111.5) nader te 
bestuderen. 
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RlASSUNTO 
Gli organi linfoidi primari possono essere considerati i elistretti dell'organismo dove hanno 
tuogo importanti interazioni immWlo-neuro-endocrine preferenzialmente. Si tratta di 
organi piuttosto complessi sia per l'eterogeneita dei gntppi cellulari che li compongono sia 
per la presenza nel loro contesto di svariate sostanze che hanno la prerogativa di 
appartenere ai tre suddetti sistemi. n sistema immune ed i sistemi nervoso ed endocrino 
possono interagire tra Ioro anche, e specialmente, mediante comWli mediatori. Tra queste 
sostanze, i neuropeptieli sembrano svolgere un molo estremamente rilevante. 
La somatostatina (5S) ha un'azione prevalentemente inibitoria sia nel sistema nervoso che 
nel sistema endocrino. Tuttavia, negli ultimi anni e eliventato sempre pill evidente i1 molo di 
immunomodulatore di questo neuropeptide ubiquitario. Infatti, i nwnerosi studi che hanno 
valutato l'azione della S5 suI sistema immWle hanno aperto una nuova e stimolante area di 
ricerca. La SS esercita i suoi effetti legandosi a specifici recettori di membrana. In 
quest'ultima decade sono stad identific.ti 5 diversi sottotipi recettoriali per I. 55 (55R) e ne 
sono stati clonati e geni. I dati relativi all'espressione dei 5 diversi sottotipi eli 5SR su cellule 
del sistema inunWle sono piuttosto conflittuali. Inoltre, i primi risultati ottenuti da studi 
effettuati su linee cellulari e su colture primarie hanno evidenziato come primo dato 
importante un'espressione dei recettori diversificata sui sistemi cellulari derivanti da animali 
e su cellule umane. Un altro aspetto che merita di essere sottolineato riguarda gli effetti 
esercitati dalla S5 su cellule del sistema inununitario, che sembra differenziarsi dai pit) noti 
effetti del neuropeptide sulle cellule nervose e sulle cellule endocrine. Infatti in cilO I. 55 
eserdta un effetto defmito "bifasicd', ovvero inibitorio a concentrazioni nanomolari, ed un 
assenza di effetto a concentrazioni micromolari. Tuttavia, sebbene vi siano alcllne 
elifferenze tra Ie interazioni della SS con cellule neuroendocrine e con cellule immunitarie, 
molti altn aspetti sonG paragonabili. 
In questa tesi l'attenzione e stata focalizzata principalmente suI timo umano, poiche 
quest'organo linfoide primario rappresenta un caso paradigmatico delle interazioni esistenti 
tra il sistema neuroendocrino e il sistema immunitario. Nel timo si svolgono complessi 
processi biologici che portano alia maturazione delle cellule immtmocompetenti della linea 
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T, gli eHettori periferici della risposta immunitaria cellulo-mediata. Diversi studi hanno 
dimostrato che una considerevole parte eli questi complessi meccanlsmi che portano alla 
maturazione ed alia selezione dei linfociti T sono sotto un sofisticato controllo da parte di 
molecole classicamente appartenenti a1 sistema neuroendocrino. E proprio ilrnolo della SS 
e dei suoi eliversi sottotipi eli recettore e stato finora molto poco esplorato nel timo umano. 
AIPinizio degli studi contenuti nella presente tesi, due sono state Ie principali problematiche 
affrontate. La prima ha riguardato soprattutto l'identificazione dei SSR espressi nel timo 
umano normale e I'impatto del sistema SS/SSR nei principali processi fisiologici che 
avvengono ali'interno di quest'organo. Successivamente e state affrontato i1 potenziale 
molo di questo sistema nelle condizioru patologiche primitive 0 associate a disfunzioni del 
timo umano. Le scoperte sugli aspetti riguardanti Ie possibili relwOIl! tra Ie azioni della SS, 
l'espressione dei suoi recettori e Ie funzion..i del timo umano potrebbero avere importanti 
conseguenze e fornire nuovi suggerimenti per Ie problematiche diagnostiche e terapeutiche 
di alcune malattie del sistema llununitariO. 
II capitolo I contiene un'introduzione approfondita alle piu recenti nozioni sull'importanza 
d..i alcuni onnoni, dei neuropeptidi e dei loro recettori nell'ambito del sistema imnuuUtario, 
con enfasi patticolare al significato ed al molo della SS e dei suoi recettori. AIl'inizio del 
secondo capitolo, i prirui due paragrafi, invece, sono di introduzione alIa stmttura ed alla 
funzione del timo umano normale, con una sezione speciale dedicata al controllo esercitato 
su queste funzioni da! sistema neuroendocrino. Seguono poi gli studi sulla distribuzione e 
caratterizzazione della SS e dei suoi recettori, con particolare attenzione alla localizzazione 
cellulare dei diversi sottotipi di recettore ed al potenziale significato di tale distribuzione 
nell'ambito della fisio-patologia del timo umano. (capitoli I1.3, 4 e 5). 
I risultati emersi dai prirui studi hanno fomito una mappa della localizzazione della SS e 
dell'espressione di tre diversi sottotipi di recettore, il cipo 1 (sstJ, sst2A e sst), 
eterogeneamente distribuiti nel tessuto e su differenti sottopopolazioni di cellule timiche. 
lnfatti Ie cellule epiteliali timiche (fEe) esprirnono selettivamente i recettori del tipo sst l e 
sst2A: inoltre questo tipo di cellule puo essere considerato una potenziale fonte di 
produzione endogena d..i SSt poiche I' mRNA codificante per il neuropeptide e stato isolato 
proprio dalle TEC (capitolo II.4). AI contmio, la SS non risultava rilev.bile nei tirnociti 
isolati da tessuto fresco. Tuttavia su queste cellule erano espressi i recettori sst2A e sst). 
Differentemente dalle TEe, nei timociti in coltura si assisteva ad una "down-regulation" 
dell'espressione d..i questi recettori (capitolo II.S). I timociti nel timo umano rappresentano 
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una popolazione cellulare molto eterogene., formata da cellule in differenti st.di della loro 
linea maturativa. Un dato molto interessante riguarda il particolare assetto del "pattern" 
recettoriale che si e andato evidenzialldo man mano che venivano studiate Ie diverse 
sottopopolazioni eli timocici. Mentre il recettore di tipo sst2A risultava progressivamente 
espresso in maruera predominante sulle fraziom di timociti pill immature, il recettore di 
tipe sst) vemva riscontrato maggiormente espresso su cellule in fase di maturazione pitI 
avanzata. n numero dei siti di legame per la SS sui timociti nsultava essere comilllque molto 
basso, in linea can 10 stesso tipo di riscontro ottenuto sui linfociti T periferici che derivano 
proprio dai timociti. n timo umano contiene anche un discreto numero di macrofagi, e su 
questa terzo componente cellulare si e riscontrata l'espressione selettiva del recettore sst2A. 
Questo dato e in accordo can 10 stesso tipo di riscontro su cellule appartenenti alIa stessa 
linea, rna in altri distretti dell'organismo ed in diverse condizioni (capitola II.S). Queste 
cellule non sembrano contenere SS, che e stata invece evidenziata nei macrofagi timid del 
topo. Quest'aspetto evidenzia ulteriormente che la distribuzione deUa SS e dei suoi recettori 
e specie-specifica, cosa che rende difficoltoso il reperimento di un modello animale adatto a 
studiare gli effetti del neuropeptide sulle cellule timiche e del sistema irrununitario in 
generale. Per questo motivo la funzionalita dei recettori della SS e stata studiata su colture 
primarie di TEC e timociti tunarll, utilizzando sia la SS nativa che un suo analogo sintetico 
octapeptidico, l'octreotide. Entrambi i composti hanno sortito un effetto inibitorio in vitro 
sulle culture primarie umane di entranlbe Ie popolazioni cellulari timiche (capitali II.4 e 
II.5). 
Considerando it peculiare microambiente timico, la sua architethU'a e 10 specifico "pattern" 
di distribuzione dei recettori della SS, si puo concludere che nel timo umano sembrano 
esistere aree specializzate dove la SS tramite i diversi sottotipi di recettore e in grado di 
esercitare un controllo pleiotropico su diverse funzioni di quest'organo. 
n recettore sstlA e it sottotipo prevalentemente espresso sulle cellule del cosiddetto 
"stroma" timico, dove sembra essere coinvolto nel mediare Ie attivit;l autocrine 0 paracrine 
della SS nell'ambito del microambiente timico. Per esempio, e stato dimostrato che la SS e 
in grado di inibire la proliferazione delle TEe basale e stimolata da fattori di crescita. 
(capitolo II.4). Non si pUD tuttavia eseludere che essa sia coinvolta anche nell. 
modulazione dell. produzione di sostanze specifiche da patte delle cellule dello stroma 
timico. Infatti sia Ie TEC che i macrofagi producono onnom timici e citochine. La presenza 
su queste cellule di un recettore, il sstlAl che ne! sistema _ endocrino e coinvolto 
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principalmente nel mediare gli efferti inibitari della SS sulla produziane di vari ormoni, fa 
pensare al suo coinvolgimento in tale tipo di modulazione anche nel sistema immtme Un 
ulteriore aspetto interessante riguarda i macrofagi. Questi svolgono la funzione di cellule 
presentanti rantigene, e poiche in altri siti e stata dimostrata un'influenza della SS su questa 
meccanismo, il suo coinvolgimento nel timo in tale attivid. e fortemente probabile. 
Vespressione dei recettori della SS sui timociti sembra essere correlata a1 livello di 
maturazione delle cellule nell'ambito del timo (capitalo I1.S). I timociti corticali pilI 
inunaturi espnmevano preferenzialmente il recettore sst2AJ mentre mvece Ie 
sottopopolazioni piu avanzate nella linea maturaciva mostravano la prevalente espressione 
del sst). Vespressione del recettore sstlA sui timociti che hanno appena coloruzzato il timo 
trova un riscontro nelrevidenza che questa sottotipo di SSR e espresso in cellule 
progenitrici nel midollo osseo. La funzione di questa recettore sui timociti immaturi 
potrebbe essere quella di modulare l'alta attivita proliferativa di queste cellule. Invece il 
recettore sst) e espresso come, abbiamo visto, sui timociti piu maturi e sui linfoeiti T 
periferici. Molti timaciti in maturazione all'interno del timo sono destinati ad essere 
selezionati negativamente e soppressi mediante apoptosi. Recentemente e state dimostrato 
che proprio il recettore sst) sembra essere coinvolto nel mediare l'apoptosi cellulare indotta 
da agonisti della 5S. La presenza di questa specifieo reeettore sui timociti e altamente 
suggestivo per W1 eoinvolgimento della 5S nella selezione dei timociti 0 perlomeno nella 
modulazione di questo processo all'interno del timo umano (capitalo I1.S). A questa 
punto e utile ricordare che altri ormoni e classici pepcidi neuroendocrini sono in grado di 
influenzare il traffieo e la migrazione dei timociti all'interno del timo. Alla luee della 
particolare distribuzione e campartimentalizzaziane dei SSR nel timo, appare probabile un 
ruola di questa neuropeptide in questi processi. lnfatti, la SS e in grada di influenzare la 
migrazione e la chemiotassi di cellule irrununocompetenti in altn distretti del corpo umano. 
La disponibilita di anticarpi specifici per i SSR ha resa passibile studiare pilI 
dettagliatamente l'esatta localizzazione cellulare di queste proteine/recettori mediante 
irrununoistochimica in diversi tessuti e tumori wnaru. Risultati incoraggianti sono stati 
recentemente ottenuti anche in tessuti piu complessi come il tessuto linfoide. Nel capitolo 
III.5 questa teenica e stata applicata su materiale timico e splenico. Una chiara 
inuntmoreattivita per il recettore sstlA e stata riscontrata quasi esclusivamente in aree dove 
Ie cellule 'stromali sana prevalenti, mentre il recettore sst} risultava localizzato 
prevalentemente sulle cellule linfaidi sia nel tima che nella milza umam (capitolo IlLS). 
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Questi risultati sui "pattern" di distribuzione dei recettori hanno confermato cio che si era 
gil. delineato con gli studi di legame e con RT-PCR Da questa tipo di studi si giunge alia 
conclllsione che i diversi sottotipi di recettore della SS sono espressi su specifiche 
sottopopolazioni cellulari ed in specifici stadi della differenziazione sia delle cellule linfoidi 
che di cellule accessorie presenti nei principali organi del sistema immune. In generale, 
questa tipo di distribuzione dei recettori nell'ambito degli organi linfoidi potrebbe in patte 
spiegare la variabilitl. degli effetti della SS sulle cellule immunitarie. 
II timo e un organo che va incontro ad un fisiologico processo di involuzione con l'eta. II 
potenziale coinvolgimento della 5S in questa processo e stato indagato nel capitolo 11.6. 
Tuttavia ulteriori studi sono necessari per chiarire se it decremento dell'espressione del S5R 
nel timo con l'aumentare dell'eta cronologica entra a far parte attiva del processo stesso 
oppure se e una conseguenza del processo involutivo. 
Nel timo umano la SS sembra agire a differenti livelli, su diverse popolazioni cellulari, e 
attraverso diversi sottotipi di recettore. Da questo punto eli vista, it neuropeptide potrehhe 
essere considerato un importante modulatore dell'omeostasi tra i van componenti cellulari 
timici, ed aIlo stesso tempo entrare a far parte della regolazione delle varie funzioni di 
queste cellule, comprese Ie attivita che sono aIla base della maturazione del corredo 
cellulare T nel sistema immunitario wnano. Un nIolo simile e stato ipotizzato anche per 
altri neuropeptidi come il '1IW:1ctire intestinal peptide (VIP) e la sostanza P (SP). Inoltre, anche 
se non ancora ben stabilito, e stata proposta I'esistenza eli tID circuito intra-timico che vede 
coinvolti e correlati proprio questi tre neuropeptidi in azioni sinergistiche 0 contrastanti. 
CoSt come per la maggior parte dei tumori che originano da tessuti bersaglio della S5, anche 
Ie neoplasie timiche possono esprimere SSR. I timomi, una eterogenea classe di tumori 
epiteliali del timo, possono essere ViSllaliZzati in vim durante scintigrafia con [ll1In_DTPA_ 
D-Phe'J-octreotide (capitolo III.4). Questo tracciante radiomarcato viene regolarmente 
usato per la localizzazione di lesioni che esprimono SSR. InoItre almeno tre diversi sottotipi 
di recettore della S5 sono stati riscontrati in questi tumori mediante immunoistochirnica. 
(capitoli 111.3 e 111.4). In particolare, i recettori sst2A e sst) sono stati trovati espressi in 
7itto in modo considerevolmente eterogeneo in una serie di timomi precedentemente 
visualizzati 01 vim !ramite scintigrafia COIl I'analogo marcato della SS (capitolo IlI.4). In 
grandi linee, il recettore sst} era maggiormente espresso in confronto al recettore sst1Al 
mostrmdo una preferenziale rna non esdusiva localizzazione sui timociti reattivi all'interno 
del tessuto neoplastico. I recetton sstlA e sst) sono espressi anche fie! timo wnano nonnale, 
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tuttavia quest'organo non Vlene generalmente visualizzato durante la scintigrafia con 
analoghi della SS marcati. Per questo motivo Ia milza, il timo normale, iperplastico e 
neoplastico sono stati ancora piu approfonditamente studiati, per cercare di capire se 
l'eterogeneita e Ia densid di distribuzione dei SSR potesse essere alla base di questa 
apparente discrepanza. (capitolo 111.5). I risultati ottenuti hanno suggerito che la presenza 
del reeettore sstl non e un prerequisito essenziale per la visualizzazione di un organo 0 
tessuto durante seintigrafia con ellln-DTPA-D-Phe1]-octreotide, e che inoltre non si puc, 
escludere il coinvolgimento del reeettore sst) dai possibili meeeanismi di captazione del 
tracciante, perlomeno in aicuni tessuti linfoidi. AlIa luce di qlleste nuove nozioni si e potuto 
concludere che mentre I'analogo deUa SS usato per studi di legarne in uhv, il ["'I·Tyr'} 
octreotide, puo essere considerato altamente selettivo per il recettore sst2, quello utilizzato 
"' vim, il ['lIln-DTPA-D.Phe'}octreotide, potrebbe esserIo in grado minore. Questo dato 
ha un importante impatto per la terapia radiometabolica con analoghi radiomarcati deUa SS. 
La disponibilitii di nuovi analoghi selettivi ed antagonisti dei sottotipi recettoriali deUa SS 
potra emarice aneora maggionnente alcum punti oscuri suI ruolo dei diversi sottotipi nei 
meccanismi di captazione di radiotraccianti in vim. 
Sono gia in fase di studio nuove potenziali applicazioni degli analoghi deUa SS neUe 
patologie autoimmWli ed in patologie neoplastiche riguardanti il sistema immunitario. 
Particolare interesse e stato destato dal trattamento con octreotide di pazienti con timoma e 
relativa sindrome paraneoplastica associata. Sebbene ulteriori studi sono necessari per la 
chiara comprensione dei meccarusmi aUa base degli effetti degli analoghi deUa SS su queste 
neopiasie, tale terapia potrebbe rappresentare una importante innovazione nel trattamento 
delle patologie a1.1toimmuru associate 0 meno a neoplasie timiche. In uno di questi casi di 
timoma studiati sia in vim ehe in vitro, l'octreotide si e dimostrato efficaee nell'inibire la 
proliferazione deUe ceUule tlUuorali in vi/IV. Iuoltre, un dato da sottolineare e che Ie ceUule 
tumorali isolate dal suddetto timoma esprimevano selettivamente il reeettore sst) (capitolo 
III.3), ed aneora piu interessante e risultata la perdita della eapaeid di produzione eli SS 
endogena in questa timoma. Anche se aueora molto preliminare, q1.1est'aspetto andrebbe 
tenuto presente per un suo probabile coinvolgimento nella patogenesi di alcum turnori del 
timo 0 delle sindromi paraneoplastiehe s1.1 base autoinUUlUle cosl frequentemente associate 
a questa tipo di neoplasia (capitolo 111.3). A questa proposito potrebbe essere molto utile 
studiare pili approfonditamente i1 significato della {{up-regulation" dei SSR riseontrata in un 
caso di iperplasia timica associata a IH;UstiXllia gravis (capitolo 111.5). 
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In conclusione, la SS e alcuni suoi sottotipi eli recettore sono espressi nel timo umano sia 
sulle cellule linfoieli che stromali, rna con un apparente criterio selettivo. Un circuito intra-
timico altamente specializzato sembra integrare la SS nella funzione principale del timo, rna 
anche in altre sue funzioni ancora inesplorate. Pur tuttavia, questi risultati evidenziano il 
ruolo importante eli questo ubiquitario neuropeptide e dei suoi recettori nell'omeostasi del 
timo. La funzione globale del timo e basata sull'equilibrio di molteplici fattori di 
regolazione, la maggior parte dei quali viene prodotta a livello locale. Alterazioni in questo 
equilibrio potrebbero indurre risposte anomale del sistema llunWle, come potrebbe essere 
il caso delle patologie autoinununi associate 0 meno a neoplasie timiche. Se elisturbi del 
circuito che vede coinvolta la SS sono implicati nell'insorgenza di tali disordini, la terapia 
con analoghi della S5 potrebbe avere un razionale in alcune di queste severe malattie. 
234 
ACKNOWLEDGEMENTS 
I will never forget the exciting period of my life spent in Rotterdam at the Department of 
Internal Medicine (Academical Hospital Dijkzigt). It is difficult to find the words for 
thanking all the people wOlking here. Without them, tlus thesis would have never been 
completed. The thesis is the result of an intensive collaboration between my Department 
and the Departments of Immunology, Pathology, Haematology and Nuclear Medicine, 
where I found the same availability and an enormous enthusiasm in all the persons 
involved in the project. 
The first acknowledgement goes to my "promotor" J or supervisor, Prof. Dr. Steven \XI.}. 
Lamberts and to my co-promotor Dr. Leo J. Hofland, my "guides" in this incredible 
experience together with Dr. P. Martin van Hagen. Thank you veiY much for the 
constructive support you gave me and for the "daily assistance" during the period of my 
staying in Rotterdam. My acknowledgement to Prof. Lamberts, Leo and Martin is not only 
for the scientific collaboration, but also, and especially, for the friendly atmosphere they 
created around me since the first day I arrived to The Department of Internal Medicine. 
Few years ago such experience could have been only in my dreams, they have made the 
dream true reality. 
For me, it has been a privilege to work in the group of Steven Lamberts. Dear Prof. 
Lamberts, you gave me the freedom in research and in the mean time you have been very 
close to me, with your availability and with your constructive advises, which allowed me to 
grow not only scientifically but also as a person. I learned from you in these years many 
important "strategies" to become an investigator, of course, but principally to be a good 
man! 
In Leo Hofland I have find a real "maestro" and a big friend. Dear Leo, you have opened 
my eyes towards a "new world" and you introduced me in the laboratory research, 
enhancing my passion for the medicine. Thank you vety much for being so close to me and 
for sharing your room with me during the most delicate phase of my research. I know I 
gave you a hard time, and I apologize for it, but I learned a lot from you during those 
235 
unforgettable days. However, I think I should apologize to Nicolette, Sandra, nse and 
Carlijn as well. I hope they will understand and forgive me for the troubles I gave to their 
"daddy", 
\X1ith my friend Martin I had great time in sharing the enthusiasm for "science'), but also in 
learning something new about music and "Thai food". Dear Martin, your are the most 
enthusiastic and stimulating person I have encountered in my working period in The 
Netherlands. Your enthusiasm is If contagious" and your capacity in introducing new and 
brillianr ideas in the research is unique. Thank you for all the suggestions and advises you 
gave me in these years as well as for creating the essential "contacts" which have made 
realizable our investigations. 
I want sincerely thank the three members of my upromotiecommissie" (doctoral 
committee), prof. Dr. R. Benner, Prof. Dr. E.P. Krenning and prof. I. Touw. 
Dear Prof. Benner, thank you for the constructive advises and for the judgements on my 
thesis. It has been a privilege to have you in the doctoral committee. Moreover, I would 
like to thank you also for allowing me "to use" the expertise of your Department in 
carrying out my investigations. 
Dear Prof. Krenning, thank you vel}' much for the final judgement on my thesis. It has 
been an honour to have you in the doctoral committee. Moreover, I would like to thank 
you for the possibility you gave me to collaborate with some of your brilliant co-workers 
and for allowing me to use your ncomputer working station" as well. 
Dear Prof. Touw, thank you for the constmctive criticisms to my thesis and for the 
stimulating discussion which improved significantly the quali!}' of my work and my 
thinking. It has been a privilege for me to meet you and share the enthusiasm with you in 
this field. 
I would sincerely like to acknowledge all the people working in the Department of Internal 
Medicine and keep them in an "ideal embrace". Without these extraordinary people the 
realization of this thesis would have been impossible. 
Joke Zuijderwijk for teaching and helping me in ligand-binding studies and for sharing with 
me the "new experience" in the field of immunohistochemistry, but principally for 
introducing me to a "strong course of high standard level laboratory procedures". Thanks, 
Joke, if I have learned something about the "education" in the laboratol}' work this is 
because you were the person with whom I started my training. Peter van Koetsveld, for 
revealing me almost all the secrets on cell cultures, in which he is the incomparable 
236 
Acknoulalgl101t 
"maestro", and for setting up the thymic cell cultures and starting with me this exciting 
adventure. "Bedankt" (thanks) Peter! Marlijn Waaijers for being there! My sweet Marlijn, in 
several occasions you saved me from troubles, not only during my first experiences with 
the "pipettes", but also in other occasions particularly in my preliminaty "contacts" with 
the Dutch habits. I know I have found a good friend in you, even if you prefer France to 
Italy! A special acknowledgement goes to the superb "RT-PCR couple", Diana Mooy and 
Elgin Lichtenauer-Kaligis. Dear Diana and Elgin, without your contribution the "molecular 
biology part" of my project would have not existed. Thank you for allowing me to "abuse" 
your expertise and forgive me for the enormous amount of samples for RT-PCRstudies I 
provided. 
To all the other people, which did not directly participate to my studies, but who shared 
with me the exciting days of the permanence in the laboratory. I sincerely thank Pia 
Uitterlinden, Jan-Willem Koper, Pieter de Lange, Elma van Rossen, Frank Wassen, Theo 
Visser, always available in every moment. A particular thanks goes to J oop Janssen for 
sharing with me the night-time in the laboratory and for the stimulating discussions often 
on IGF-I, less on somatostatin, rarely on their common link, GH! I would like to thank for 
their friendship Baberte Rozier, Ellen ter Averst, Virgil Dalm. It has been very important 
for me to know that I have good friends. A very friendly thank to Ank de Graaf for her 
kindness and sweetness and to Aart-Jan van der Lely for the gift of his fabulous computer, 
the object with which I have spent most of my time during the last weeks. 
Annemiek ten Bokurn, Martie Verschuren and Ton Langerak from the Department of 
Immunology, thank you very much for the valid support in my first dealing with something 
for me very important, but completely new, the thymus. 
In the Department of Pathology I had the occasion to meet a second incomparable group 
of people who helped me in developing and carrying out an important part of my project. 
Frieda van der Ham, Pieter Derkx, Marcel van der Weiden, Monique Keldar and Jeanine 
van Leeuwen from the laboratory of immunohistochemistty, thank you for the incredible 
kindness and for the important support in my ftrst experience with all those "colours". 
Thanks also to Ron Teijgeman and Nel Stouten which have tolerated all my incursions in 
"their territory". A special thanks to Ynske Yzendoom, Mustalfa Abbou and Eric 
Lindstedt, very nice friends, which have shared with me the "colouring experience" and 
supported me when everything turned out in ... black & white. I want to thank the 
experienced pathologists who have spent many hours with me at microscope try explaining 
237 
me "the right combination of colours", a concept which I still think it is a matter of taste! 
"Grazie" (thanks) to Ronald de Krijger and Max Kross, which were directly involved in my 
studies. However, I would like to thank Don Hayes and Ingeborg Bajema as well, two vel)' 
special friends, although also pathologists! 
Special and vel)' intense collaboration occurred with the Department of Nuclear Medicine. 
A particular and sincere acknowledge goes to Dik K wekkeboom with all my admiration for 
his Italian style. Dear Dik, you convinced me definitively that nuclear medicine physicians 
are also ... good photographers! From the same Department I would like to thank Lisa 
Bodei, being in Rotterdam for a brief stage, and Peter Kooij for the friendly collaboration. 
A special thank to Sigrid Oomen from the Department of Haematology. Sigrid, with your 
excellent research you indirectly helped me in understanding some peculiar aspects of my 
investigations. 
My gratitude goes to Prof. Dr. AdJ.J.C. Bogers from the Thorax Surgel)'who significantly 
contributed to the realization of this project constantly providing the thymic specimens for 
our investigations. 
I would sincerely acknowledge piet Smaal from the Audio Visuel Centrum for his kindness 
although my "impossible" requests. Many figures included in the present thesis are the 
result of his accurate and sophisticate work. 
And what I can say to my "paraninfen" Wouter W. de Herder and Rosario Pivonello? I 
think that a combination like the one between these two vel)' special friends of mine is 
explosive! Thank you, dear \Vouter and Ross, I am sure you will make my promotion 
something I could never forget... I am confident in your "association" as much as I am in 
the alliance KLM-Alitalia! I would like to thank Rosario for the big support and the 
contribution to the studies included in this thesis as weU. 
Now I would like to spend a few words for Annamaria Colao, with whom I started many 
years ago my adventure in medical research. My dear Annamaria, to you my infinite 
gratitude for having made possible all this is happening to me. I thank you from the deep 
of my hearth for having believed in me much more than I did. 
I want also particularly thank Prof. Dr. Gaetano Lombardi from the Department of 
Molecular & Clinical Endocrinology and Oncology and Prof. Dr. Lucio Annunziato from 
the Department of Pharmacology of the "Federico II" University in Napoli. Thank you 
vel)' much for having made so many big efforts to allow me completing my stage in 
Rotterdam. I sincerely hope that I can bring back the experience accuml~ated in Rotterdam 
238 
Aclmou"-4!nQl! 
in order to join you again for my studies in the future. I cannot forget to thank also all my 
colleagnes in Napoli, I hope to do not forget anybody: Carolina Di Somma, Paolo 
Marzullo, Tania Cerbone, Antonella Di Sarno, Maria Luisa Landi, Antongiulio Faggiano, 
Maria Giovanna Filippella and Susy Giaccio. 
The gratitude for my parents is inconunensurable; I could not have had better parents, 
which fully supported me in all my choices and in the difficulties in my life. A special 
thinking to my sweet aunt Delia and my uncle Theo, which is actually Dutch. They could 
think of me like a second son who will never take the place of their own son, but who 
loves them vel)' much. A brief but important thank to my best friends in Italy who cared 
of all the problems I left in Italy. Thank you vel)' much, especially to Pasquale, but also to 
Mario and Roberto. 
Lastly, but not less important, my best thank goes to all those children who entered a 
surgical department just few days after their birth. The generosity of their parents allowed 
us to perform most of the studies included in tius thesis. My wish for them is to have a 
happy and healthy life, hoping they will not remember their earlier experience. 
239 
CURRICULUM VITAE 
The author of this thesis was born on the 11 ili of Febnuuy 1962 in Capri, Italy. In 1981 he 
graduated from High School (Classic Lyceum) at the Liceo Classico Publio Virgilio Marone 
in Capri. Thereafter, he attended medical school at the "Federico II" University in Napoli, 
Italy (1982-1992). During his medical studies, he attended as pre-graduate fellow the 
Department of Molecular & Clinical Endocrinology and Oncology of the above mentioned 
university (chair prof. Dr. Gaetano Lombardi), where he was involved in studies on 
pathogenesis, diagnosis and therapy of pituitary diseases (1988-1992). In 1992 he obtained 
the degree in Medicine (110/110), as well as the licence to practice as meclical doctor in 
Napoli (90/90). He continued his attendance as post-graduate fellow at the Department of 
Molecular & Clinical Endocrinology and Oncology and started his training in 
Endocrinology and Metabolic Diseases in 1992 till the post·graduate degree magna cum 
laude (50/50) granted in Napoli in 1997. In the same year he was registered as Specialist in 
Endocrinology and Metabolic Diseases. 
Since February 1997 he is research fellow at the Department of Internal Medicine of the 
Erasmus University Hospital Rotterdam Dijkzigt (chair: Prof. Dr. Steven W.J. Lamberts). 
In January 1998 he was admitted after open competition as fellow at the School of 
Specialization in Phannacology of the Institute of Neuroscience at "Federico II" University 
in Napoli (chair: Prof. Dr. Lucio Anmmziato). 
240 
ESSENTIAL BIBLIOGRAPHY 
PUBLICA nONS BY DIEGO PERoNE 
Merola B, Colao A, Ferone D, Sellen A, Di Sarno A, Marzullo P, Spaziante R, Rossi E, 
Biondi B, Lombardi G. Effects of a chronic treatment with octreotide in patients with 
functionless pituitruy adenomas. HonnRes. 1993;40:149·155. 
Merola B, Cittadini A, Colao A, Ferone D, Fazio 5, Sabatini D, Biondi B, Sacca L, 
Lombardi G. Chronic treatment with the somatostatin analog octreotide improves cardiac 
abnormalities in acromegaly.] aUI Endro;'IOIMetab. 1993;77:790·793. 
Colao A, Merola B, Ferone D, Calabrese MR, Longobardi S, Di Renzo GF, Annunziato L, 
Lombardi G. Effect of corticotropin-releasing hormone administration on growth 
hormone levels in acromegaly: in viw and in vitm studies. Ellr] Endro&1011994; 131: 1419. 
Lastoria 5, Colao A, Vergara E, Ferone D, Varrella P, Merola B, Lombardi G, Salvatore M. 
Teclmetiwn-99m pentavalent dimercaptosuccinic acid imaging in patients with pituitruy 
adenomas. Ellr] Endro;,lOl1995;133:38-47. 
Colao A, Merola B, Ferone D, Marzullo P, Cerbone G, Longobardi S, Di Somma C, 
Lombardi G. Acute and chronic effects of octreotide on thyroid axis in GH-secreting and 
clinically nonfuctioning pituitruy adenomas. Ellr] Endroind. 1995; 133:189-194. 
Colao A, Ferone D, Lastoria 5, Marzullo P, Cerbone G, Di Sarno A, Longobardi S, Merola 
B, Salvatore M, Lombardi G. Prediction of efficacy of octreotide therapy in patients with 
acromegaly.] ab, Endarirxl Metab. 1996;8/:2356-2362. 
Colao A, Merola B, Ferone D, Lombardi G. Acromegaly. ] ain Endroinol Metab. 
1997;82:2777-2781. 
CoI.o A, Ferone D, Capp.bianca P, Del Basso de Caro ML, Marzullo P, Monticelli A, 
Alfieri A, Merola B, Call A, de Divitiis E, Lombardi G. Effect of octreotide pretreatment 
on surgical outcome in acromegaly.] ain Endro;,wlMetab. 1997;82:3308-3314. 
Ferone OJ Lastoria S, Colao A, Varrella P, Cerbone G, Acampa \Y/, Merola B, Salvatore M, 
Lombardi G. Correlation of scintigraphic results using I2lI-methoxybenzamide with 
hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. 
] elin Endocrinci Metab. 1998;83:248-252. 
Colao A, Lastoria S, Ferone D, Pivonello R, Macchia PE, Vassallo P, Bon.volont' G, 
Muto P, Lombardi G, Fenzi G. Orbital scintigraphy with [11lIn-DTPA-D·Phe1}octreotide 
predicts the clinical response to corticosteroid therapy in patients with Graves' 
ophtalmopathy.] ain Enda:rinol Metab. 1998;83:3790-3794. 
241 
Ferone D, van Hagen PM, van Koetsveld PM, Zuijderwijk J, Mooy OM, Lichtenauer-
Kaligis EGR, Colao A, Bogers AJJC, Lombardi G, Lamberts SWJ, Hofland LJ_ In ,xlm 
characterization of somatostatin receptors in the human thymus and effects of 
somatostatin and octreotide on c,Jtured thymic epithelial cell. Endocrindogy. 1999;140:373-
380. 
Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimonte L, Salvatore M, 
Lombardi G. Effects of I-year treatment with octreotide on cardiac performance in 
patients with acromegaly.] ain Enda:,;"d Melab. 1999;84: V -23. 
Colao A, Marzullo P, Ferone D, Marino V, Pivonello R, Di Sonuna C, Di Sarno A, Merola 
B, Lombardi G. Effectiveness and tolerability of slow release lanreotide treatment in active 
acromegaly.] Endarinol Imest 1998;22:40-47. 
Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa 
W, Salvatore M, Lombardi G. The pituitary uptake of [,IIIn-DTPA-D-Phe']-octreotide in 
the normal pituitary and in pituitary adenomas.] Endocrind lmest. 1999;22:176-183. 
van Hagen PM, Hofland LJ, ten Bokum AM, Lichtenauer-Kaligis EGR, Kwekkeboom DJ, 
Ferone D, Lamberts SW. Neuropeptide and their receptors in the imrmme system. Ann 
Med. 1999;31(suppI2): 15-22. 
Ferone D, van Hagen PM, Colao A, Annunziato L, Lamberts SWJ, Hofland LJ. 
Somatostatin receptors in the thymus. AnllMed. 1999;31(suppI2): 28-33. 
Colao A, Marzullo P, Vallone G, Giaccio A, Perone D, Rossi E, Scarpa R, Smaltino F, 
Lombardi G. Ultrasonographic evidence of joint thickening reversibility in acromegalic 
patients treated with lanreotide for 12 months. ainEndarinol. 1999;51:611-618. 
Ferone D, van Hagen PM, Colao A, Lombardi G, Lamberts SWJ, Hofland LJ. 
Distribution, role and function of somatostatin receptors in immune cells. Omeotide: 71Je 
NextDecennilim. BioScientifica Ltd. Steven \V,j Lamberts, (ed). Bristol, UK. 1999; 259-275. 
Ferone D, van Hagen PM, van Koetsveld PM, Mooy OM, Bogers AJJC, Colao A, 
Lamberts S\V,j, Hofland LJ. Somatostatin receptors in human thymoma and inhibition of 
cell proliferation by octreotide in ,xtm.] ain Endrx:rind Metab. 2000;85: in press. 
Ferone D, Pivonello R, Lastoria $, Faggiano A, del Basso de Caro L, Cappabianca P, 
Lombardi G. Colao A. In Uw and in,xlm effects of octreotide, quinagolide and cabergoline 
in four hyperprolactinemie acromegalies. Correlation with somatostatin and dopamine D2 
receptor scintigraphy. ain Endarinol 2000, in press. 
Ferone D, Pivonello R, van Hagen PM, Waaijers M, Zuijderwijk J, Colao A, Lombardi G, 
Bogers AJJC, Lamberts S\V,j, Hofland LJ. Age-related decrease of somatostatin receptors 
number ill the normal human thymus. Am] Pbysid 2000, in press. 
Ferone D, Pivonello R, Lichtenauer-Kaligis EGR, van Hagen PM, \'\faaijers M, van 
Koetsveld PM, Mooy OM, Colao A, Lamberts S\l7J, Hofland LJ. Quantitative and 
242 
functional expression of somatostatin receptors in human thymocytes. 2000, submitted for 
publication. 
Ferone D, Colao A, van der Lely A-J, Lamberts SWJ. Phannacotherapy or surgery as 
primary treatment for acromegaly? Dnl?,S&Aging. 2000, submitted for publication. 
Ferone D, Lichtenauer-Kaligis EGR, Pivonello R, van Hagen PM, Zuijderwijk J, Kooij 
PPM, Colao A, de Krijger RR, Hofland LJ, Lamberts S\'V)'. Inununohistochemical 
localization and quantitative expression of somatostatin receptors in normal human spleen, 
thymus and thymoma. 2000, submitted for publication. 
Lastoria S, Ferone D, Hofland LJ, De Chiara A, Montella L, van Hagen PM, Muto P, 
Lamberts S\'V)', Palmieri G. In vim detection and VI vi/m localization of somatostatin 
receptors in human thymic tumors: preliminary study on 14 cases. 2000, submitted for 
publication. 
243 

